EP2019687B1 - Vaccine against streptococci - Google Patents
Vaccine against streptococci Download PDFInfo
- Publication number
- EP2019687B1 EP2019687B1 EP07759635.1A EP07759635A EP2019687B1 EP 2019687 B1 EP2019687 B1 EP 2019687B1 EP 07759635 A EP07759635 A EP 07759635A EP 2019687 B1 EP2019687 B1 EP 2019687B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- streptococcus equi
- dna
- infection
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 187
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 178
- 229920001184 polypeptide Polymers 0.000 claims description 169
- 241000194048 Streptococcus equi Species 0.000 claims description 119
- 239000012634 fragment Substances 0.000 claims description 96
- 102000040430 polynucleotide Human genes 0.000 claims description 96
- 108091033319 polynucleotide Proteins 0.000 claims description 96
- 239000002157 polynucleotide Substances 0.000 claims description 96
- 239000000203 mixture Substances 0.000 claims description 87
- 239000013598 vector Substances 0.000 claims description 59
- 241000283073 Equus caballus Species 0.000 claims description 51
- 208000015181 infectious disease Diseases 0.000 claims description 38
- 239000013612 plasmid Substances 0.000 claims description 35
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 26
- 239000013604 expression vector Substances 0.000 claims description 25
- 241000124008 Mammalia Species 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 17
- 230000003053 immunization Effects 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 206010061372 Streptococcal infection Diseases 0.000 claims description 12
- 238000002649 immunization Methods 0.000 claims description 8
- 241000598171 Human adenovirus sp. Species 0.000 claims description 7
- 230000009851 immunogenic response Effects 0.000 claims description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000230501 Equine herpesvirus sp. Species 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 description 99
- 230000002163 immunogen Effects 0.000 description 87
- 108020004414 DNA Proteins 0.000 description 77
- 102000053602 DNA Human genes 0.000 description 77
- 238000000034 method Methods 0.000 description 67
- 102000004169 proteins and genes Human genes 0.000 description 67
- 235000018102 proteins Nutrition 0.000 description 64
- 239000013615 primer Substances 0.000 description 55
- 241000699670 Mus sp. Species 0.000 description 51
- 238000003752 polymerase chain reaction Methods 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 46
- 108091034117 Oligonucleotide Proteins 0.000 description 44
- 150000007523 nucleic acids Chemical class 0.000 description 44
- 239000000427 antigen Substances 0.000 description 35
- 108091007433 antigens Proteins 0.000 description 34
- 102000036639 antigens Human genes 0.000 description 34
- 102000039446 nucleic acids Human genes 0.000 description 32
- 108020004707 nucleic acids Proteins 0.000 description 32
- 238000002255 vaccination Methods 0.000 description 31
- 201000010099 disease Diseases 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 238000009396 hybridization Methods 0.000 description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 27
- 239000002671 adjuvant Substances 0.000 description 27
- 150000001413 amino acids Chemical group 0.000 description 26
- 230000028993 immune response Effects 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 description 23
- 238000010367 cloning Methods 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 239000011324 bead Substances 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 19
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 18
- 229940031626 subunit vaccine Drugs 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 238000003259 recombinant expression Methods 0.000 description 15
- 241000283086 Equidae Species 0.000 description 14
- 229920002477 rna polymer Polymers 0.000 description 14
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 241000282465 Canis Species 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 238000007918 intramuscular administration Methods 0.000 description 12
- 239000011534 wash buffer Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 11
- 108010024636 Glutathione Proteins 0.000 description 11
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 108010008038 Synthetic Vaccines Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- -1 immunogens Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 229940124551 recombinant vaccine Drugs 0.000 description 8
- 241000700618 Vaccinia virus Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000282836 Camelus dromedarius Species 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000725578 Equid gammaherpesvirus 2 Species 0.000 description 5
- 241000283074 Equus asinus Species 0.000 description 5
- 241001331845 Equus asinus x caballus Species 0.000 description 5
- 208000000666 Fowlpox Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282832 Camelidae Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010035039 Piloerection Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000005371 pilomotor reflex Effects 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- 229960004854 viral vaccine Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000700663 Avipoxvirus Species 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 241000710886 West Nile virus Species 0.000 description 3
- 241000710951 Western equine encephalitis virus Species 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000013077 scoring method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940023147 viral vector vaccine Drugs 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000178270 Canarypox virus Species 0.000 description 2
- 206010008531 Chills Diseases 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101710188144 Eag protein Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101150017040 I gene Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940118526 interleukin-9 Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 244000000023 zoonotic pathogen Species 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-KVTDHHQDSA-N (2r,3r,4r)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@@H](O)[C@H]1O JNYAEWCLZODPBN-KVTDHHQDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
- UMHYVXGZRGOICM-AUYXYSRISA-N 2-[(z)-octadec-9-enoyl]oxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC\C=C/CCCCCCCC UMHYVXGZRGOICM-AUYXYSRISA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical class CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 101900341263 Borrelia burgdorferi Outer surface protein A Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 108010074124 Escherichia coli Proteins Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001197893 Glyptemys herpesvirus Species 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010060708 Induration Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 108700009548 Lactobacillus sakacin P Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710183187 Major outer membrane lipoprotein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 102100032965 Myomesin-2 Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMETVXNVLXCEFC-UHFFFAOYSA-N Sakacin P Chemical compound NC(=O)C(=O)C(C)NC(=O)OC(C)(C)C VMETVXNVLXCEFC-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 101000792544 Spinacia oleracea Putative uncharacterized protein ycf15 Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001339231 Streptococcus equi subsp. equi Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 101150108190 US2 gene Proteins 0.000 description 1
- 101710116703 Uncharacterized gene 67 protein Proteins 0.000 description 1
- 206010062233 Uterine infection Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 101150042732 aroC gene Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940015418 ketaset Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910001463 metal phosphate Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 101150044129 nirB gene Proteins 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940010310 propylene glycol dioleate Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000030218 transient fever Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56944—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Definitions
- the present invention relates to polypeptides of streptococcal bacteria, more particularly of Streptococcus equi, which may be used to prevent, diagnose and/or treat streptococcal infection.
- Streptococcus equi ( S. equi subsp. equi ) is a gram-positive coccus that has a large capsule.
- S. equi is the causative agent of strangles in equine, canine and Camelids, notably in horses, donkeys, mules, dogs, camels and dromedaries. Strangles is a highly contagious infection of the upper respiratory tract and associated lymph nodes. In equine, the disease is characterized by fever, thick mucopurulent nasal discharge, swelling and abscessation of the submandibular, submaxillary, and retropharyngeal lymph nodes.
- S. equi After infection, S. equi generally has an incubation period 3 to 14 days before the onset of clinical signs. The organism rapidly translocates the mucosa into the lymphatic channels and from there moves to one or more of the regional lymph nodes leading to inflammation and swelling.
- the enlarging lymph nodes soon develop purulent centers with fluctuant liquefaction.
- Submandibular lymph nodes typically rupture externally through the skin, whilst abscesses formed in the retropharyngeal lymph nodes typically rupture into the guttural pouch. This may take up to 2 weeks to occur after the onset of signs.
- Protection against the disease is primarily mediated by antibodies of the IgA and IgG subclasses locally produced in the nasopharynx.
- Serum antibodies to Streptococcus equi can be measured by a variety of assays including ELISA ( Reif et al., Proc. Am. Assoc. Equine Practitioners, 1982, 27, 33-40 ), the mouse protection test ( Bazely P.L., Aust. Vet. J., 1943, 19, 62-85 ), and the gel diffusion precipitin test.
- Bacterin-type vaccines aften cause undesirable local and systemic reactions consisting of edema, induration, stiffness, transient fever, and neutrophilia, effects that are probably due to cell wall peptidoglycan. Furthermore, purpura hemorrhagica can develop after vaccination of horses previously sensitised to streptococcal antigens.
- Streptococcus zooepidemicus ( S. equi subsp. zooepidemicus ) is an important cause of respiratory disease and metritis in equine.
- S. zooepidemicus is an opportunist pathogen that causes purulent respiratory infections of weanling and yearling horses and uterine infections in elderly mares. In the situation of concurrent influenza infection high temperature or transport stress, it can be a devasting and rapid fatal pathogen in the respiratory tract. Although rare, S.
- zooepidemicus is a very serious zoonotic pathogen of Camelids ( Younan M et al., J Vet Med B Infect Dis Vet Public Health, 2005, 52(3): 142-146 ), of humans infected by contact with horses ( Downar J et al., J Clin Microbiol, 2001, 39(6): 2358-2359 ; Ural O et al., Scand J Infect Dis, 2003, 35(3): 206-207 ) and of canine animals having respiratory disease, notably already infected by Bordetella bronchiseptica ( Chalker V J et al., Vet Microbiol, 2003, 95(1-2): 149-156 ).
- S. equi affected mammals may harbor the bacteria for several months in, among other places, the guttoral pouches and, thus, shed and act as reservoirs of S. equi.
- S. equi is quite sensitive to penicillin and other antibiotics, antibiotic treatment is for various reasons mostly ineffective. In order to combat the disease and mitigate serious clinical complications, research has mainly been aimed at developing efficient vaccines.
- WO2004032957 discloses a method for treatment of S. equi infection using SCLC1.
- the document also discloses an ELISA for determining anti-SCLC1 antibody titers in horses with or without a history of previous strangles.
- the disclosure relates to subunit immunogenic or vaccine compositions which may comprise at least one polypeptide of the disclosure; e.g., polypeptides of Streptococcus equi.
- the disclosure therefore further relates to methods for preparing and/or formulating such compositions; e.g., admixing the polypeptides with a suitable veterinary or pharmaceutically acceptable carrier, excipient, diluent or vehicle and/or an adjuvant and/or stabilizer.
- the disclosure also relates to the use of such subunit compositions; e.g., a method for eliciting an immunogenic response or a protective immune response, which may comprise administering the composition to a mammal susceptible to streptococcal infection.
- the disclosure relates to recombinant immunogenic or vaccine compositions which may comprise at least one recombinant expression vector encoding at least one polypeptide of the invention, able to express in vivo this polypeptide in a mammal susceptible to streptococcal infection.
- a immunogenic or vaccine composition which may comprise at least one recombinant expression vector is named a recombinant immunogenic or vaccine composition.
- the disclosure therefore further relates to methods for preparing such vectors, e.g., inserting at least one polynucleotide encoding a polypeptide according to the invention into a plasmid vector or viral vector so that the vector contains and expresses the polynucleotide in the host.
- the disclosure therefore further relates to methods for formulating such recombinant immunogenic or vaccine compositions; e.g., admixing the vectors with a suitable veterinary or pharmaceutically acceptable carrier, excipient, diluent or vehicle and/or an adjuvant and/or stabilizer.
- the disclosure also relates to the use of such recombinant immunogenic or vaccine compositions; e.g., a method for eliciting an immunogenic response or a protective immune response, which may comprise administering the composition to a mammal susceptible to streptococcal infection.
- mammals susceptible to streptococcal infection encompasse equine (i.e. horses, mares, foals, donkeys and mules), camelids (i.e. camels, dromedaries), canine (i.e. dogs, bitchs, puppies), bovine (i.e. cattle, cows, calves), ovine (i.e sheeps, ewes, lambs), caprine (i.e. goats), porcine (i.e. pigs, sows, piglets) and human.
- Mammals susceptible to Streptococcus equi infection encompass equine (i.e. horses, mares, foals, donkeys and mules), camelids (i.e.
- camels, dromedaries camels, dromedaries
- canine i.e. dogs, bitchs, puppies
- Mammals susceptible to Streptococcus zooepidemicus infection encompasse equine (i.e. horses, mares, foals, donkeys and mules), canine (i.e. dogs, bitchs, puppies), Camelids (i.e. camels, dromedaries) and human.
- the disclosure also relates to uses recombinant expression vectors; e.g., a method for producing a polypeptide of the invention, which may comprise culturing, growing or propagating prokaryotic or eucaryotic cells transformed to contain the recombinant expression vectors and to express a polynucleotide encoding the polypeptide under conditions suitable for expression, and harvesting or isolating or separating the polypeptide from cells transformed to express it.
- recombinant expression vectors e.g., a method for producing a polypeptide of the invention, which may comprise culturing, growing or propagating prokaryotic or eucaryotic cells transformed to contain the recombinant expression vectors and to express a polynucleotide encoding the polypeptide under conditions suitable for expression, and harvesting or isolating or separating the polypeptide from cells transformed to express it.
- the disclosure further relates to methods for inducing in an equine, i.e. a horse, a donkey and a mule, an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the equine a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the disclosure.
- an equine i.e. a horse, a donkey and a mule
- an immunogenic or protective immune response against streptococcal bacteria such as Streptococcus equi or Streptococcus zooepidemicus
- the disclosure further relates to methods for inducing in a canine, i.e. a dog, a bitch, a puppy, an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the canine a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the disclosure.
- a canine i.e. a dog, a bitch, a puppy
- an immunogenic or protective immune response against streptococcal bacteria such as Streptococcus equi or Streptococcus zooepidemicus
- the disclosure further relates to methods for inducing in a Camelid, i.e. a camel, a dromedary, an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the Camelid a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the invention.
- a Camelid i.e. a camel, a dromedary, an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus
- the disclosure further relates to methods for inducing in a human an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the human a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the disclosure.
- the disclosure relates to a polypeptide having an amino acid sequence coded by a polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23 and 25.
- the invention further relates to a polypeptide having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23 and 25.
- the disclosure relates to a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52.
- the invention further relates to a polypeptide analog having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52.
- the disclosure further relates to a polypeptide fragment, containing at least one epitope, which is a part of a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52 or analogs thereof, and notably a fragment containing at least one epitope selected from the group consisting of polypeptides identified SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58. And, the disclosure relates to uses, compositions and methods involving such polypeptides, analogs thereof or fragments thereof as herein described.
- the disclosure relates to a recombinant expression vector, wherein said vector contains at least one polynucleotide which codes for a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, and combinations thereof.
- the disclosure further relates to a recombinant expression vector, wherein said vector has at least one polynucleotide which codes for a polypeptide analog having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, and combinations thereof.
- the disclosure further relates to a recombinant expression vector, wherein said vector has at least one polynucleotide which codes for a polypeptide fragment, containing at least one epitope which is a part of a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52 or analogs thereof, and notably a fragment selected from the group consisting of polypeptides identified SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58.
- the disclosure relates to a recombinant expression vector, wherein said vector has at least one polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23, 25, 31, 33, 35, 37, 39, 47, 49, 51, 53, 55 and 57, and combinations thereof.
- the disclosure further relates to a recombinant expression vector, wherein said vector has at least one polynucleotide having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with a polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23, 25, 31, 33, 35, 37, 39, 47, 49, 51, 53, 55 and 57, and combinations thereof. And, the disclosure relates to uses, compositions and methods involving such vectors as herein described.
- Polynucleotides of the disclosure may be used in hybridization reactions (e.g. Northern or Southern blots, or in nucleic acid microarrays or "gene chips") or in amplification reactions (e.g. polymerase chain reaction or PCR).
- hybridization reactions e.g. Northern or Southern blots, or in nucleic acid microarrays or "gene chips”
- amplification reactions e.g. polymerase chain reaction or PCR
- Polynucleotides according to the disclosure may be prepared in many ways (e.g. by chemical synthesis, from genomic or cDNA libraries, from the streptococcus itself etc.) and may take various forms (e.g. single stranded, double stranded, primers, probes etc.).
- Polynucleotides according to the disclosure may be labeled e.g. with a radioactive or fluorescent label. This is particularly useful as a primer or as a probe.
- polynucleotide includes DNA and RNA, and also their analogues, such as those containing modified backbones.
- an antibody preparation which may comprise at least one antibody specific to a polypeptide of the disclosure.
- This antibody may be polyclonal or monoclonal.
- the antibody preparation may also comprise a fragment of said antibody.
- the disclosure also involves a diagnostic kit for detecting infection by streptococcal bacteria, including at least one polypeptide according to the invention or an antibody preparation which may comprise at least one antibody specific to a polypeptide of the invention.
- the disclosure also involves a diagnostic method for detecting infection by streptococcal bacteria in mammals, which may comprise using a diagnostic kit of the invention and detecting in a sample the polypeptide or an antibody specific to that polypeptide.
- the disclosure further concerns a passive immunization method which may comprise administering the antibody preparation to a mammal susceptible to infection by streptococcal bacteria or infected by streptococcal bacteria.
- the passive immunization method comprises administering the antibody preparation to an equine susceptible to infection by the streptococcal bacterium or infected by the streptococcal bacterium, notably susceptible to infection by Streptococcus equi or infected by Streptococcus equi.
- the present disclosure relates to the identification of polypeptides of Streptococcus equi able, when administered to a mammal, to elicit an immunogenic or immune response, and to the identification of polynucleotides encoding these polypeptides. These polypeptides are useful for the production of subunit immunogenic compositions or subunit vaccines. These polynucleotides are useful for the production of DNA immunogenic compositions, DNA vaccines, recombinant viral vector immunogenic compositions or recombinant viral vector vaccines.
- the disclosure concerns compositions, uses and methods against infections caused by bacteria of the Streptococcal family, notably caused by Streptococcus equi, e.g. strangles disease in equine, camelid, canine and human, and against infections caused by Streptococcus zooepidemicus in equine, camelid, canine and human.
- the disclosure concerns polypeptides, polynucleotides and genes obtained or derived from Streptococcus equi.
- the present invention may relate also to polypeptides, polynucleotides and genes obtained or derived from other streptococci, notably from Streptococcus zooepidemicus, Streptococcus suis, Streptococcus uberis, Streptococcus dysgatactiae, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes.
- a particular aspect of the disclosure is a polypeptide selected from the amino acid sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52.
- Streptococcus equi The whole genome of Streptococcus equi is available in the Sanger database (http://www.sanger.ac.uk/Projects/S_equi/).
- polypeptides are identified as SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52 for Se50, Se1459, Se595, Se528, Se358, Se1631, Se1681 and Sla, respectively.
- a particular aspect of the disclosure is a polynucleotide selected from the nucleotide sequences SEQ ID NOS: 17, 19, 21, 23 and 25.
- the polynucleotides are identified as SEQ ID NOS: 17, 19, 21, 23 and 25 for Se50, Se1459, Se595, Se528 and Se358, respectively.
- complementarity or “complementary” is meant, for the purposes of the specification or claims, a sufficient number in the oligonucleotide of complementary base pairs in its sequence to interact specifically (hybridize) with a target nucleic acid sequence of the gene polymorphism to be amplified or detected. As known to those skilled in the art, a very high degree of complementarity is needed for specificity and sensitivity involving hybridization, although it need not be 100%. Thus, for example, an oligonucleotide that is identical in nucleotide sequence to an oligonucleotide disclosed herein, except for one base change or substitution, may function equivalently to the disclosed oligonucleotides.
- a “complementary DNA” or “cDNA” gene includes recombinant genes synthesized by reverse transcription of messenger RNA ("mRNA").
- a "cyclic polymerase-mediated reaction” refers to a biochemical reaction in which a template molecule or a population of template molecules is periodically and repeatedly copied to create a complementary template molecule or complementary template molecules, thereby increasing the number of the template molecules over time.
- detecttable moiety is meant, for the purposes of the specification or claims, a label molecule (isotopic or non-isotopic) which is incorporated indirectly or directly into an oligonucleotide, wherein the label molecule facilitates the detection of the oligonucleotide in which it is incorporated, for example when the oligonucleotide is hybridized to amplified gene polymorphic sequences.
- “detectable moiety” is used synonymously with “label molecule”.
- Synthesis of oligonucleotides can be accomplished by any one of several methods known to those skilled in the art.
- Label molecules known to those skilled in the art as being useful for detection, include chemiluminescent, fluorescent or luminescent molecules.
- Various fluorescent molecules are known in the art which are suitable for use to label a nucleic acid for the method of the present invention. The protocol for such incorporation may vary depending upon the fluorescent molecule used. Such protocols are known in the art for the respective fluorescent molecule.
- DNA amplification refers to any process that increases the number of copies of a specific DNA sequence by enzymatically amplifying the nucleic acid sequence.
- a variety of processes are known. One of the most commonly used is the polymerase chain reaction (PCR) process of Mullis as described in U.S. Pat. Nos. 4,683,195 and 4,683,202 .
- PCR polymerase chain reaction
- PCR involves the use of a thermostable DNA polymerase, known sequences as primers, and heating cycles, which separate the replicating deoxyribonucleic acid (DNA), strands and exponentially amplify a gene of interest.
- a thermostable DNA polymerase known sequences as primers
- Any type of PCR such as quantitative PCR, RT-PCR, hot start PCR, LAPCR, multiplex PCR, touchdown PCR, etc.
- real-time PCR is used.
- the PCR amplification process involves a cyclic enzymatic chain reaction for preparing exponential quantities of a specific nucleic acid sequence. It requires a small amount of a sequence to initiate the chain reaction and oligonucleotide primers that will hybridize to the sequence.
- extension product of the chain reaction will be a discrete nucleic acid duplex with a termini corresponding to the ends of the specific primers employed.
- enzymatically amplify or “amplify” is meant, for the purposes of the specification or claims, DNA amplification, i.e., a process by which nucleic acid sequences are amplified in number.
- DNA amplification i.e., a process by which nucleic acid sequences are amplified in number.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- RNA ribonucleic acid
- SDA strand displacement amplification
- QßRA Qß replicase amplification
- SSR self-sustained replication
- NASBA nucleic acid sequence-based amplification
- fragment of a molecule such as a protein or nucleic acid is meant to refer to any portion of the amino acid or nucleotide genetic sequence.
- the term “genome” refers to all the genetic material in the chromosomes of a particular organism. Its size is generally given as its total number of base pairs. Within the genome, the term “gene” refers to an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a specific functional product (e.g., a protein or RNA molecule). In general, an animal's genetic characteristics, as defined by the nucleotide sequence of its genome, are known as its "genotype,” while the animal's physical traits are described as its "phenotype.”
- hybridization or “hybridizing,” as used herein, is meant the formation of A-T and C-G base pairs between the nucleotide sequence of a fragment of a segment of a polynucleotide and a complementary nucleotide sequence of an oligonucleotide.
- complementary is meant that at the focus of each A, C, G or T (or U in a ribonucleotide) in the fragment sequence, the oligonucleotide sequenced has a T, G, C or A, respectively.
- the hybridized fragment/ oligonucleotide is called a "duplex.”
- a “hybridization complex”, such as in a sandwich assay, means a complex of nucleic acid molecules including at least the target nucleic acid and a sensor probe. It may also include an anchor probe.
- melting temperature is meant the temperature at which hybridized duplexes dehybridize and return to their single-stranded state. Likewise, hybridization will not occur in the first place between two oligonucleotides, or, herein, an oligonucleotide and a fragment, at temperatures above the melting temperature of the resulting duplex. It is presently advantageous that the difference in melting point temperatures of oligonucleotide-fragment duplexes of this disclosure be from about 1 °C to about 10°C so as to be readily detectable.
- nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof.
- the nucleic acid molecule can be single-stranded or double-stranded, but advantageously is double-stranded DNA.
- DNA refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix.
- This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.
- sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
- An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid.
- a “nucleoside” refers to a base linked to a sugar.
- the base may be adenine (A), guanine (G) (or its substitute, inosine (I)), cytosine (C), or thymine (T) (or its substitute, uracil (U)).
- the sugar may be ribose (the sugar of a natural nucleotide in RNA) or 2-deoxyribose (the sugar of a natural nucleotide in DNA).
- a “nucleotide” refers to a nucleoside linked to a single phosphate group.
- oligonucleotide refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction.
- a short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue.
- Oligonucleotides may be chemically synthesized and may be used as primers or probes.
- Oligonucleotide means any nucleotide of more than 3 bases in length used to facilitate detection or identification of a target nucleic acid, including probes and primers.
- a “polymerase” is an enzyme that catalyzes the sequential addition of monomeric units to a polymeric chain, or links two or more monomeric units to initiate a polymeric chain.
- the "polymerase” will work by adding monomeric units whose identity is determined by and which is complementary to a template molecule of a specific sequence.
- DNA polymerases such as DNA pol 1 and Taq polymerase add deoxyribonucleotides to the 3' end of a polynucleotide chain in a template-dependent manner, thereby synthesizing a nucleic acid that is complementary to the template molecule.
- thermostable polymerases may be used either to extend a primer once or repetitively or to amplify a polynucleotide by repetitive priming of two complementary strands using two primers.
- a "thermostable polymerase” refers to a DNA or RNA polymerase enzyme that can withstand extremely high temperatures, such as those approaching 100°C.
- thermostable polymerases are derived from organisms that live in extreme temperatures, such as Thermus aquaticus. Examples of thermostable polymerases include Taq, Tth, Pfu, Vent, deep vent, UlTma, and variations and derivatives thereof.
- a “polynucleotide” refers to a linear chain of nucleotides connected by a phosphodiester linkage between the 3'-hydroxyl group of one nucleoside and the 5'-hydroxyl group of a second nucleoside which in turn is linked through its 3'-hydroxyl group to the 5'-hydroxyl group of a third nucleoside and so on to form a polymer comprised of nucleosides linked by a phosphodiester backbone.
- a “modified polynucleotide” refers to a polynucleotide in which one or more natural nucleotides have been partially,substantially, or completely replaced with modified nucleotides.
- a “primer” is an oligonucleotide, the sequence of at least of portion of which is complementary to a segment of a template DNA which is to be amplified or replicated.
- primers are used in performing the polymerase chain reaction (PCR).
- a primer hybridizes with (or “anneals” to) the template DNA and is used by the polymerase enzyme uses as the starting point for the replication/amplification process.
- the primers herein are selected to be “substantially” complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template.
- a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand.
- non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.
- Probes refer to oligonucleotides nucleic acid sequences of variable length, used in the detection of identical, similar, or complementary nucleic acid sequences by hybridization.
- An oligonucleotide sequence used as a detection probe may be labeled with a detectable moiety.
- polynucleotides a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers.
- a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracil, other sugars and linking groups such as fluororibose and thiolate, and nucleotide branches.
- sequence of nucleotides may be further modified after polymerization, such as by conjugation, with a labeling component.
- modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides or solid support.
- an “isolated" polynucleotide or polypeptide is one that is substantially pure of the materials with which it is associated in its native environment. By substantially free, is meant at least 50%, at least 55%, at least 60%, at least 65%, at advantageously at least 70%, at least 75%, more advantageously at least 80%, at least 85%, even more advantageously at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, most advantageously at least 98%, at least 99%, at least 99.5%, at least 99.9% free of these materials.
- nucleic acid molecule is a nucleic acid molecule separate and discrete from the whole organism with which the molecule is found in nature; or a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences (as defined below) in association therewith.
- polynucleotide encoding a protein refers to a DNA fragment or isolated DNA molecule encoding a protein, or the complementary strand thereto; but, RNA is not excluded, as it is understood in the art that thymidine (T) in a DNA sequence is considered equal to uracil (U) in an RNA sequence.
- RNA sequences for use in the invention e.g., for use in RNA vectors, can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.
- a DNA "coding sequence” or a “nucleotide sequence encoding" a particular protein is a DNA sequence which is transcribed and translated into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory elements. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus.
- a coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences.
- a transcription termination sequence will usually be located 3' to the coding sequence.
- “Homology” refers to the percent identity between two polynucleotide or two polypeptide moieties.
- Two DNA, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, preferably at least about 90%, 91%, 92%, 93%, 94% and most preferably at least about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% sequence identity over a defined length of the molecules.
- substantially homologous also refers to sequences showing complete identity (100% sequence identity) to the specified DNA or polypeptide sequence.
- Homology can be determined by hybridization of polynucleotides under conditions that form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments.
- DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al. supra; DNA Cloning, supra; Nucleic Acid Hybridization, supra.
- Two nucleic acid fragments are considered to be "selectively hybridizable" to a polynucleotide if they are capable of specifically hybridizing to a nucleic acid or a variant thereof or specifically priming a polymerase chain reaction: (i) under typical hybridization and wash conditions, as described, for example, in Sambrook et al.
- hybridizing under stringent conditions refers to annealing a first nucleic acid to a second nucleic acid under stringent conditions as defined below.
- Stringent hybridization conditions typically permit the hybridization of nucleic acid molecules having at least 70% nucleic acid sequence identity with the nucleic acid molecule being used as a probe in the hybridization reaction.
- the first nucleic acid may be a test sample or probe
- the second nucleic acid may be the sense or antisense strand of a nucleic acid or a fragment thereof.
- Hybridization of the first and second nucleic acids may be conducted under stringent conditions, e.g., high temperature and/or low salt content that tend to disfavor hybridization of dissimilar nucleotide sequences.
- hybridization of the first and second nucleic acid may be conducted under reduced stringency conditions, e.g. low temperature and/or high salt content that tend to favor hybridization of dissimilar nucleotide sequences.
- Low stringency hybridization conditions may be followed by high stringency conditions or intermediate medium stringency conditions to increase the selectivity of the binding of the first and second nucleic acids.
- the hybridization conditions may further include reagents such as, but not limited to, dimethyl sulfoxide (DMSO) or formamide to disfavor still further the hybridization of dissimilar nucleotide sequences.
- reagents such as, but not limited to, dimethyl sulfoxide (DMSO) or formamide to disfavor still further the hybridization of dissimilar nucleotide sequences.
- a suitable hybridization protocol may, for example, involve hybridization in 6 x SSC (wherein 1 x SSC comprises 0.015 M sodium citrate and 0.15 M sodium chloride), at 65° Celsius in an aqueous solution, followed by washing with 1 x SSC at 65° C.
- Formulae to calculate appropriate hybridization and wash conditions to achieve hybridization permitting 30% or less mismatch between two nucleic acid molecules are disclosed, for example, in Meinkoth et al. (1984) Anal. Biochem. 138: 267-284 .
- stringent conditions will be those in which the salt concentration is less than about 1.5 M sodium ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) from about pH 7.0 to about pH 8.3 and the temperature is at least about 30° Celsius for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C for long probes (e.g., greater than 50 nucleotides).
- Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
- Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37° Celsius, and a wash in 1-2 x SSC at 50 to 55° Celsius.
- Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37° Celsius, and a wash in 0.5-1 x SSC at 55 to 60° Celsius.
- Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37° Celsius, and a wash in 0.1 x SSC at 60 to 65° Celsius.
- fragments of polypeptide selected from the sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52. Fragments of polypeptide and epitope determination procedures, such as, generating overlapping peptide libraries ( Hemmer B. et al., Immunology Today, 1998, 19 (4), 163-168 ), Pepscan ( Geysen H. M. et al., Proc. Nat. Acad. Sci. USA, 1984, 81 (13), 3998-4002 ; Geysen H. M. et al., Proc. Nat. Acad. Sci. USA, 1985, 82 (1), 178-182 ; Van der Zee R. et al., Eur. J.
- polypeptides or fragments thereof are produced advantageously by in vitro expression.
- Another aspect of the disclosure is the use of the polynucleotides according to the invention, for the expression and the production of peptides, polypeptides or proteins, or more generally, expression products, e.g., immunogens, antigens or epitopes.
- the polypeptides or peptides or proteins encoded by these polynucleotides may be used as subunit immunogens or antigens or epitopes in immunogenic compositions or vaccines.
- the disclosure also embraces the immunogenic fragments of these polypeptides, having at least a chain of 8 amino acids of the polypeptide, at least 10, at least 20, such as at least 30, advantageously at least 50 and more advantageously at least 70, e.g., fragments of the polypeptides containing at least 8 contiguous amino acids of the polypeptide, at least 10 contiguous amino acids of the polypeptide, advantageously at least 20, such as at least 30 and more advantageously at least 50 contiguous amino acids of the polypeptide, and even more advantageously at least 70 contiguous amino acids of the polypeptide.
- a fragment is less than the entire polypeptide.
- a fragment can be combined with other polypeptides, e.g., in fusion polypeptides; for instance, a polypeptide of the disclosure or fragment thereof can be a portion of a fusion polypeptide which includes another portion (another polypeptide) (i.e. fused to glutathione S-transferase gene (GST) ( Chanter N et al., Microb.
- GST glutathione S-transferase gene
- an immunogenicity-enhancing portion and/or a secretion-enhancing portion such as a lipoprotein portion that enhances immunogenicity, such as a T-cell epitope peptide or a signal or leader sequence portion.
- the disclosure envisions the expression of polypeptides, proteins, antigens, immunogens or epitopes - whether herein identified sequences or fragments thereof or those that are heterologous to the vectors of the disclosure as fusions, e.g., as a portion of a fusion polypeptide, e.g., a fusion polypeptide that advantageously includes an immuogenicity enhancing portion such as a lipoprotein portion and/or a secretion-enhancing portion such as a signal or leader sequence portion.
- fusions e.g., as a portion of a fusion polypeptide, e.g., a fusion polypeptide that advantageously includes an immuogenicity enhancing portion such as a lipoprotein portion and/or a secretion-enhancing portion such as a signal or leader sequence portion.
- the term "antigen” or “immunogen” means a substance that induces a specific immune response in a host animal.
- the antigen may comprise a whole organism, killed, attenuated or live; a subunit or portion of an organism; a recombinant vector containing an insert with immunogenic properties; a piece or fragment of DNA capable of inducing an immune response upon presentation to a host animal; a protein, a polypeptide, a peptide, an epitope, a hapten, or any combination thereof.
- the immunogen or antigen may comprise a toxin or antitoxin.
- immunological protein or peptide also refers includes peptides and polypeptides that are immunologically active in the sense that once administered to the host, it is able to evoke an immune response of the humoral and/or cellular type directed against the protein.
- the protein fragment is such that it has substantially the same immunological activity as the total protein.
- a protein fragment according to the disclosure comprises or consists essentially of or consists of at least one epitope or antigenic determinant.
- epitope relates to a protein site able to induce an immune reaction of the humoral type (B cells) and/or cellular type (T cells).
- immunological response as defined herein.
- particularly preferred substitutions will generally be conservative in nature, i.e., those substitutions that take place within a family of amino acids.
- amino acids are generally divided into four families: (1) acidic--aspartate and glutamate; (2) basic--lysine, arginine, histidine; (3) non-polar--alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar--glycine, asparagine, glutamine, cystine, serine threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids.
- epitope refers to the site on an antigen or hapten to which specific B cells and/or T cells respond.
- the term is also used interchangeably with "antigenic determinant” or "antigenic determinant site”.
- Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.
- an "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest.
- an "immunological response” includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest.
- the host will display either a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered viral titer in the infected host.
- immunogenic protein or polypeptide as used herein also refers to an amino acid sequence which elicits an immunological response as described above.
- immunogenic fragment is meant a fragment of a protein which includes one or more epitopes and thus elicits the immunological response described above. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N.J .
- linear epitopes may be determined by e.g ., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports.
- Such techniques are known in the art and described in, e.g., U.S. Pat. No. 4,708,871 ; Geysen et al. (1984) Proc. Natl. Acad. Sci. USA 81:3998-4002 ; Geysen et al. (1986) Molec. Immunol. 23:709-715 .
- conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g ., x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra.
- Synthetic antigens are also included within the definition, for example, polyepitopes, flanking epitopes, and other recombinant antigens. See, e.g., Bergmann et al. (1993) Eur. J. Immunol. 23:2777-2781 ; Bergmann et al. (1996) J. Immunol. 157:3242-3249 ; Suhrbier, A. (1997) Immunol. and Cell Biol. 75:402-408 ; Gardner et al. (1998) 12th World AIDS Conference, Geneva, Switzerland, Jun. 28-Jul. 3, 1998 .
- Immunogenic fragments for purposes of the present invention, will usually include at least about 3 amino acids, preferably at least about 5 amino acids, more preferably at least about 10-15 amino acids, and most preferably 25 or more amino acids, of the molecule. There is no critical upper limit to the length of the fragment, which could comprise nearly the full-length of the protein sequence, or even a fusion protein comprising at least one epitope of the protein.
- a minimum structure of a polynucleotide expressing an epitope is that it comprises or consists essentially of or consists of nucleotides to encode an epitope or antigenic determinant of the protein or polyprotein of interest.
- a polynucleotide encoding a fragment of the total protein or polyprotein more advantageously, comprises or consists essentially of or consists of a minimum of 21 nucleotides, advantageously at least 42 nucleotides, and preferably at least 57, 87 or 150 consecutive or contiguous nucleotides of the sequence encoding the total protein or polyprotein.
- Epitope determination procedures such as, generating overlapping peptide libraries ( Hemmer B.
- the fragments of polypeptide are selected from the sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, which are respectively encoded by the nucleotide sequences SEQ ID NOS: 31, 33, 35, 37, 39, 53, 55 and 57.
- the fragments of polypeptides SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58 are part of Se50, Se1459, Se595, Se528, Se358, Se1631, Se1681 and Sla, respectively.
- polynucleotides encoding polypeptides according to the present invention, analogs thereof or fragments thereof are inserted into a vector, linked to regulatory elements such as promoter, ribosome binding region and terminator, and start codon and stop codon.
- the polypeptides, analogs thereof and fragments thereof can be produced by in vitro expression in host cells.
- the in vitro expression vectors are expression vectors used for the in vitro expression of proteins in an appropriate cell system. This can be produced in prokaryotic host cells, i.e. in Escherichia coli ( Mahona F et al., Biochimie 1994, 46(1): 9-14 ; Watt M A et al., Cell Stress Chaperones 1997, 2(3): 180-90 ; Frey J Res. Microbiol. 1992, 143(3): 263-9 ) or in Lactobacillus ( Seegers J F, Trends Biotechnol.
- BL21(DE3) strain Novagen or Invitrogen; see Hedayati M A et al., Protein Expr Purif, 2005, 43(2): 133-139
- Origami2(DE3) strain Novagen or Invitrogen
- Y1089 Galan J E et al., Infect Immun, 1987, 55(12): 3181-3187
- Vectors are advantageously plasmids, i.e. pGEX plasmids (GE Healthcare), pET plasmids (Novagen or Invitrogen) ( Jiang X Y et al., J Biochem Mol Biol.
- Vectors can also be a virus, notably a bacteriophage, i.e. lambda-gt11 phage ( Galan J E et al., Infect Immun, 1987, 55(12): 3181-3187 ).
- Another approach is to use fused genes for the production of chimeric proteins between a Streptococcus protein and a Escherichia coli protein, notably lipoprotein ( Cullen P A et al., Plasmid, 2003, 49(1): 18-29 ), or with GST ( Zhao G et al., Protein Expr Purif, 1999, 16(2): 331-339 ).
- the Streptococcal insert can be linked to promoter, i.e. bacteriophage T7 promoter ( Yamamoto M et al., FEMS Microbiol Lett, 1995, 132(3): 209-213 ), signal peptide sequence, i.e.
- Lactobacillus different strains can be used, notably Lactobacillus brevis, Lactobacillus plantarum, Lactobacillus casei ( Seegers J F, Trends Biotechnol., 2002, 20(12): 508-515 ). Promoters and regulatory genes involved in production of sakacin P are suitable for establishing inducible high-level gene expression in Lactobacillus ( Mathiesen G et al., Lett Appl Microbiol., 2004, 39(2): 137-143 ), or lactose operon promoter ( Oliveira M L et al., FEMS Microbiol Lett., 2003, 227(1): 25-31 ).
- Another approach is to use fused genes for the production of chimeric proteins between a Lactobacillus protein and a Streptococcus protein ( Hung J et al., FEMS Microbiol Lett., 2002, 211(1): 71-75 ).
- vectors are advantageously viruses, i.e. baculoviruses (see, e.g., U.S. Patent No. 4,745,051 ; Vialard J. et al., J. Virol., 1990 64 (1), 37-50 ; Verne A., Virology, 1988, 167, 56-71 ; Oker-Blom C et al., Brief Funct Genomic Proteomic. 2003, 2(3), 244-253 ), e.g. Autographa californica Nuclear Polyhedrosis Virus AcNPV, and insect cells are Sf9 Spodoptera frugiperda cells (ATCC CRL 1711; see also U.S.
- Patents Nos. 6,228,846 , 6,103,526 Protein production can take place by the transfection of mammalian cells by plasmids, by replication or expression without productive replication of viral vectors on mammal cells or avian cells.
- Mammalian cells which can be used are advantageously hamster cells (e.g. CHO or BHK-21) or monkey cells (e.g. COS or VERO) or bovine cells (e.g. MDBK), i.e. culture of EHV-1 vectors in MDBK cells ( Wheat el S M et al., Microbiol.
- a "host cell” denotes a prokaryotic or eukaryotic cell that has been genetically altered, or is capable of being genetically altered by administration of an exogenous polynucleotide, such as a recombinant plasmid or vector.
- an exogenous polynucleotide such as a recombinant plasmid or vector.
- genetically altered cells the term refers both to the originally altered cell and to the progeny thereof.
- the in vitro expression vectors can be introduced into a suitable host cell for replication and amplification.
- the vectors containing the polynucleotides of interest can be introduced into the host cell by any of a number of appropriate means, including direct uptake, endocytosis, transfection, f-mating, electroporation, transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (where the vector is infectious, for instance, a retroviral vector).
- the choice of introducing vectors or polynucleotides will often depend on features of the host cell.
- the expressed proteins can be harvested in or from the culture supernatant after, or not after secretion (if there is no secretion a cell lysis typically occurs or is performed), optionally concentrated by concentration methods such as ultrafiltration and/or purified by purification means, such as affinity, ion exchange or gel filtration-type chromatography methods, notably by affinity chromatography, i.e. using Ni NTA Superflow (Qiagen) or Ni Sepharose fastflow (Amersham), or by gel-filtration, i.e. using Sephacryl® or Superdex® (Amersham GE Healthcare).
- concentration methods such as ultrafiltration and/or purified by purification means, such as affinity, ion exchange or gel filtration-type chromatography methods, notably by affinity chromatography, i.e. using Ni NTA Superflow (Qiagen) or Ni Sepharose fastflow (Amersham), or by gel-filtration, i.e. using Sephacryl® or Superdex® (Amersham GE Healthcare).
- polypeptides and fragments thereof can also be obtained by extraction, notably acid extraction or mutanolysin extraction ( Boschwitz J S et al., Cornell Vet., 1991, 81(1): 25-36 ), and purification, notably immunoprecipitation ( Erickson E D et al., Can J Comp Med., 1975, 39(2): 110-115 ), from crude culture of streptococcal bacteria, notably of Streptococcus equi.
- polypeptides and fragments thereof can also be synthesised chemically ( Luo Y et al., Vaccine 1999, 17(7-8): 821-31 ).
- subunit vaccine composition is meant a composition containing at least one immunogenic polypeptide or a polynucleotide able to express at least one, but not all, antigen derived from or homologous to an antigen from a pathogen of interest. Such a composition is substantially free of intact pathogen cells or particles, or the lysate of such cells or particles.
- a “subunit vaccine composition” is prepared from at least partially purified (preferably substantially purified) immunogenic polypeptides from the pathogen, or recombinant analogs thereof.
- a subunit vaccine composition can comprise the subunit antigen or antigens of interest substantially free of other antigens or polypeptides from the pathogen.
- An object of the disclosure is a subunit immunogenic composition or subunit vaccine comprising at least one polypeptide, analog thereof or fragment thereof according to the disclosure, and a pharmaceutically acceptable excipient, diluent or vehicle, and optionally an adjuvant and/or a stabilizer.
- the subunit immunogenic or vaccine composition can comprise at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof, or fragments thereof.
- the subunit immunogenic or vaccine composition can advantageously comprise two or three or four or five polypeptides selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof, or fragments thereof.
- the subunit immunogenic or vaccine composition can comprise at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- the subunit immunogenic or vaccine composition can advantageously comprise two or three or four or five polypeptides selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- Another object of the disclosure is a recombinant immunogenic composition or vaccine comprising at least one recombinant in vivo expression vector, and a pharmaceutically acceptable excipient, diluent or vehicle, and optionally an adjuvant and/or a stabilizer.
- the recombinant in vivo expression vectors are vectors comprising polynucleotides or their fragments inserted hereinto and able to express in vivo in the targeted mammal the polypeptide encoded by this polynucleotide or fragment thereof.
- the vectors can be a polynucleotide vectors or plasmids ( EP-A2-1001025 ; Chaudhuri P Res. Vet. Sci.
- herpesvirus such as equine herpesvirus type 1 ( Trapp S et al., J. Virol. 2005, 79(9): 5445-5454 ), equine herpesvirus type 2, equine herpesvirus type 4; poxvirus virus such as vaccinia virus or avipox virus, like fowlpox ( US-A-5,174,993 US-A-5,505,941 and US-A-5,766,599 ) or canarypox ( US-A-5,756,103 ); adenovirus such as human adenovirus ( Chroboczek J et al., Virol.
- herpesvirus such as equine herpesvirus type 1 ( Trapp S et al., J. Virol. 2005, 79(9): 5445-5454 ), equine herpesvirus type 2, equine herpesvirus type 4; poxvirus virus such as vaccinia virus or avipox
- encephalitis virus such as venezuelean equine encephalitis virus ( Pushko P et al. Virol. 1997, 239: 389-401 ; Davis N L et al. J. Virol. 2000, 74: 371-378 )) for recombinant viral vector immunogenic compositions and recombinant viral vector vaccines.
- the polynucleotides or their fragments may be inserted into recombinant in vivo expression bacterial vectors, notably into Salmonella, to produce live recombinant bacterial immunogenic compositions or vaccines.
- plasmid covers any DNA transcription unit comprising a polynucleotide according to the invention and the elements necessary for its in vivo expression in a cell or cells of the desired host or target; and, in this regard, it is noted that a supercoiled or non-supercoiled, circular plasmid, as well as a linear form, are intended to be within the scope of the invention.
- the pVR1020 or 1012 plasmid VICAL Inc.; Luke C. et al., Journal of Infectious Diseases, 1997, 175, 91-97 ; Hartikka J.
- the pVR1020 plasmid is derived from pVR1012 and contains the human tPA signal sequence.
- Each plasmid comprises or contains or consists essentially of, in addition to the polynucleotide or analog thereof or fragment thereof, operably linked to a promoter or under the control of a promoter or dependent upon a promoter. In general, it is advantageous to employ a strong promoter functional in eukaryotic cells.
- the preferred strong promoter is the immediate early cytomegalovirus promoter (CMV-IE) of human or murine origin, or optionally having another origin such as the rat or guinea pig.
- CMV-IE promoter can comprise the actual promoter part, which may or may not be associated with the enhancer part.
- EP-A-260 148 EP-A-323 597
- U.S. Patents Nos. 5,168,062 , 5,385,839 , and 4,968,615 as well as to PCT Application No WO-A-87/03905 .
- the CMV-IE promoter is advantageously a human CMV-IE ( Boshart M.
- the promoter has either a viral or a cellular origin.
- a strong viral promoter other than CMV-IE that may be usefully employed in the practice of the invention is the early/late promoter of the SV40 virus or the LTR promoter of the Rous sarcoma virus.
- a strong cellular promoter that may be usefully employed in the practice of the invention is the promoter of a gene of the cytoskeleton, such as e.g. the desmin promoter ( Kwissa M. et al., Vaccine, 2000, 18, 2337-2344 ), or the actin promoter ( Miyazaki J.
- a promoter in the practice of the invention consequently includes derivatives and sub fragments of a full-length promoter that maintain an adequate promoting activity and hence function as a promoter, preferably promoting activity substantially similar to that of the actual or fulllength promoter from which the derivative or sub fragment is derived, e.g., akin to the activity of the truncated CMV-IE promoters of U.S. Patent No. 6,156,567 to the activity of full-length CMV-IE promoters.
- a CMV-IE promoter in the practice of the invention can comprise or consist essentially of or consist of the promoter portion of the full-length promoter and/or the enhancer portion of the full-length promoter, as well as derivatives and sub fragments.
- the plasmids comprise or consist essentially of other expression control elements. It is particularly advantageous to incorporate stabilizing sequence(s), e.g., intron sequence(s), preferably the first intron of the hCMV-IE ( PCT Application No. WO-A-89/01036 ), the intron II of the rabbit ⁇ -globin gene ( van Ooyen et al., Science, 1979, 206, 337-344 ).
- polyA polyadenylation signal
- Attenuated strains i.e. EHV-1 KyA strains ( Zhang Y et al., Virology, 2000, 268(2): 482-492 )
- attenuated by mutation or deletion of genes involve in pathogenicity ( Kirisawa R et al., Vet. Microbiol., 2003, 95(3): 159-174 ) or by serial culture passages ( US-A-4,110,433 )
- the insertion can be made in the intergenic region between ORF 62 and ORF 63 ( Wheat el S M et al., Microbiol.
- the insertion can be made in glycoprotein I gene and glycoprotein E gene ( Damiani A M et al., Virus Res., 2000, 67(2): 189-202 ), in US2 or TK or glycoprotein E gene ( US-A-5,741,696 ; US-A-5,731,188 ), eventually after a partial or complete deletion of the genes.
- the polynucleotide to be expressed is inserted under the control of a promoter functional in eukaryotic cells, advantageously a CMV-IE promoter (murine or human).
- a poly(A) sequence and terminator sequence can be inserted downstream the polynucleotide to be expressed, e.g. bovine growth hormone or a rabbit ⁇ -globin gene polyadenylation signal.
- a vaccinia virus or an attenuated vaccinia virus for instance, MVA, a modified Ankara strain obtained after more than 570 passages of the Ankara vaccine strain on chicken embryo fibroblasts; see Stickl & Hochstein-Mintzel, Munch. Med. Wschr., 1971, 113, 1149-1153 ; Sutter et al., Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 10847-10851 ; available as ATCC VR-1508; or NYVAC, see U.S. Patent No. 5,494,807 , for instance, Examples 1 to 6 and et seq of U.S.
- MVA a modified Ankara strain obtained after more than 570 passages of the Ankara vaccine strain on chicken embryo fibroblasts
- Sutter et al. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 10847-10851 ; available as ATCC VR-1508
- Patent No. 5,494,807 which discuss the construction of NYVAC, as well as variations of NYVAC with additional ORFs deleted from the Copenhagen strain vaccinia virus genome, as well as the insertion of heterologous coding nucleic acid molecules into sites of this recombinant, and also, the use of matched promoters; see also WO-A-96/40241 ), an avipox virus or an attenuated avipox virus (e.g., canarypox, fowlpox, dovepox, pigeonpox, quailpox, ALVAC or TROVAC; see, e.g., U.S. Patent No.
- an avipox virus or an attenuated avipox virus e.g., canarypox, fowlpox, dovepox, pigeonpox, quailpox, ALVAC or TROVAC; see, e.g.
- Attenuated canarypox viruses are described in U.S. Patent No. 5,756,103 (ALVAC) and WO-A-01/05934 . Reference is also made to U.S. Patent No. 5,766,599 which pertains to the attenuated fowlpox strain TROVAC. Reference is made to the canarypox available from the ATCC under access number VR-111. Numerous fowlpox virus vaccination strains are also available, e.g. the DIFTOSEC CT strain marketed by MERIAL and the NOBILIS VARIOLE vaccine marketed by INTERVET.
- insertion site or sites for the polynucleotide or polynucleotides to be expressed are advantageously at the thymidine kinase (TK) gene or insertion site, the hemagglutinin (HA) gene or insertion site, the region encoding the inclusion body of the A type (ATI); see also documents cited herein, especially those pertaining to vaccinia virus.
- TK thymidine kinase
- HA hemagglutinin
- ATI inclusion body of the A type
- the insertion site or sites are ORF(s) C3, C5 and/or C6; see also documents cited herein, especially those pertaining to canarypox virus.
- the insertion site or sites are ORFs F7 and/or F8; see also documents cited herein, especially those pertaining to fowlpox virus.
- the insertion site or sites for MVA virus area advantageously as in various publications, including Carroll M. W. et al., Vaccine, 1997, 15 (4), 387-394 ; Stittelaar K. J. et al., J. Virol., 2000, 74 (9), 4236-4243 ; Sutter G.
- the polynucleotide to be expressed is inserted under the control of a specific poxvirus promoter, e.g., the vaccinia promoter 7.5 kDa ( Cochran et al., J. Virology, 1985, 54, 30-35 ), the vaccinia promoter I3L ( Riviere et al., J.
- the vaccinia promoter HA Shida, Virology, 1986, 150, 451-457
- the cowpox promoter ATI Funahashi et al., J. Gen. Virol., 1988, 69, 35-47
- the vaccinia promoter H6 Taylor J. et al., Vaccine, 1988, 6, 504-508 ; Guo P. et al. J. Virol., 1989, 63, 4189-4198 ; Perkus M. et al., J. Virol., 1989, 63, 3829-3836 ), inter alia.
- a human adenovirus for recombinant vector based on adenovirus vector, a human adenovirus (HAV), advantageously, a human adenovirus serotype 5 (Ad5) vector, an E1-deleted and/or disrupted adenovirus, an E3-deleted and/or disrupted adenovirus or an E1- and E3-deleted and/or disrupted adenovirus can be used.
- E4 may be deleted and/or disrupted from any of the adenoviruses described above.
- the viral vector is a human adenovirus, in particular a serotype 5 adenovirus, rendered incompetent for replication by a deletion in the E1 region of the viral genome.
- the deleted adenovirus is propagated in E1-expressing 293 cells or PER cells, in particular PER.C6 ( F. Falloux et al Human Gene Therapy 1998, 9, 1909-1917 ).
- the human adenovirus can be deleted in the E3 region eventually in combination with a deletion in the E 1 region (see, e.g. J.shriver et al. Nature, 2002, 415, 331-335 , F. Graham et al Methods in Molecular Biology Vol .7: Gene Transfer and Expression Protocols Edited by E. Murray, The Human Press Inc, 1991, p 109-128 ; Y. Ilan et al Proc. Natl. Acad. Sci. 1997, 94, 2587-2592 ; S. Tripathy et al Proc. Natl. Acad. Sci. 1994, 91, 11557-11561 ; B. Tapnell Adv. Drug Deliv.
- the insertion sites can be the E1 and/or E3 loci eventually after a partial or complete deletion of the E1 and/or E3 regions.
- the polynucleotide to be expressed is inserted under the control of a promoter functional in eukaryotic cells, such as a strong promoter, preferably a cytomegalovirus immediate-early gene promoter (CMV-IE promoter).
- CMV-IE promoter is advantageously of murine or human origin.
- the promoter of the elongation factor 1 ⁇ can also be used.
- a muscle specific promoter can also be used ( X. Li et al Nat. Biotechnol. 1999, 17, 241-245 ). Strong promoters are also discussed herein in relation to plasmid vectors.
- a poly(A) sequence and terminator sequence can be inserted downstream of the polynucleotide to be expressed, e.g. a bovine growth hormone gene or a rabbit ⁇ -globin gene polyadenylation signal.
- a venezuelean equine encephalitis virus can be used ( Nelson E L et al., Breast Cancer Res. Treat., 2003, 82(3): 169-183 ), in particular as a replicon, that is to say as a self-replicating RNA containing all of the VEEV non-structural genes and a multiple-cloning site in place of the VEEV structural genes ( Lee J S et al., Infect. Immun., 2003, 71(3): 1491-1496 ; Velders M P et al., Cancer Res., 2001, 61(21): 7861-7867 ).
- the polynucleotides to be expressed are inserted into this multiple-cloning site, optionally linked to the nucleotide sequence encoding a secretory sequence or a tissue plasminogen activator secretory sequence.
- the polynucleotides to be expressed can also be inserted downstream of the subgenomic 26S promoter in place of the viral VEEV structural genes ( Lee J S et al., Infect. Immun., 2001, 69(9): 5709-5715 ; Pushko P et al., Vaccine, 2000, 19(1): 142-153 ).
- Salmonella For recombinant vectors based on bacteria, Salmonella, notably Salmonella typhimurium ( Yang X L et al., Biomed. Environ. Sci., 2005, 18(6): 411-418 ; Dunstan S J et al., FEMS Immunol. Med. Microbiol., 2003, 37(2-3): 111-119 ), Salmonella typhi ( Santiago-Machuca A E et al., Plasmid., 2002, 47(2): 108-119 ) can be used.
- the polynucleotides to be expressed can be inserted into the flagellin gene of Salmonella ( Chauhan N et al., Mol Cell Biochem., 2005, 276(1-2): 1-6 ), or into the aroC gene ( Santiago-Machuca A E et al., Plasmid., 2002, 47(2): 108-119 ).
- the polynucleotides to be expressed can also be inserted under the control of the anaerobically inducible nirB promoter ( Santiago-Machuca A E et al., Plasmid., 2002, 47(2): 108-119 ).
- the recombinant immunogenic or vaccine composition can contain at least one recombinant expression vector comprising at least one polynucleotide encoding a polypeptide selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof or fragments thereof.
- the recombinant immunogenic or vaccine composition can contain at least one recombinant expression vector comprising at least one polynucleotide encoding a polypeptide selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- the recombinant immunogenic or vaccine composition can advantageously contain at least one recombinant expression vector comprising at least one polynucleotide encoding two or three or four or five polypeptides selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- the vectors of the disclosure may further comprise at least one heterologous polynucleotide. This is useful for reproducing or replicating heterologous polynucleotides and/or for expression of heterologous polynucleotides, either in vivo or in vitro. Such vectors are also useful for preparing multivalent immunogenic or vaccine compositions, notably multivalent DNA immunogenic compositions or vaccines and multivalent recombinant viral vector immunogenic compositions or vaccines.
- heterologous nucleic acid sequence advantageously codes for an immunogen, antigen or epitope from a pathogenic viral, parasitic or bacterial agent, such bacterial agent is different from the streptococcal bacteria at the origin of the polynucleotides encoding the polypeptides according to the disclosure.
- This heterologous sequence may encode an immunogen, antigen or epitope from western equine encephalitis virus (WEEV), eastern equine encephalitis virus (EEEV), venezuelean equine encephalitis virus (VEEV), equine influenza virus, equine herpesvirus type 1 (EHV-1), equine herpesvirus type 2 (EHV-2), equine herpesvirus type 4 (EHV-4), Equine Artheritis virus (EAV), West Nile virus (WNV), tetanus, rhodococcus.
- WEEV western equine encephalitis virus
- EEEV eastern equine encephalitis virus
- VEEV venezuelean equine encephalitis virus
- EAV Equine Artheritis virus
- WNV West Nile virus
- tetanus rhodococcus
- the heterologous sequence may encode an immunogen, antigen or epitope from equine influenza virus and from EHV-1 and/or EHV-4.
- An immunogen or antigen is a protein or polypeptide able to induce an immune response against the pathogenic agent or a secreted antigen of the pathogenic agent, and contains one or more epitopes; an epitope is a peptide or polypeptide which is able to induce an immune response against the pathogenic agent or a secreted antigen of the pathogenic agent.
- the subunit immunogenic composition or vaccine of the disclosure can be combined with one or more immunogens, antigens or epitopes selected from other pathogenic micro-organisms or viruses to form a multivalent subunit immunogenic composition or vaccine.
- a multivalent subunit immunogenic composition or vaccine may comprises at least one polypeptide according to the present invention and at least one immunogen, antigen or epitope from WEEV, EEEV, VEEV, equine influenza virus, EHV-1, EHV-4, EAV, WNV, tetanus, rhodococcus.
- such a multivalent subunit immunogenic composition or vaccine may comprises at least one polypeptide according to the present invention and at least one immunogen, antigen or epitope from equine influenza virus and from EHV-1 and/or EHV-4.
- the pharmaceutically or veterinary acceptable excipient, diluent or vehicle may be water or saline, buffer but it may, for example, also comprise Streptococcus culture medium.
- a pharmaceutically or veterinarily acceptable carrier or vehicle or excipient can be a 0.9% NaCl (e.g., saline) solution or a phosphate buffer.
- Other pharmaceutically or veterinarily acceptable carrier or vehicle or excipients that can be used for methods of this disclosure include, but are not limited to, poly-(L-glutamate) or polyvinylpyrrolidone.
- the pharmaceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or combination of compounds facilitating the administration of the vector (or protein expressed from an inventive vector in vitro ); advantageously, the carrier, vehicle or excipient may facilitate transfection and/or improve preservation of the vector (or protein). Doses and dose volumes are herein discussed in the general description and can also be determined by the skilled artisan from this disclosure read in conjunction with the knowledge in the art, without any undue experimentation.
- the cationic lipids containing a quaternary ammonium salt which are advantageously but not exclusively suitable for plasmids, are advantageously those having the following formula: in which R 1 is a saturated or unsaturated straight-chain aliphatic radical having 12 to 18 carbon atoms, R 2 is another aliphatic radical containing 2 or 3 carbon atoms and X is an amine or hydroxyl group, e.g. the DMRIE.
- the cationic lipid can be associated with a neutral lipid, e.g. the DOPE.
- DMRIE N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propane ammonium; WO96/34109
- DOPE dioleoyl-phosphatidyl-ethanol amine
- the plasmid mixture with the adjuvant is formed extemporaneously and advantageously contemporaneously with administration of the preparation or shortly before administration of the preparation; for instance, shortly before or prior to administration, the plasmid-adjuvant mixture is formed, advantageously so as to give enough time prior to administration for the mixture to form a complex, e.g. between about 10 and about 60 minutes prior to administration, such as approximately 30 minutes prior to administration.
- the DMRIE:DOPE molar ratio is advantageously about 95: about 5 to about 5:about 95, more advantageously about 1: about 1, e.g., 1:1.
- the DMRIE or DMRIE-DOPE adjuvant:plasmid weight ratio can be between about 50: about 1 and about 1: about 10, such as about 10: about 1 and about 1:about 5, and advantageously about 1: about 1 and about 1: about 2, e.g., 1:1 and 1:2.
- the immunogenic compositions and vaccines according to the invention may comprise or consist essentially of one or more adjuvants.
- Suitable adjuvants for use in the practice of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl derivative polymers, (2) immunostimulating sequences (ISS), such as oligodeoxyribonucleotide sequences having one ore more non-methylated CpG units ( Klinman et al., Proc. Natl. Acad.
- the oil in water emulsion (3) which is especially appropriate for viral vectors, can be based on: light liquid paraffin oil (European pharmacopoeia type), isoprenoid oil such as squalane, squalene, oil resulting from the oligomerization of alkenes, e.g. isobutene or decene, esters of acids or alcohols having a straight-chain alkyl group, such as vegetable oils, ethyl oleate, propylene glycol, di(caprylate/caprate), glycerol tri(caprylate/caprate) and propylene glycol dioleate, or esters of branched, fatty alcohols or acids, especially isostearic acid esters.
- light liquid paraffin oil European pharmacopoeia type
- isoprenoid oil such as squalane, squalene
- oil resulting from the oligomerization of alkenes e.g. isobutene or
- the oil is used in combination with emulsifiers to form an emulsion.
- the emulsifiers may be nonionic surfactants, such as: esters of on the one hand sorbitan, mannide (e.g. anhydromannitol oleate), glycerol, polyglycerol or propylene glycol and on the other hand oleic, isostearic, ricinoleic or hydroxystearic acids, said esters being optionally ethoxylated, or polyoxypropylene-polyoxyethylene copolymer blocks, such as Pluronic, e.g., L121.
- esters of on the one hand sorbitan mannide (e.g. anhydromannitol oleate), glycerol, polyglycerol or propylene glycol and on the other hand oleic, isostearic, ricinoleic or hydroxystearic acids, said esters being optionally e
- type (1) adjuvant polymers preference is given to polymers of crosslinked acrylic or methacrylic acid, especially crosslinked by polyalkenyl ethers of sugars or polyalcohols. These compounds are known under the name carbomer ( Pharmeuropa, vol. 8, no. 2, June 1996 ).
- carbomer Pharmeuropa, vol. 8, no. 2, June 1996 .
- U.S. Patent No. 2,909,462 which provides such acrylic polymers crosslinked by a polyhydroxyl compound having at least three hydroxyl groups, preferably no more than eight such groups, the hydrogen atoms of at least three hydroxyl groups being replaced by unsaturated, aliphatic radicals having at least two carbon atoms.
- the preferred radicals are those containing 2 to 4 carbon atoms, e.g.
- the unsaturated radicals can also contain other substituents, such as methyl.
- Products sold under the name Carbopol (BF Goodrich, Ohio, USA) are especially suitable. They are crosslinked by allyl saccharose or by allyl pentaerythritol. Among them, reference is made to Carbopol 974P, 934P and 971P.
- EMA Monsanto
- EMA are straight-chain or crosslinked ethylene-maleic anhydride copolymers and they are, for example, crosslinked by divinyl ether. Reference is also made to J. Fields et al., Nature 186: 778-780, June 4, 1960 .
- acrylic or methacrylic acid polymers and EMA are preferably formed by basic units having the following formula: in which:
- These polymers are soluble in water or physiological salt solution (20 g/l NaCl) and the pH can be adjusted to 7.3 to 7.4, e.g., by soda (NaOH), to provide the adjuvant solution in which the expression vector(s) can be incorporated.
- the polymer concentration in the final vaccine composition can range between 0.01 and 1.5% w/v, advantageously 0.05 to 1% w/v and preferably 0.1 to 0.4% w/v.
- the cytokine or cytokines (5) can be in protein form in the immunogenic or vaccine composition, or can be co-expressed in the host with the immunogen or immunogens or epitope(s) thereof. Preference is given to the co-expression of the cytokine or cytokines, either by the same vector as that expressing the immunogen or immunogens or epitope(s) thereof, or by a separate vector therefor.
- the disclosure comprehends preparing such combination compositions; for instance by admixing the active components, advantageously together and with an adjuvant, carrier, cytokine, and/or diluent.
- Cytokines that may be used in the present disclosure include, but are not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), interferon ⁇ (IFN ⁇ ), interferon ⁇ (IFN ⁇ ), interferon ⁇ , (IFN ⁇ ), interleukin-1 ⁇ (IL-1 ⁇ ), interleukin-1 ⁇ (IL-1 ⁇ ), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12 (IL-12), tumor necrosis factor ⁇ (TNF ⁇ ), tumor necrosis factor ⁇ (TNF ⁇ ), and transforming growth factor ⁇ (TGF ⁇ ).
- cytokines can be co-administered and/or sequentially administered with the immunogenic or vaccine composition of the present invention.
- the vaccine of the instant invention can also contain an exogenous nucleic acid molecule that expresses in vivo a suitable cytokine, e.g., a cytokine matched to this host to be vaccinated or in which an immunclogical response is to be elicited (for instance, a canine cytokine for preparations to be administered to dogs).
- compositions and/or formulations according to the invention comprise or consist essentially of or consist of an effective quantity to elicit a therapeutic response of one or more expression vectors and/or polypeptides as discussed herein; and, an effective quantity can be determined from this disclosure, including the documents incorporated herein, and the knowledge in the art, without undue experimentation.
- the recombinant viral vector immunogenic compositions and the recombinant viral vector vaccines according to the invention may be freeze-dried advantageously with a stabiliser. Freeze-drying can be done according to well-known standard freeze-drying procedures.
- the pharmaceutically or veterinary acceptable stabilisers may be carbohydrates (e.g.
- sorbitol, mannitol, lactose, sucrose, glucose, dextran, trehalose), sodium glutamate Tsvetkov T et al., Cryobiology 1983, 20(3): 318-23 ; Israeli E et al., Cryobiology 1993, 30(5): 519-23
- proteins such as peptone, albumin, lactalbumin or casein, protein containing agents such as skimmed milk ( Mills C K et al., Cryobiology 1988, 25(2): 148-52 ; Wolff E et al., Cryobiology 1990, 27(5): 569-75
- buffers e.g. phosphate buffer, alkaline metal phosphate buffer.
- An adjuvant may be used to make soluble the freeze-dried preparations.
- the present disclosure concerns the use of at least one polypeptide having an amino acid sequence as shown in SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof or fragments thereof, for the treatment and/or vaccination of mammals against streptococcal infection, notably of equine, canine and human species.
- these fragments are selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- a particular embodiment concerns the use of at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 32, 34, 36, 38, 40, 48, 50, 52, 54, 56 and 58, or analogs thereof, for the treatment and/or vaccination of equines against strangles disease.
- a preferred embodiment concerns the use of at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof, for the treatment and/or vaccination of equines against strangles disease.
- the fragments are SEQ ID NOS 31 or 32.
- a further embodiment concerns the use of at least one polypeptide having an amino acid sequence as shown in SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof or fragments thereof, for the preparation of a subunit vaccine protecting equine against Strepcoccus equi infection.
- This further embodiment concerns preferrably the use of at least one polypeptide having an amino acid sequence as shown in SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof, for the preparation of a subunit vaccine protecting equine against Strepcoccus equi infection.
- Another further embodiment concerns the use of at least one recombinant vector and of at least one polynucleotide inserted therein coding for a polypeptide having an amino acid sequence as shown in SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or an analog thereof or a fragment thereof, and said vector is able to express in vivo this polypeptide in a mammal susceptible to streptococcal infection, for the preparation of a recombinant vaccine protecting equine against Strepcoccus equi infection.
- This further embodiment concerns preferrably the use of at least one recombinant vector and of at least one polynucleotide inserted therein coding for a polypeptide having an amino acid sequence as shown in SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or an analog thereof, and said vector is able to express in vivo this polypeptide in a mammal susceptible to streptococcal infection, for the preparation of a recombinant vaccine protecting equine against Strepcoccus equi infection.
- An additional embodiment concerns the use of at least one recombinant vector and at least one polynucleotide inserted therein, wherein said polynucleotide has a nucleotide sequence as shown in SEQ ID NOS: 17, 19, 21, 23, 25, 31, 33, 35, 37, 39, 47, 49, 51, 53, 55 and 57, or an analog thereof, and said vector is able to express in vivo the polypeptide encoded by said polynucleotide in a mammal susceptible to streptococcal infection, for the preparation of a recombinant vaccine protecting equine against Strepcoccus equi infection.
- combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of at least one polypeptide selected from a first group of polypeptides consisting of SEQ ID NOS: 18, 20, 22, 24, 26, 32, 34, 36, 38, 40, 48, 50, 52, 54, 56 and 58, or analogs thereof or combinations thereof, and at least one another Streptococcus equi immunogen, which is not present in this first group, notably at least one immunogen selected from a second group of polypeptides consisting of FNZ protein, EAG protein, SFS protein, SEC protein, SFSC1 fragment, FNZN fragment, SEC2.16 fragment, SEC1.18 fragment, SclC1 fragment ( WO-A-2004/032957 ) and SEQ ID NOS: 28, 30 or analogs thereof or fragments thereof, or combinations thereof.
- this first group consists of SEQ ID NOS: 32, 34, 36, 38, 40, 54,56 and 58, or analogs thereof or combinations thereof.
- the present disclosure also concerns the use of these combinations of peptides for the preparation of subunit vaccines protecting equines against Streptococcus equi infection.
- the use of polypeptides may be replaced by the use of recombinant expression vectors according to the present invention comprising at least one polynucleotide encoding said polypeptides.
- At least one recombinant expression vector comprising at least one polynucleotide encoding at least one polypeptide selected from a first group of polypeptides consisting of SEQ ID NOS: 18, 20, 22, 24, 26, 32, 34, 36, 38, 40, 48, 50, 52, 54, 56 and 58, or analogs thereof, and at least one polynucleotide encoding at least one another Streptococcus equi immunogen, which is not present in this first group, notably at least one immunogen selected from a second group of polypeptides consisting of FNZ protein, EAG protein, SFS protein, SEC protein, SFSC1 fragment, FNZN fragment, SEC2.16 fragment, SEC1.18 fragment, SclC1 fragment ( WO-A-2004/032957 ) and SEQ ID NOS: 28, 30 or analogs thereof or fragments thereof, or combinations thereof, are used for the treatment and/or vaccination of equines against strangles disease.
- this first group consists of SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof or combinations thereof.
- the present invention also concerns the use of these recombinant expression vectors for the preparation of recombinant vaccines protecting equines against Streptococcus equi infection.
- the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22 and 26, or analogs thereof, or fragments thereof.
- the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36 and 40, or analogs thereof.
- the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22, 26 and 50, or analogs thereof, or fragments thereof.
- the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36, 40 and 56, or analogs thereof.
- the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22, 26 and 20, or analogs thereof, or fragments thereof.
- the combinations cf polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36, 40 and 34, or analogs thereof.
- the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22, 26 and 18, or analogs thereof, or fragments thereof.
- the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36, 40 and 32, or analogs thereof.
- the present disclosure relates to methods to immunise against or to prevent streptococcal infection in mammals, preferably in equine, canine and in human species.
- a subunit immunogenic composition or vaccine of the present invention or (2) a recombinant immunogenic composition or vaccine of the present disclosure, or their combinations, are administered.
- embodiments of the disclosure may be employed with other vaccines or immunogenic compositions that are not of the invention, e.g., in prime-boost processes, such as where a vaccine or immunogenic composition of the disclosure is administered first and a different vaccine or immunogenic composition is administered thereafter, or vice versa.
- prime-boost processes may be that a subunit vaccine or immunogenic composition of the disclosure is administered first and a recombinant vaccine or immunogenic composition of the invention is administered thereafter, or vice versa.
- the administration may be notably made by intramuscular (IM), intradermal (ID), subcutaneous (SC) or transdermal injection or via intranasal, intratracheal, oral administration, or through the ears or the lip.
- IM intramuscular
- ID intradermal
- SC subcutaneous
- the immunogenic composition or the vaccine according to the disclosure is administered by syringe, a syringe with a microneedle (i.e. BDTM Intradermal Delivery System of Becton, Dickinson and Company, Franklin Lakes, NJ, USA), needleless apparatus (like for example Pigjet, Avijet, Dermojet or Biojector (Bioject, Oregon, USA), see US-A-2006/0034867 ) or a spray.
- BDTM Intradermal Delivery System of Becton, Dickinson and Company Franklin Lakes, NJ, USA
- needleless apparatus like for example Pigjet, Avijet, Dermojet or Biojector (Bioject, Oregon, USA), see US-A-2006
- the administration is preferrably made by IM injection with a syringe, or by transdermal injection with a needleless apparatus or with a syringe with a microneedle (i.e. BDTM Intradermal Delivery System), or by intranasal or oral administration with a spray, i.e. a liquid nebulisation of a vaccine of the invention, or by oral or nasal administration of a micronized powder of a freeze-dried vaccine according to the invention.
- a spray i.e. a liquid nebulisation of a vaccine of the invention
- a micronized powder of a freeze-dried vaccine i.e. a freeze-dried vaccine according to the invention.
- the quantity of immunogenic compositions or vaccines can be determined and optimised by the skilled person, without undue experimentation from this disclosure and the knowledge in the art.
- an animal including a human
- a dose can comprise, consist essentially of or consist of, in general terms, about in 1 ⁇ g to about 2000 ⁇ g, advantageously about 50 ⁇ g to about 1000 ⁇ g and more advantageously from about 100 ⁇ g to about 800 ⁇ g of plasmid expressing the antigen, epitope, immunogen, peptide or polypeptide of interest.
- the dose of plasmid is generally between about 0.1 ⁇ g and 1mg, advantageously between about 1 ⁇ g and 100 ⁇ g, advantageously between about 2 ⁇ g and 50 ⁇ g.
- the dose volumes can be between about 0.1 and about 2 ml, advantageously between about 0.2 and about 1 ml.
- the volume of one single dosage unit by syringe can be between about 0.2 ml and about 5.0 ml and advantageously between about 0.5 ml and about 2.0 ml and more advantageously about 1.0 ml.
- the volume of one single dosage unit by needleless apparatus can be between about 0.1 ml and about 1.0 ml and advantageously between about 0.2 ml and about 0.5 ml.
- the volume of one single dosage unit by liquid spray can be between about 2.0 ml and about 10.0 ml and and advantageously about 5.0 ml (for powder spray, the quantities administered are corresponding to the equivalent volumes).
- foals that is to say horses of 2 to 6 months old and preferably 3 to 4 months old, are vaccinated with subunit vaccines of the present invention, adjuvanted with CTB and/or CTA and/or Carbopol®, via the intranasal or oral route.
- foals are vaccinated with recombinant viral vaccines of the present invention, adjuvanted or not with Carbopol®, via the oral route with a spray and liquid nebulisation.
- the viral vectors of these recombinant viral vaccines are EHV-4 or EHV-2, or EHV-1.
- foals are vaccinated with recombinant viral vaccines of the present invention, via the lips with a syringe.
- the viral vectors of these recombinant viral vaccines are EHV-4 or EHV-2 or EHV-1.
- Boost administrations may be injected every 6 months or annually.
- a boost administration may be injected 2 to 4 weeks before the expected foaling date.
- Polypeptides of the disclosure and fragments thereof may also be used in therapy.
- kits for detecting infection by the streptococcal bacterium.
- Kits e.g. ELISA, can include at least one polypeptide or fragment according to the disclosure (e.g., at least one polypeptide identified by sequence herein or a fragment thereof as herein discussed).
- Antibodies against the herein polypeptides or fragments can be used as a diagnostic reagent or in passive immunization or vaccination or in therapy.
- the amounts of antibody administered in passive immunization can be the same as or analogous to amounts used in the art, such that from the knowledge in the art, the skilled artisan can practice passive immunization without undue experimentation.
- Proteins encoded by the novel viruses of the present disclosure, or their fragments can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with an antigen of the present disclosure, or its fragment, or a mutated antigen. Serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al. (1985) J. Chrom. 348:363-370 . If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known procedures.
- a selected mammal e.g., mouse, rabbit, goat, horse, etc.
- Serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al. (1985) J. Chrom. 348:363
- an antibody preparation comprising an antibody specific to a polypeptide or a fragment according to the disclosure and methods of diagnosis using the same.
- an antibody specific to a polypeptide it is meant that the antibody binds preferentially to the polypeptide, e.g., the antibody binds to the polypeptide and not to other polypeptides or has a specificity to the polypeptide that is acceptably particular to the polypeptide such that the antibody can be used to isolate the polypeptide from a sample or detect its presence in a sample with no more than 5% false positives, using techniques known in the art or discussed in documents cited herein, including Sambrook, infra.
- Antibodies can be polyclonal or monoclonal.
- a selected animal e.g. mouse, rabbit, goat, horse, etc.
- a selected animal e.g. mouse, rabbit, goat, horse, etc.
- Serum from the immunized animal is collected and treated according to known procedures and possibly purified. See, e.g. Jurgens et al. J. Chrom., 1985, 348: 363-370 .
- Monoclonal antibodies to the proteins and to the fragments thereof can also be readily produced by one skilled in the art.
- the general methodology for making monoclonal antibodies by using hybridoma technology is well known.
- Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., Hybridoma Techniques (1980 ); Hammerling et al., Monoclonal Antibodies and T-cell Hybridomas (1981 ); Kennett et al., Alonoclonal Antibodies (1980 ); see also U.S. Pat. Nos.
- Panels of monoclonal antibodies produced against the desired protein, or fragment thereof, can be screened for various properties; i.e., for isotype, epitope, affinity, etc.
- Monoclonal antibodies are useful in purification, using immunoaffinity techniques, of the individual antigens which they are directed against. Both polyclonal and monoclonal antibodies can also be used for passive immunization or can be combined with subunit vaccine preparations to enhance the immune response. Polyclonal and monoclonal antibodies are also useful for diagnostic purposes.
- One embodiment of the disclosure is a method of eliciting an immune response against the antigen, epitope, immunogen, peptide or polypeptide of interest in an animal, comprising administering a formulation for delivery and expression of a recombinant vaccine in an effective amount for eliciting an immune response.
- Still another embodiment of the disclosure is a method of inducing an immunological or protective response in an animal, comprising administering to the animal an effective amount of a formulation for delivery and expression of an antigen, epitope, immunogen, peptide or polypeptide of interest wherein the formulation comprises a recombinant vaccine and a pharmaceutically or veterinarily acceptable carrier, vehicle or excipient.
- the disclosure relates to a method to elicit, induce or stimulate the immune response of an animal, advantageously a mammal or a vertebrate.
- kits for performing a method of inducing an immunological or protective response against an antigen, epitope, immunogen, peptide or polypeptide of interest in an animal comprising a recombinant vaccine and instructions for performing the method of delivery in an effective amount for eliciting an immune response in the animal.
- the IgG antibody responses directed towards Streptococcus equi cell surface proteins in sera taken from ponies intranasally challenged with 4 doses of Streptococcus equi strain 4047 were determined by ELISA. These Streptococcus equi proteins were obtened by in vitro expression in Escherichia coli.
- the antibody responses in sera from the six ponies receiving the higher doses of 3x10 7 and 3x10 5 cfu were averaged and compared to those from ponies challenged with 3000 and 30 cfu of Streptococccus equi 4047.
- Ponies receiving the higher doses developed strangles. Those receiving the low doses remained healthy throughout the study.
- polypeptides of Streptococcus equi were selected for expression in Escherichia coli and for test of efficacy in mice and in ponies.
- Example 2 Expression of recombinant Streptococcus equi polypeptides in Escherichia coli
- Polynucleotides encoding fragments of Se50, Se1459 and Se358 were produced using Vent DNA polymerase (New England Biolabs® Inc.) as per the manufacturers recommended conditions with a 5 minute denaturation step followed by 35 cycles using 30 seconds annealing at 50-55°C, 1 minute extension at 72°C, and 30 second denaturing at 95°C. Products were finished off with a 4-minute 72°C extension.
- the template in each case was Streptococcus equi strain 4047 chromosomal DNA.
- the fragments of Se50, Se1459 and Se358 are those designated as SEQ ID NOS: 32, 34 and 40, respectively.
- Polynucleotides encoding fragments of Se528 and Se595 were produced using the pfu polymerase with same conditions as above apart from the extension time extended to two minutes at 72°C.
- the fragments of Se528 and Se595 are those designated as SEQ ID NOS: 38 and 36, respectively.
- Table 1 Primers used to clone and sequence recombinant subunits.
- PCR products were purified using the Qiaquick PCR purification kit (Qiagen) with a 32 ⁇ l elution volume, then digested with the addition of EcoRI buffer (3.5 ⁇ l) (New England Biolabs® Inc.), BamHI (0.75 ⁇ l) and EcoRI (0.75 ⁇ l) for 2 hours at 37°C. 1 ⁇ g of pGEX-3X plasmid (GE Healthcare) was also digested with EcoRI and BamHI as described above.
- the pGEX-3X plasmids have a multiple cloning site, a tac promoter, glutathione S-transferase gene (GST) and stop codons in all three frames, for the production of GST fusion proteins and their isolation and purification.
- GST glutathione S-transferase gene
- Ligation reactions were set up using 16.5 ⁇ l of purified digested PCR product and 1 ⁇ l of pGEX-3X plasmid with 2 ⁇ l of ligase buffer and 0.5 ⁇ l of ligase, and incubated overnight at room temperature (rtp).
- the ligation reactions were transformed into E.coli DH10B strain and plated onto L-agar plates supplemented with 50 ⁇ g/ml ampicillin and incubated overnight at 37°C. Transformants were tested for the presence of insert by colony PCR. A single colony was resuspended in 4 ⁇ l of water and 2 ⁇ l of this was added to a Taq DNA polymerase PCR reaction containing the appropriate cloning primers for the polynucleotide of interest and a 35 cycle extension was performed as described above (1 minute for Se50, Se1459 and Se358 and 2 minutes for Se595 and Se528). The presence of the desired insert was confirmed by running the PCR reaction on 0.7% TAE agarose gels.
- Plasmids of each of the clones were prepared and sequenced using the 5' and 3' pGEX-3X PCR primers for all of the clones (Table 1). Due to its size, Se595 was also sequenced using the additional primers listed above (Table 1). All of the cloned polynucleotides were confirmed to have the same sequence as the assembled Streptococcus equi strain 4047 genome sequence (http://www.sanger.ac.uk/Projects/S_equi/).
- Clones of Se1459, Se595, Se528, Se50 and Se358 were induced for expression using the following protocol.
- a single colony was inoculated into 50ml 2 x YT culture medium containing 50 ⁇ g/ml ampicillin and was grown overnight with shaking at 220 rpm at 37°C. This culture was then added to 500ml of pre-warmed (37°C) and pre-gassed 2 x YT and incubated for 1 hour at 37°C.
- IPTG isopropyl-beta-D-thiogalactopyranoside
- the pellets were resuspended in 20ml of ice cold PBS (Oxoid Limited, catalog # BR0014G), PMSF (Phenylmethyl sulphonyl fluoride) was added to a final concentration of 0.1mM and the cells were lysed by sonication on ice with 6x10 second pulses with a 10 second rest between each pulse. Triton X-100 was added to 0.1% (v/v) and the insoluble and intact cells were removed by centrifugation (11,000g, 5 min 4°C). Samples of the soluble bacterial lysate and insoluble material were analysed by SDS-PAGE.
- PMSF Phenylmethyl sulphonyl fluoride
- DTT dithiothreitol; Cleland's reagent
- 5mM glutathione sepharose 4B
- the mixture was incubated at room temperature for 1 hour and then the beads were collected by centrifugation (800g, 2 min, rtp) and washed three times with 50 ml of ice cold PBST (PBS with 0.1% v/v Triton X-100). Samples of each wash (washes 1-3) were taken for analysis by SDS-PAGE as was a sample of the fusion protein attached to the beads. All samples were analysed using 10% SDS-PAGE.
- cleavage reactions were performed with the fusion protein attached to the glutathione sepharose beads.
- the beads were first equilibriated once with 20ml of wash buffer (Tris-HCL, 50 mM, pH 7.5, NaCl, 150 mM) and then twice with 20ml cleavage buffer (wash buffer with CaCl 2 , 1.0mM) and finally resuspended in 1ml of cleavage buffer.
- wash buffer Tris-HCL, 50 mM, pH 7.5, NaCl, 150 mM
- 20ml cleavage buffer wash buffer with CaCl 2 , 1.0mM
- Factor Xa New England Biolabs® Inc.
- the released protein was recovered by pelleting the glutathione beads (800g, 2 min, rtp) and retaining the supernatant. The beads were washed twice with 1ml of wash buffer and the supernatant was retained each time. Aliquots of each supernatant and the remaining glutathione beads were analysed by SDS-PAGE. The beads were washed three times with wash buffer 2 (Tris-HCL, 50 mM, pH8.0) and eluted with 3ml of wash buffer 2 containing 5.0mM reduced glutathione for 2 min at room temperature followed by pelleting the beads (800g, 2 min, rtp) and retaining the supernatant. This elution was repeated twice and the purity of each fraction was analysed by SDS-PAGE.
- wash buffer 2 Tris-HCL, 50 mM, pH8.0
- Example 3 Protection in mice after subunit vaccine administration and Streptococcus equi challenge
- the objective of this study was to determine if vaccination with Streptococcus equi subunit vaccine protected mice from subsequent intranasal Streptococcus equi challenge.
- Streptococcus equi subunit vaccines were used, Se595, Se358, Se1459, Se50 and Se528. All these vaccines used the Streptococcus equi proteins obtained in Example 2.
- the Se595, Se358, Se1459, Se50 and Se528 recombinant Streptococcus equi proteins were purified by buffer exchanged into 20mM Sodium Phosphate pH7.4 and concentrated to give a concentration equivalent to the molar concentration of Se358 at 10 ⁇ g/ml where possible. Proteins, Se595 and Se528 were insoluble at the desired concentration. The actual protein concentrations used are shown in Table 2.
- Table 2 Actual doses of recombinant subunits administered Protein Dose administered Dose equivalent to Se358 Se595 11.2 ⁇ g 5.3 ⁇ g Se358 10 ⁇ g 10 ⁇ g Se1459 1.7 ⁇ g 10 ⁇ g Se50 1.9 ⁇ g 9.6 ⁇ g Se528 4.2 ⁇ g 3.4 ⁇ g
- mice Groups of 20 3-4 week old female BalbC mice were vaccinated on day 0 (D0) with each of five Streptococcus equi subunit vaccines. Vaccinations were given by intramuscular injection in the thigh and intranasally. These mice were given a booster vaccination after 4 weeks (D28) and challenged with Streptococcus equi after a further 2 weeks (D42). An additional control group receiving no vaccination was also included, and was challenged on D42. A group of 5 control mice was not vaccinated or challenged with Streptococcus equi (see Table 3).
- the group size is sufficient to detect 50% protection of vaccinated mice with 80% infection of controls. Blood was taken before vaccination, before boost, before challenge and on euthanasia to determine the level of antibody response to vaccination and challenge.
- Streptococcus equi strain 4047 was grown for challenge in Todd Hewitt broth (THB) supplemented with 10% foetal calf serum (FCS). An overnight culture was diluted 1:20 to inoculate fresh pre-warmed and gassed THB+10% FCS and the culture grown until an OD 600nm of 0.3 was reached. At this point, dilutions of the culture were made. Following preparation of the required dose of Streptococcus equi strain 4047, mice were sedated with 100mg/kg of Ketaset by intramuscular injection and challenged by intranasal administration of 10 ⁇ l of challenge inocula containing approximately 1x10 4 cfu S. equi.
- the dose administered was quantified by back titration and was found to contain 0.9x10 4 cfu.
- mice All the mice were carefully monitored to ensure complete recovery from sedation and checked regularly for the onset of clinical signs of disease. These included malaise, shivering or staring coat and were taken as a sign of moderate effect with the onset of more severe effects possible. Mice were finally euthanased.
- Table 3 Summary of study protocol # of mice Age of mice Vaccine Subunit Dose Booster Challenge dose (cfu) Route 20 3-4 weeks Se595 + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 20 3-4 weeks Se358 + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 20 3-4 weeks Se1459 + Adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 20 3-4 weeks Se50 + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 20 3-4 weeks Se528 + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 60 3-4 weeks No vaccine No vaccine No 1x10 4 10 ⁇ l IN 5 3-4 weeks None None No none 10 ⁇ l IN
- the vaccination phase proceeded without incident, all groups gained weight in line with controls. No adverse injection site reactions were identified. All mice seroconverted with respect to the vaccination administered.
- mice vaccinated with Se595, Se358, Se1459, Se528 and Se50 generally had reduced clinical signs of disease, reduced weight loss, more weight gain, reduced nasal colonisation and improved survival when compared with controls.
- Each mouse was examined on the day of challenge and on each of the following 7 days for the occurrence of symptoms associated with Streptococcus equi (lethargy, weight loss, sneezing, piloerection, hunched up, inner ear imbalance). Mice were examined at least 4 times a day.
- mice Weights of mice were analysed on a spreadsheet each day to determine %weight loss relative to the day of challenge.
- Example 4 Expression of recombinant Streptococcus equi Se1631, Se1681 and SIa polypeptides in Escherichia coli
- Polynucleotides encoding fragments of Se1631, Se1681 and Sla were produced using Vent DNA polymerase (New England Biolabs® Inc.) as per the manufacturers recommended conditions with a 5 minute denaturation step followed by 35 cycles using 30 seconds annealing at 50-55°C, 1 minute extension at 72°C, and 30 second denaturing at 95°C. Products were finished off with a 4-minute 72°C extension.
- the template in each case was Streptococcus equi strain 4047 chromosomal DNA.
- the fragments of Se1631, Se1681 and Sla are those designated as SEQ ID NOS: 53, 55 and 57, respectively.
- Table 6 Primers used to clone and sequence recombinant subunits.
- Primer name Sequence Function SEQ ID NO: 5'1631GST AAAGGATCCTGCAGTCTACAAATGACAATAC Se1631 cloning 41 3'1631GST AAAGAATTCTTATTTTTCTGACTTAGATTTAGAAG Se1631 cloning 42 5'1681GST AAAGGATCCTGGCGACTACCCTAGCAGGACAAAC Se1681 cloning 43 3'1681GST AAAGAATTCTTATGTATCTTGACAGTGCTTAAG Se1681 cloning 44 5'SLAGST CCCGGATCCTAGAAGGGATAAATGATAAAATAG Sla cloning 45 3'SLAGST TTTGAATTCTTACAAAACATCTACTACTGGCAAC Sla clowning 46
- PCR products were purified using the Qiaquick PCR purification kit (Qiagen) with a 32 ⁇ l elution volume, then digested with the addition of EcoRI buffer (3.5 ⁇ l) (New England Biolabs® Inc.), BamHI (0.75 ⁇ l) and EcoRI (0.75 ⁇ l) for 2 hours at 37°C. 1 ⁇ g of pGEX-3X plasmid (GE Healthcare) was also digested with EcoRI and BamHI as described above.
- the pGEX-3X plasmids have a multiple cloning site, a tac promoter, glutathione S-transferase gene (GST) and stop codons in all three frames, for the production of GST fusion proteins and their isolation and purification.
- GST glutathione S-transferase gene
- Ligation reactions were set up using 1 6.5 ⁇ l of purified digested PCR product and 1 ⁇ l of pGEX-3X plasmid with 2 ⁇ l of ligase buffer and 0.5 ⁇ l of ligase, and incubated overnight at room temperature (rtp).
- the ligation reactions were transformed into E.coli DH10B strain and plated onto L-agar plates supplemented with 50 ⁇ g/ml ampicillin and incubated overnight at 37°C. Transformants were tested for the presence of insert by colony PCR. A single colony was resuspended in 4 ⁇ l of water and 2 ⁇ l of this was added to a Taq DNA polymerase PCR reaction containing the appropriate cloning primers for the polynucleotide of interest and a 35 cycle extension was performed as described above. The presence of the desired insert was confirmed by running the PCR reaction on 0.7% TAE agarose gels.
- Plasmids of each of the clones were prepared and sequenced using the 5' and 3' pGEX-3X PCR primers for all of the clones (Table 6). All of the cloned polynucleotides were confirmed to have the same sequence as the assembled Streptococcus equi strain 4047 genome sequence (http://www.sanger.ac.uk/Projects/S_equi/).
- All clones were induced for expression using the following protocol.
- a single colony was inoculated into 50ml 2 x YT culture medium containing 50 ⁇ g/ml ampicillin and was grown overnight with shaking at 220 rpm at 37°C. This culture was then added to 500ml of pre-warmed (37°C) and pre-gassed 2 x YT and incubated for 1 hour at 37°C. After 1 hour, 200 ⁇ l was removed and the cells were collected for analysis (this being the pre-induction sample), IPTG (isopropyl-beta-D-thiogalactopyranoside) was added to a final concentration of 0.1mM, and the temperature was lowered to 28°C. The culture was induced for a further four hours and a 100 ⁇ l sample was removed for analysis, after which the cells were harvested by centrifugation and stored at -70°C.
- the pellets were resuspended in 20ml of ice cold PBS (Oxoid Limited, catalog # BR0014G), PMSF (Phenylmethyl sulphonyl fluoride) was added to a final concentration of 0.1mM and the cells were lysed by sonication on ice with 6x10 second pulses with a 10 second rest between each pulse. Triton X-100 was added to 0.1 % (v/v) and the insoluble and intact cells were removed by centrifugation (11,000g, 5 min 4°C). Samples of the soluble bacterial lysate and insoluble material were analysed by SDS-PAGE.
- DTT dithiothreitol; Cleland's reagent
- 5mM glutathione sepharose 4B
- the mixture was incubated at room temperature for 1 hour and then the beads were collected by centrifugation (800g, 2 min, rtp) and washed three times with 50 ml of ice cold PBST (PBS with 0.1% v/v Triton X-100). Samples of each wash (washes 1-3) were taken for analysis by SDS-PAGE as was a sample of the fusion protein attached to the beads. All samples were analysed using 10% SDS-PAGE.
- Cleavage reactions were performed with the fusion protein attached to the glutathione sepharose beads.
- the beads were first equilibriated once with 20ml of wash buffer (Tris-HCL, 50 mM, pH 7.5, NaCl, 150 mM) and then twice with 20ml cleavage buffer (wash buffer with CaCl 2 , 1.0mM) and finally resuspended in 1ml of cleavage buffer.
- Factor Xa New England Biolabs® Inc.
- the released protein was recovered by pelleting the glutathione beads (800g, 2 min, rtp) and retaining the supernatant.
- the beads were washed twice with 1ml of wash buffer and the supernatant was retained each time. Aliquots of each supernatant and the remaining glutathione beads were analysed by SDS-PAGE. The beads were washed three times with wash buffer 2 (Tris-HCL, 50 mM, pH8.0) and eluted with 3ml of wash buffer 2 containing 5.0mM reduced glutathione for 2 min at room temperature followed by pelleting the beads (800g, 2 min, rtp) and retaining the supernatant. This elution was repeated twice and the purity of each fraction was analysed by SDS-PAGE.
- wash buffer 2 Tris-HCL, 50 mM, pH8.0
- wash buffer 2 Tris-HCL, 50 mM, pH8.0
- wash buffer 2 5.0 mM reduced glutathione for 2 min at room temperature
- pelleting the beads 800g, 2 min, rtp
- This elution was repeated twice and the purity of each fraction was analysed by SDS-PAGE.
- Example 5 Protection in mice after Se1631, Se1681 or Sla subunit vaccine administration and Streptococcus equi challenge
- mice Groups of 20 3/4 week old female BalbC mice were vaccinated with each of Se1631, Se 1681 and Sla S. equi peptides, and a GST + adjuvant control group. This group size is sufficient to detect 50% protection of mice with 80% infection of controls. An additional control group of 5 mice receiving no vaccination or challenge was included (see Table 7).
- Streptococcus equi subunit vaccines were used, Se1631, Se1681358 and Sla. All these vaccines used the Streptococcus equi proteins obtained in Example 4.
- Recombinant proteins were prepared for vaccination by centricon concentration in 0.02M phosphate buffer pH 7.4 to 1.5 mg/ml and adding 2 parts of TS6 adjuvant (example 1 of US-A-2005/0079185).
- mice were vaccinated on Day 0 and boosted on Day 28.
- IM vaccinations were administered into the left hind leg on Day 0 and the right hind leg on Day 28 according to the following table.
- IN vaccinations will be administered via a pipette onto the nares of mice.
- mice were challenged with S . equi after a further 2 weeks.
- S . equi strain 4047 were prepared as described in example 3. Following dilution to the required dose, 10 ⁇ l were administered to sedated mice by the intranasal route in a contained environment. Mice were carefully monitored to ensure complete recovery from sedation and checked regularly for the onset of clinical signs of disease. These include malaise, shivering or staring coat and were taken as a sign of moderate effect with the onset of more severe effects possible.
- Table 7 Summary of study protocol # of mice Age of mice Vaccine Subunit Dose Booster Challenge dose (cfu) Route 20 3-4 weeks Se1631 + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 20 3-4 weeks Se1681 + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 20 3-4 weeks Sla + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 20 3-4 weeks GST + adjuvant 20 ⁇ l IN + IM Yes 1x10 4 10 ⁇ l IN 5 3-4 weeks None None No none 10 ⁇ l IN
- Clinical signs of disease were observed from D44, 2 days post challenge.
- the vaccinated groups generally had lower clinical signs than the control groups.
- Mice vaccinated with Se1631 had the lowest level of clinical signs of disease.
- Those vaccinated with Se1681 and Sla had clinical signs of disease for a reduced period compared with controls ( FIG. 4 ).
Description
- The present invention relates to polypeptides of streptococcal bacteria, more particularly of Streptococcus equi, which may be used to prevent, diagnose and/or treat streptococcal infection.
- Streptococcus equi (S. equi subsp. equi) is a gram-positive coccus that has a large capsule. S. equi is the causative agent of strangles in equine, canine and Camelids, notably in horses, donkeys, mules, dogs, camels and dromedaries. Strangles is a highly contagious infection of the upper respiratory tract and associated lymph nodes. In equine, the disease is characterized by fever, thick mucopurulent nasal discharge, swelling and abscessation of the submandibular, submaxillary, and retropharyngeal lymph nodes. In severe cases, the infection may become disseminated with internal and external abscess formation and may ultimately result in death. It can occur in susceptible horses of any age. Transmission occurs through direct contact or indirectly through fomites that have been contaminated by respiratory tract secretions or saliva. Although rare, S. equi is a very serious zoonotic pathogen of Camelids (Sechi L A et al., New Microbiol, 1999, 22(4): 383-387), of humans infected by contact with horses (Elsayed S et al., Clin Microbiol Infect, 2003, 9(8): 869-872). In human, mortality was high (25%), especially among older patients and patients with endocarditis, meningitis and disseminated infection (Bradley S F et al., Rev Infect Dis, 1991, 13(2): 270-280; Popescu G A et al., South Med J, 2006, 99(2): 190-191).
- After infection, S. equi generally has an
incubation period 3 to 14 days before the onset of clinical signs. The organism rapidly translocates the mucosa into the lymphatic channels and from there moves to one or more of the regional lymph nodes leading to inflammation and swelling. - The enlarging lymph nodes soon develop purulent centers with fluctuant liquefaction. Submandibular lymph nodes typically rupture externally through the skin, whilst abscesses formed in the retropharyngeal lymph nodes typically rupture into the guttural pouch. This may take up to 2 weeks to occur after the onset of signs.
- The majority (70%) of animals are immune to further attacks of strangles after recovery from a first infection. However, a substantial proportion of animals (30%) can contract the disease a second time, and of these a small proportion can contract the disease more than twice (Todd A.G., J. Comp. Pathol. Ther., 1910, 23, 212-229). Up to 10% of affected animals continue to shed S. equi intermittently for prolonged periods after clinical signs have resolved. This carrier state is probably caused by incomplete drainage of exudate from the guttural pouches (empyaema) and/or sinuses following rupture of abscesses formed in the retropharyngeal lymph nodes (Newton J R et al., Vet Record, 1997, 140: 84-90). Drying and hardening of exudate leads to the formation of discrete bodies called chondroids that can remain in the guttural pouch for several years. It is becoming increasingly recognised around the world that sub-clinical persistent carriage of S. equi is fundamental to the persistence of this infection between outbreaks (Fintl C et al., Vet Record, 2000, 147: 480-484; Newton J R et al., Vet Record, 1997, 140: 84-90; Newton J R et al., Equine Vet J, 2000, 32: 515-526; Timoney J F et al., Vet Record, 1998, 142: 648) and this remains true despite the advent of modern vaccines (Newton R et al., Vet Record, 2005, 156: 291-292).
- Protection against the disease is primarily mediated by antibodies of the IgA and IgG subclasses locally produced in the nasopharynx.
- Serum antibodies to Streptococcus equi (S. equi) can be measured by a variety of assays including ELISA (Reif et al., Proc. Am. Assoc. Equine Practitioners, 1982, 27, 33-40), the mouse protection test (Bazely P.L., Aust. Vet. J., 1943, 19, 62-85), and the gel diffusion precipitin test.
- Commercially available vaccines consisting of heat-inactivated bacterin or M-protein-rich extracts have been widely used in the field. Although effective in stimulating serum bactericidal antibodies, these vaccines apparently do not stimulate a useful level of nasopharyngeal antibody and so the level of protection stimulated in a horse population is disappointing. An avirulent, genetically modified strain of S. equi administered intranasally has recently been shown to stimulate local nasopharyngeal antibodies similar to those found in convalescent immune horses. Vaccinated horses were immune to subsequent experimental challenge with virulent S. equi (Timoney and Galan, 1985, The protective response of the horse to an avirulent strain of Streptococcal equi. In Y. Kimura, S. Kotami and Y. Shokawa, eds., Recent Advances in Streptococci and Streptococcal disease. Reedbooks, Surrey, England, p. 294-295). It therefore appears that an effective strangles vaccine must be able to stimulate a nasopharyngeal immune response.
- Bacterin-type vaccines aften cause undesirable local and systemic reactions consisting of edema, induration, stiffness, transient fever, and neutrophilia, effects that are probably due to cell wall peptidoglycan. Furthermore, purpura hemorrhagica can develop after vaccination of horses previously sensitised to streptococcal antigens.
- Streptococcus zooepidemicus (S. equi subsp. zooepidemicus) is an important cause of respiratory disease and metritis in equine. S. zooepidemicus is an opportunist pathogen that causes purulent respiratory infections of weanling and yearling horses and uterine infections in elderly mares. In the situation of concurrent influenza infection high temperature or transport stress, it can be a devasting and rapid fatal pathogen in the respiratory tract. Although rare, S. zooepidemicus is a very serious zoonotic pathogen of Camelids (Younan M et al., J Vet Med B Infect Dis Vet Public Health, 2005, 52(3): 142-146), of humans infected by contact with horses (Downar J et al., J Clin Microbiol, 2001, 39(6): 2358-2359; Ural O et al., Scand J Infect Dis, 2003, 35(3): 206-207) and of canine animals having respiratory disease, notably already infected by Bordetella bronchiseptica (Chalker V J et al., Vet Microbiol, 2003, 95(1-2): 149-156).
- S. equi affected mammals may harbor the bacteria for several months in, among other places, the guttoral pouches and, thus, shed and act as reservoirs of S. equi. Although S. equi is quite sensitive to penicillin and other antibiotics, antibiotic treatment is for various reasons mostly ineffective. In order to combat the disease and mitigate serious clinical complications, research has mainly been aimed at developing efficient vaccines.
- The development of vaccines has been slow, possibly in part, because vaccines must be able to control infection without inducing a marked inflammatory response.
- It is therefore desirable to develop vaccines having a high degree of immunogenicity and which exhibit a good safety profile with limited or no side effects.
- Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.
-
WO2004032957 discloses a method for treatment of S. equi infection using SCLC1. The document also discloses an ELISA for determining anti-SCLC1 antibody titers in horses with or without a history of previous strangles. - In its broadest sense the invention pertains to subject-matter as defined in the appended claims pertaining to SEQ ID 31 and 32.
- The disclosure relates to subunit immunogenic or vaccine compositions which may comprise at least one polypeptide of the disclosure; e.g., polypeptides of Streptococcus equi. The disclosure therefore further relates to methods for preparing and/or formulating such compositions; e.g., admixing the polypeptides with a suitable veterinary or pharmaceutically acceptable carrier, excipient, diluent or vehicle and/or an adjuvant and/or stabilizer. The disclosure also relates to the use of such subunit compositions; e.g., a method for eliciting an immunogenic response or a protective immune response, which may comprise administering the composition to a mammal susceptible to streptococcal infection.
- The disclosure relates to recombinant immunogenic or vaccine compositions which may comprise at least one recombinant expression vector encoding at least one polypeptide of the invention, able to express in vivo this polypeptide in a mammal susceptible to streptococcal infection. Herein such a immunogenic or vaccine composition which may comprise at least one recombinant expression vector is named a recombinant immunogenic or vaccine composition. The disclosure therefore further relates to methods for preparing such vectors, e.g., inserting at least one polynucleotide encoding a polypeptide according to the invention into a plasmid vector or viral vector so that the vector contains and expresses the polynucleotide in the host. The disclosure therefore further relates to methods for formulating such recombinant immunogenic or vaccine compositions; e.g., admixing the vectors with a suitable veterinary or pharmaceutically acceptable carrier, excipient, diluent or vehicle and/or an adjuvant and/or stabilizer. The disclosure also relates to the use of such recombinant immunogenic or vaccine compositions; e.g., a method for eliciting an immunogenic response or a protective immune response, which may comprise administering the composition to a mammal susceptible to streptococcal infection.
- By definition, mammals susceptible to streptococcal infection encompasse equine (i.e. horses, mares, foals, donkeys and mules), camelids (i.e. camels, dromedaries), canine (i.e. dogs, bitchs, puppies), bovine (i.e. cattle, cows, calves), ovine (i.e sheeps, ewes, lambs), caprine (i.e. goats), porcine (i.e. pigs, sows, piglets) and human. Mammals susceptible to Streptococcus equi infection encompass equine (i.e. horses, mares, foals, donkeys and mules), camelids (i.e. camels, dromedaries), canine (i.e. dogs, bitchs, puppies) and human. Mammals susceptible to Streptococcus zooepidemicus infection encompasse equine (i.e. horses, mares, foals, donkeys and mules), canine (i.e. dogs, bitchs, puppies), Camelids (i.e. camels, dromedaries) and human.
- The disclosure also relates to uses recombinant expression vectors; e.g., a method for producing a polypeptide of the invention, which may comprise culturing, growing or propagating prokaryotic or eucaryotic cells transformed to contain the recombinant expression vectors and to express a polynucleotide encoding the polypeptide under conditions suitable for expression, and harvesting or isolating or separating the polypeptide from cells transformed to express it.
- The disclosure further relates to methods for inducing in an equine, i.e. a horse, a donkey and a mule, an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the equine a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the disclosure.
- The disclosure further relates to methods for inducing in a canine, i.e. a dog, a bitch, a puppy, an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the canine a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the disclosure.
- The disclosure further relates to methods for inducing in a Camelid, i.e. a camel, a dromedary, an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the Camelid a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the invention.
- The disclosure further relates to methods for inducing in a human an immunogenic or protective immune response against streptococcal bacteria, such as Streptococcus equi or Streptococcus zooepidemicus, which may comprise administering to the human a subunit immunogenic or vaccine composition of the disclosure or a recombinant immunogenic or vaccine composition of the disclosure.
- The disclosure relates to a polypeptide having an amino acid sequence coded by a polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23 and 25. The invention further relates to a polypeptide having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23 and 25. The disclosure relates to a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52. The invention further relates to a polypeptide analog having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52. The disclosure further relates to a polypeptide fragment, containing at least one epitope, which is a part of a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52 or analogs thereof, and notably a fragment containing at least one epitope selected from the group consisting of polypeptides identified SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58. And, the disclosure relates to uses, compositions and methods involving such polypeptides, analogs thereof or fragments thereof as herein described.
- Thus, the disclosure relates to a recombinant expression vector, wherein said vector contains at least one polynucleotide which codes for a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, and combinations thereof. The disclosure further relates to a recombinant expression vector, wherein said vector has at least one polynucleotide which codes for a polypeptide analog having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, and combinations thereof. The disclosure further relates to a recombinant expression vector, wherein said vector has at least one polynucleotide which codes for a polypeptide fragment, containing at least one epitope which is a part of a polypeptide selected from the group consisting of polypeptides identified SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52 or analogs thereof, and notably a fragment selected from the group consisting of polypeptides identified SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58. The disclosure relates to a recombinant expression vector, wherein said vector has at least one polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23, 25, 31, 33, 35, 37, 39, 47, 49, 51, 53, 55 and 57, and combinations thereof. The disclosure further relates to a recombinant expression vector, wherein said vector has at least one polynucleotide having an identity which is equal or more than about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% with a polynucleotide selected from the group consisting of polynucleotides identified SEQ ID NOS: 17, 19, 21, 23, 25, 31, 33, 35, 37, 39, 47, 49, 51, 53, 55 and 57, and combinations thereof. And, the disclosure relates to uses, compositions and methods involving such vectors as herein described.
- Polynucleotides of the disclosure may be used in hybridization reactions (e.g. Northern or Southern blots, or in nucleic acid microarrays or "gene chips") or in amplification reactions (e.g. polymerase chain reaction or PCR).
- It should be appreciated that the disclosure provides polynucleotides which may comprise sequences complementary to those described above.
- Polynucleotides according to the disclosure may be prepared in many ways (e.g. by chemical synthesis, from genomic or cDNA libraries, from the streptococcus itself etc.) and may take various forms (e.g. single stranded, double stranded, primers, probes etc.).
- Polynucleotides according to the disclosure may be labeled e.g. with a radioactive or fluorescent label. This is particularly useful as a primer or as a probe.
- In addition, the term "polynucleotide" includes DNA and RNA, and also their analogues, such as those containing modified backbones.
- Further still, the disclosure envisions an antibody preparation which may comprise at least one antibody specific to a polypeptide of the disclosure. This antibody may be polyclonal or monoclonal. The antibody preparation may also comprise a fragment of said antibody.
- The disclosure also involves a diagnostic kit for detecting infection by streptococcal bacteria, including at least one polypeptide according to the invention or an antibody preparation which may comprise at least one antibody specific to a polypeptide of the invention. The disclosure also involves a diagnostic method for detecting infection by streptococcal bacteria in mammals, which may comprise using a diagnostic kit of the invention and detecting in a sample the polypeptide or an antibody specific to that polypeptide.
- The disclosure further concerns a passive immunization method which may comprise administering the antibody preparation to a mammal susceptible to infection by streptococcal bacteria or infected by streptococcal bacteria. In particular, the passive immunization method comprises administering the antibody preparation to an equine susceptible to infection by the streptococcal bacterium or infected by the streptococcal bacterium, notably susceptible to infection by Streptococcus equi or infected by Streptococcus equi.
- It is noted that in this disclosure and particularly in the claims, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
- These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.
- The following detailed description, given by way of example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings, in which:
-
FIG. 1 shows the mean clinical scores of vaccinated and control mice following challenge with Streptococcus equi; -
FIG. 2 shows the mean percentage of change in mass of vaccinated and control mice after Streptococcus equi challenge; -
FIG. 3 shows the mean nose dabs score of vaccinated and control mice after Streptococcus equi challenge; -
FIG. 4 shows the mean clinical scores of Se1631, Se1681, Sla vaccinated and control mice following challenge with Streptococcus equi; -
FIG. 5 shows the mean percentage of change in mass of Se1631, Se1681, Sla vaccinated and control mice after Streptococcus equi challenge; -
FIG. 6 shows the mean nose dabs score of Se1631, Se1681, Sla vaccinated and control mice after Streptococcus equi challenge (expressed in colony forming unit (cfu)) and -
FIG. 7 shows the percentage of mice surviving and not losing more than 7% weight of Se1631, Se1681, Sla vaccinated and control mice after Streptococcus equi challenge. - The present disclosure relates to the identification of polypeptides of Streptococcus equi able, when administered to a mammal, to elicit an immunogenic or immune response, and to the identification of polynucleotides encoding these polypeptides. These polypeptides are useful for the production of subunit immunogenic compositions or subunit vaccines. These polynucleotides are useful for the production of DNA immunogenic compositions, DNA vaccines, recombinant viral vector immunogenic compositions or recombinant viral vector vaccines.
- The disclosure concerns compositions, uses and methods against infections caused by bacteria of the Streptococcal family, notably caused by Streptococcus equi, e.g. strangles disease in equine, camelid, canine and human, and against infections caused by Streptococcus zooepidemicus in equine, camelid, canine and human.
- The disclosure concerns polypeptides, polynucleotides and genes obtained or derived from Streptococcus equi. The present invention may relate also to polypeptides, polynucleotides and genes obtained or derived from other streptococci, notably from Streptococcus zooepidemicus, Streptococcus suis, Streptococcus uberis, Streptococcus dysgatactiae, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes.
- A particular aspect of the disclosure is a polypeptide selected from the amino acid sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52.
- The whole genome of Streptococcus equi is available in the Sanger database (http://www.sanger.ac.uk/Projects/S_equi/).
- The polypeptides are identified as SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52 for Se50, Se1459, Se595, Se528, Se358, Se1631, Se1681 and Sla, respectively.
- A particular aspect of the disclosure is a polynucleotide selected from the nucleotide sequences SEQ ID NOS: 17, 19, 21, 23 and 25.
- The polynucleotides are identified as SEQ ID NOS: 17, 19, 21, 23 and 25 for Se50, Se1459, Se595, Se528 and Se358, respectively.
- The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Press; DNA Cloning, Vols. I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Animal Cell Culture (R. K. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL press, 1986); Perbal, B., A Practical Guide to Molecular Cloning (1984); the series, Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); and Handbook of Experimental Immunology, Vols. I-IV (D. M. Weir and C. C. Blackwell eds., 1986, Blackwell Scientific Publications).
- Before describing the present invention in detail, it is to be understood that this invention is not limited to particular DNA, polypeptide sequences or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.
- By the term "complementarity" or "complementary" is meant, for the purposes of the specification or claims, a sufficient number in the oligonucleotide of complementary base pairs in its sequence to interact specifically (hybridize) with a target nucleic acid sequence of the gene polymorphism to be amplified or detected. As known to those skilled in the art, a very high degree of complementarity is needed for specificity and sensitivity involving hybridization, although it need not be 100%. Thus, for example, an oligonucleotide that is identical in nucleotide sequence to an oligonucleotide disclosed herein, except for one base change or substitution, may function equivalently to the disclosed oligonucleotides. A "complementary DNA" or "cDNA" gene includes recombinant genes synthesized by reverse transcription of messenger RNA ("mRNA").
- A "cyclic polymerase-mediated reaction" refers to a biochemical reaction in which a template molecule or a population of template molecules is periodically and repeatedly copied to create a complementary template molecule or complementary template molecules, thereby increasing the number of the template molecules over time.
- By the term "detectable moiety" is meant, for the purposes of the specification or claims, a label molecule (isotopic or non-isotopic) which is incorporated indirectly or directly into an oligonucleotide, wherein the label molecule facilitates the detection of the oligonucleotide in which it is incorporated, for example when the oligonucleotide is hybridized to amplified gene polymorphic sequences. Thus, "detectable moiety" is used synonymously with "label molecule". Synthesis of oligonucleotides can be accomplished by any one of several methods known to those skilled in the art. Label molecules, known to those skilled in the art as being useful for detection, include chemiluminescent, fluorescent or luminescent molecules. Various fluorescent molecules are known in the art which are suitable for use to label a nucleic acid for the method of the present invention. The protocol for such incorporation may vary depending upon the fluorescent molecule used. Such protocols are known in the art for the respective fluorescent molecule.
- "DNA amplification" as used herein refers to any process that increases the number of copies of a specific DNA sequence by enzymatically amplifying the nucleic acid sequence. A variety of processes are known. One of the most commonly used is the polymerase chain reaction (PCR) process of Mullis as described in
U.S. Pat. Nos. 4,683,195 and4,683,202 . Methods, devices and reagents as described inU.S. Patent Nos. 6,951,726 ;6,927,024 ;6,924,127 ;6,893,863 ;6,887,664 ;6,881,559 ;6,855,522 ;6,855,521 ;6,849,430 ;6,849,404 ;6,846,631 ;6,844,158 ;6,844,155 ;6,818,437 ;6,818,402 ;6,794,177 ;6,794,133 ;6,790,952 ;6,783,940 ;6,773,901 ;6,770,440 ;6,767,724 ;6,750,022 ;6,744,789 ;6,733,999 ;6,733,972 ;6,703,236 ;6,699,713 ;6,696,277 ;6,664,080 ;6,664,064 ;6,664,044 ;RE38,352 ;6,650,719 ;6,645,758 ;6,645,720 ;6,642,000 ;6,638,716 ;6,632,653 ;6,617,107 ;6,613,560 ;6,610,487 ;6,596,492 ;6,586,250 ;6,586,233 ;6,569,678 ;6,569,627 ;6,566,103 ;6,566,067 ;6,566,052 ;6,558,929 ;6,558,909 ;6,551,783 ;6,544,782 ;6,537,752 ;6,524,830 ;6,518,020 ;6,514,750 ;6,514,706 ;6,503,750 ;6,503,705 ;6,493,640 ;6,492,114 ;6,485,907 ;6,485,903 ;6,482,588 ;6,475,729 ;6,468,743 ;6,465,638 ;6,465,637 ;6,465,171 ;6,448,014 ;6,432,646 ;6,428,987 ;6,426,215 ;6,423,499 ;6,410,223 ;6,403,341 ;6,399,320 ;6,395,518 ;6,391,559 ;6,383,755 ;6,379,932 ;6,372,484 ;6,368,834 ;6,365,375 ;6,358,680 ;6,355,422 ;6,348,336 ;6,346,384 ;6,319,673 ;6,316,195 ;6,316,192 ;6,312,930 ;6,309,840 ;6,309,837 ;6,303,343 ;6,300,073 ;6,300,072 ;6,287,781 ;6,284,455 ;6,277,605 ;6,270,977 ;6,270,966 ;6,268,153 ;6,268,143 ;D445,907 ;6,261,431 ;6,258,570 ;6,258,567 ;6,258,537 ;6,258,529 ;6,251,607 ;6,248,567 ;6,235,468 ;6,232,079 ;6,225,093 ;6,221,595 ;D441,091 ;6,218,153 ;6,207,425 ;6,183,999 ;6,183,963 ;6,180,372 ;6,180,349 ;6,174,670 ;6,153,412 ;6,146,834 ;6,143,496 ;6,140,613 ;6,140,110 ;6,103,468 ;6,087,097 ;6,072,369 ;6,068,974 ;6,063,563 ;6,048,688 ;6,046,039 ;6,037,129 ;6,033,854 ;6,031,960 ;6,017,699 ;6,015,664 ;6,015,534 ;6,004,747 ;6,001,612 ;6,001,572 ;5,985,619 ;5,976,842 ;5,972,602 ;5,968,730 ;5,958,686 ;5,955,274 ;5,952,200 ;5,936,968 ;5,909,468 ;5,905,732 ;5,888,740 ;5,883,924 ;5,876,978 ;5,876,977 ;5,874,221 ;5,869,318 ;5,863,772 ;5,863,731 ;5,861,251 ;5,861,245 ;5,858,725 ;5,858,718 ;5,856,086 ;5,853,991 ;5,849,497 ;5,837,468 ;5,830,663 ;5,827,695 ;5,827,661 ;5,827,657 ;5,824,516 ;5,824,479 ;5,817,797 ;5,814,489 ;5,814,453 ;5,811,296 ;5,804,383 ;5,800,997 ;5,780,271 ;5,780,222 ;5,776,686 ;5,774,497 ;5,766,889 ;5,759,822 ;5,750,347 ;5,747,251 ;5,741,656 ;5,716,784 ;5,712,125 ;5,712,090 ;5,710,381 ;5,705,627 ;5,702,884 ;5,693,467 ;5,691,146 ;5,681,741 ;5,674,717 ;5,665,572 ;5,665,539 ;5,656,493 ;5,656,461 ;5,654,144 ;5,652,102 ;5,650,268 ;5,643,765 ;5,639,871 ;5,639,611 ;5,639,606 ;5,631,128 ;5,629,178 ;5,627,054 ;5,618,703 ;5,618,702 ;5,614,388 ;5,610,017 ;5,602,756 ;5,599,674 ;5,589,333 ;5,585,238 ;5,576,197 ;5,565,340 ;5,565,339 ;5,556,774 ;5,556,773 ;5,538,871 ;5,527,898 ;5,527,510 ;5,514,568 ;5,512,463 ;5,512,462 ;5,501,947 ;5,494,795 ;5,491,225 ;5,487,993 ;5,487,985 ;5,484,699 ;5,476,774 ;5,475,610 ;5,447,839 ;5,437,975 ;5,436,144 ;5,426,026 ;5,420,009 ;5,411,876 ;5,393,657 ;5,389,512 ;5,364,790 ;5,364,758 ;5,340,728 ;5,283,171 ;5,279,952 ;5,254,469 ;5,241,363 ;5,232,829 ;5,231,015 ;5,229,297 ;5,224,778 ;5,219,727 ;5,213,961 ;5,198,337 ;5,187,060 ;5,142,033 ;5,091,310 ;5,082,780 ;5,066,584 ;5,023,171 and5,008,182 may also be employed in the practice of the present invention. PCR involves the use of a thermostable DNA polymerase, known sequences as primers, and heating cycles, which separate the replicating deoxyribonucleic acid (DNA), strands and exponentially amplify a gene of interest. Any type of PCR, such as quantitative PCR, RT-PCR, hot start PCR, LAPCR, multiplex PCR, touchdown PCR, etc., may be used. Advantageously, real-time PCR is used. In general, the PCR amplification process involves a cyclic enzymatic chain reaction for preparing exponential quantities of a specific nucleic acid sequence. It requires a small amount of a sequence to initiate the chain reaction and oligonucleotide primers that will hybridize to the sequence. In PCR the primers are annealed to denatured nucleic acid followed by extension with an inducing agent (enzyme) and nucleotides. This results in newly synthesized extension products. Since these newly synthesized sequences become templates for the primers, repeated cycles of denaturing, primer annealing, and extension results in exponential accumulation of the specific sequence being amplified. The extension product of the chain reaction will be a discrete nucleic acid duplex with a termini corresponding to the ends of the specific primers employed. - By the terms "enzymatically amplify" or "amplify" is meant, for the purposes of the specification or claims, DNA amplification, i.e., a process by which nucleic acid sequences are amplified in number. There are several means for enzymatically amplifying nucleic acid sequences. Currently the most commonly used method is the polymerase chain reaction (PCR). Other amplification methods include LCR (ligase chain reaction) which utilizes DNA ligase, and a probe consisting of two halves of a DNA segment that is complementary to the sequence of the DNA to be amplified, enzyme QB replicase and a ribonucleic acid (RNA) sequence template attached to a probe complementary to the DNA to be copied which is used to make a DNA template for exponential production of complementary RNA; strand displacement amplification (SDA); Qß replicase amplification (QßRA); self-sustained replication (3SR); and NASBA (nucleic acid sequence-based amplification), which can be performed on RNA or DNA as the nucleic acid sequence to be amplified.
- A "fragment" of a molecule such as a protein or nucleic acid is meant to refer to any portion of the amino acid or nucleotide genetic sequence.
- As used herein, the term "genome" refers to all the genetic material in the chromosomes of a particular organism. Its size is generally given as its total number of base pairs. Within the genome, the term "gene" refers to an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a specific functional product (e.g., a protein or RNA molecule). In general, an animal's genetic characteristics, as defined by the nucleotide sequence of its genome, are known as its "genotype," while the animal's physical traits are described as its "phenotype."
- By "hybridization" or "hybridizing," as used herein, is meant the formation of A-T and C-G base pairs between the nucleotide sequence of a fragment of a segment of a polynucleotide and a complementary nucleotide sequence of an oligonucleotide. By complementary is meant that at the focus of each A, C, G or T (or U in a ribonucleotide) in the fragment sequence, the oligonucleotide sequenced has a T, G, C or A, respectively. The hybridized fragment/ oligonucleotide is called a "duplex."
- A "hybridization complex", such as in a sandwich assay, means a complex of nucleic acid molecules including at least the target nucleic acid and a sensor probe. It may also include an anchor probe.
- A "melting temperature" is meant the temperature at which hybridized duplexes dehybridize and return to their single-stranded state. Likewise, hybridization will not occur in the first place between two oligonucleotides, or, herein, an oligonucleotide and a fragment, at temperatures above the melting temperature of the resulting duplex. It is presently advantageous that the difference in melting point temperatures of oligonucleotide-fragment duplexes of this disclosure be from about 1 °C to about 10°C so as to be readily detectable.
- As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule can be single-stranded or double-stranded, but advantageously is double-stranded DNA. "DNA" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid.
- A "nucleoside" refers to a base linked to a sugar. The base may be adenine (A), guanine (G) (or its substitute, inosine (I)), cytosine (C), or thymine (T) (or its substitute, uracil (U)). The sugar may be ribose (the sugar of a natural nucleotide in RNA) or 2-deoxyribose (the sugar of a natural nucleotide in DNA). A "nucleotide" refers to a nucleoside linked to a single phosphate group.
- As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides may be chemically synthesized and may be used as primers or probes. Oligonucleotide means any nucleotide of more than 3 bases in length used to facilitate detection or identification of a target nucleic acid, including probes and primers.
- A "polymerase" is an enzyme that catalyzes the sequential addition of monomeric units to a polymeric chain, or links two or more monomeric units to initiate a polymeric chain. The "polymerase" will work by adding monomeric units whose identity is determined by and which is complementary to a template molecule of a specific sequence. For example, DNA polymerases such as
DNA pol 1 and Taq polymerase add deoxyribonucleotides to the 3' end of a polynucleotide chain in a template-dependent manner, thereby synthesizing a nucleic acid that is complementary to the template molecule. Polymerases may be used either to extend a primer once or repetitively or to amplify a polynucleotide by repetitive priming of two complementary strands using two primers. A "thermostable polymerase" refers to a DNA or RNA polymerase enzyme that can withstand extremely high temperatures, such as those approaching 100°C. Often, thermostable polymerases are derived from organisms that live in extreme temperatures, such as Thermus aquaticus. Examples of thermostable polymerases include Taq, Tth, Pfu, Vent, deep vent, UlTma, and variations and derivatives thereof. - A "polynucleotide" refers to a linear chain of nucleotides connected by a phosphodiester linkage between the 3'-hydroxyl group of one nucleoside and the 5'-hydroxyl group of a second nucleoside which in turn is linked through its 3'-hydroxyl group to the 5'-hydroxyl group of a third nucleoside and so on to form a polymer comprised of nucleosides linked by a phosphodiester backbone. A "modified polynucleotide" refers to a polynucleotide in which one or more natural nucleotides have been partially,substantially, or completely replaced with modified nucleotides.
- A "primer" is an oligonucleotide, the sequence of at least of portion of which is complementary to a segment of a template DNA which is to be amplified or replicated. Typically primers are used in performing the polymerase chain reaction (PCR). A primer hybridizes with (or "anneals" to) the template DNA and is used by the polymerase enzyme uses as the starting point for the replication/amplification process. The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.
- "Probes" refer to oligonucleotides nucleic acid sequences of variable length, used in the detection of identical, similar, or complementary nucleic acid sequences by hybridization. An oligonucleotide sequence used as a detection probe may be labeled with a detectable moiety.
- The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracil, other sugars and linking groups such as fluororibose and thiolate, and nucleotide branches. The sequence of nucleotides may be further modified after polymerization, such as by conjugation, with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides or solid support.
- An "isolated" polynucleotide or polypeptide is one that is substantially pure of the materials with which it is associated in its native environment. By substantially free, is meant at least 50%, at least 55%, at least 60%, at least 65%, at advantageously at least 70%, at least 75%, more advantageously at least 80%, at least 85%, even more advantageously at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, most advantageously at least 98%, at least 99%, at least 99.5%, at least 99.9% free of these materials.
- An "isolated" nucleic acid molecule is a nucleic acid molecule separate and discrete from the whole organism with which the molecule is found in nature; or a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences (as defined below) in association therewith.
- The term "polynucleotide encoding a protein" as used herein refers to a DNA fragment or isolated DNA molecule encoding a protein, or the complementary strand thereto; but, RNA is not excluded, as it is understood in the art that thymidine (T) in a DNA sequence is considered equal to uracil (U) in an RNA sequence. Thus, RNA sequences for use in the invention, e.g., for use in RNA vectors, can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.
- A DNA "coding sequence" or a "nucleotide sequence encoding" a particular protein, is a DNA sequence which is transcribed and translated into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory elements. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding sequence.
- "Homology" refers to the percent identity between two polynucleotide or two polypeptide moieties. Two DNA, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, preferably at least about 90%, 91%, 92%, 93%, 94% and most preferably at least about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% sequence identity over a defined length of the molecules. As used herein, substantially homologous also refers to sequences showing complete identity (100% sequence identity) to the specified DNA or polypeptide sequence.
- Homology can be determined by hybridization of polynucleotides under conditions that form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al. supra; DNA Cloning, supra; Nucleic Acid Hybridization, supra.
- Two nucleic acid fragments are considered to be "selectively hybridizable" to a polynucleotide if they are capable of specifically hybridizing to a nucleic acid or a variant thereof or specifically priming a polymerase chain reaction: (i) under typical hybridization and wash conditions, as described, for example, in Sambrook et al. supra and Nucleic Acid Hybridization, supra, (ii) using reduced stringency wash conditions that allow at most about 25-30% basepair mismatches, for example: 2x SSC, 0.1 % SDS, room temperature twice, 30 minutes each; then 2x SSC, 0.1% SDS, 37°C once, 30 minutes; then 2 x SSC room temperature twice, 10 minutes each, or (iii) selecting primers for use in typical polymerase chain reactions (PCR) under standard conditions (described for example, in Saiki, et al. (1988) Science 239:487-491).
- The term "capable of hybridizing under stringent conditions" as used herein refers to annealing a first nucleic acid to a second nucleic acid under stringent conditions as defined below. Stringent hybridization conditions typically permit the hybridization of nucleic acid molecules having at least 70% nucleic acid sequence identity with the nucleic acid molecule being used as a probe in the hybridization reaction. For example, the first nucleic acid may be a test sample or probe, and the second nucleic acid may be the sense or antisense strand of a nucleic acid or a fragment thereof. Hybridization of the first and second nucleic acids may be conducted under stringent conditions, e.g., high temperature and/or low salt content that tend to disfavor hybridization of dissimilar nucleotide sequences. Alternatively, hybridization of the first and second nucleic acid may be conducted under reduced stringency conditions, e.g. low temperature and/or high salt content that tend to favor hybridization of dissimilar nucleotide sequences. Low stringency hybridization conditions may be followed by high stringency conditions or intermediate medium stringency conditions to increase the selectivity of the binding of the first and second nucleic acids. The hybridization conditions may further include reagents such as, but not limited to, dimethyl sulfoxide (DMSO) or formamide to disfavor still further the hybridization of dissimilar nucleotide sequences. A suitable hybridization protocol may, for example, involve hybridization in 6 x SSC (wherein 1 x SSC comprises 0.015 M sodium citrate and 0.15 M sodium chloride), at 65° Celsius in an aqueous solution, followed by washing with 1 x SSC at 65° C. Formulae to calculate appropriate hybridization and wash conditions to achieve hybridization permitting 30% or less mismatch between two nucleic acid molecules are disclosed, for example, in Meinkoth et al. (1984) Anal. Biochem. 138: 267-284. Protocols for hybridization techniques are well known to those of skill in the art and standard molecular biology manuals may be consulted to select a suitable hybridization protocol without undue experimentation. See, for example, Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Press.
- Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M sodium ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) from about pH 7.0 to about pH 8.3 and the temperature is at least about 30° Celsius for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37° Celsius, and a wash in 1-2 x SSC at 50 to 55° Celsius. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37° Celsius, and a wash in 0.5-1 x SSC at 55 to 60° Celsius. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37° Celsius, and a wash in 0.1 x SSC at 60 to 65° Celsius.
- Also encompassed by the present disclosure is fragments of polypeptide selected from the sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52. Fragments of polypeptide and epitope determination procedures, such as, generating overlapping peptide libraries (Hemmer B. et al., Immunology Today, 1998, 19 (4), 163-168), Pepscan (Geysen H. M. et al., Proc. Nat. Acad. Sci. USA, 1984, 81 (13), 3998-4002; Geysen H. M. et al., Proc. Nat. Acad. Sci. USA, 1985, 82 (1), 178-182; Van der Zee R. et al., Eur. J. Immunol., 1989, 19 (1), 43-47; Geysen H. M., Southeast Asian J. Trop. Med. Public Health, 1990, 21 (4), 523-533; Multipin® Peptide Synthesis Kits de Chiron) and algorithms (De Groot A. et al., Nature Biotechnology, 1999, 17, 533-561), can be used in the practice of the invention, without undue experimentation.
- The polypeptides or fragments thereof are produced advantageously by in vitro expression. Another aspect of the disclosure is the use of the polynucleotides according to the invention, for the expression and the production of peptides, polypeptides or proteins, or more generally, expression products, e.g., immunogens, antigens or epitopes. In an embodiment, the polypeptides or peptides or proteins encoded by these polynucleotides may be used as subunit immunogens or antigens or epitopes in immunogenic compositions or vaccines. The disclosure also embraces the immunogenic fragments of these polypeptides, having at least a chain of 8 amino acids of the polypeptide, at least 10, at least 20, such as at least 30, advantageously at least 50 and more advantageously at least 70, e.g., fragments of the polypeptides containing at least 8 contiguous amino acids of the polypeptide, at least 10 contiguous amino acids of the polypeptide, advantageously at least 20, such as at least 30 and more advantageously at least 50 contiguous amino acids of the polypeptide, and even more advantageously at least 70 contiguous amino acids of the polypeptide. Of course, a fragment is less than the entire polypeptide. A fragment can be combined with other polypeptides, e.g., in fusion polypeptides; for instance, a polypeptide of the disclosure or fragment thereof can be a portion of a fusion polypeptide which includes another portion (another polypeptide) (i.e. fused to glutathione S-transferase gene (GST) (Chanter N et al., Microb. Pathog., 1999, 27(3): 133-143), or to cholera toxin (Sheoran A S et al., Vaccine, 2002, 20(11-12): 1653-1659)), e.g., an immunogenicity-enhancing portion and/or a secretion-enhancing portion such as a lipoprotein portion that enhances immunogenicity, such as a T-cell epitope peptide or a signal or leader sequence portion. Accordingly, the disclosure envisions the expression of polypeptides, proteins, antigens, immunogens or epitopes - whether herein identified sequences or fragments thereof or those that are heterologous to the vectors of the disclosure as fusions, e.g., as a portion of a fusion polypeptide, e.g., a fusion polypeptide that advantageously includes an immuogenicity enhancing portion such as a lipoprotein portion and/or a secretion-enhancing portion such as a signal or leader sequence portion.
- As used herein, the term "antigen" or "immunogen" means a substance that induces a specific immune response in a host animal. The antigen may comprise a whole organism, killed, attenuated or live; a subunit or portion of an organism; a recombinant vector containing an insert with immunogenic properties; a piece or fragment of DNA capable of inducing an immune response upon presentation to a host animal; a protein, a polypeptide, a peptide, an epitope, a hapten, or any combination thereof. Alternately, the immunogen or antigen may comprise a toxin or antitoxin.
- The term "immunogenic protein or peptide" as used herein also refers includes peptides and polypeptides that are immunologically active in the sense that once administered to the host, it is able to evoke an immune response of the humoral and/or cellular type directed against the protein. Preferably the protein fragment is such that it has substantially the same immunological activity as the total protein. Thus, a protein fragment according to the disclosure comprises or consists essentially of or consists of at least one epitope or antigenic determinant. The term epitope relates to a protein site able to induce an immune reaction of the humoral type (B cells) and/or cellular type (T cells).
- The term "immunogenic protein or peptide" further contemplates deletions, additions and substitutions to the sequence, so long as the polypeptide functions to produce an immunological response as defined herein. In this regard, particularly preferred substitutions will generally be conservative in nature, i.e., those substitutions that take place within a family of amino acids. For example, amino acids are generally divided into four families: (1) acidic--aspartate and glutamate; (2) basic--lysine, arginine, histidine; (3) non-polar--alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar--glycine, asparagine, glutamine, cystine, serine threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. It is reasonably predictable that an isolated replacement of leucine with isoleucine or valine, or vice versa; an aspartate with a glutamate or vice versa; a threonine with a serine or vice versa; or a similar conservative replacement of an amino acid with a structurally related amino acid, will not have a major effect on the biological activity. Proteins having substantially the same amino acid sequence as the reference molecule but possessing minor amino acid substitutions that do not substantially affect the immunogenicity of the protein are, therefore, within the definition of the reference polypeptide.
- The term "epitope" refers to the site on an antigen or hapten to which specific B cells and/or T cells respond. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site". Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.
- An "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest. Usually, an "immunological response" includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will display either a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered viral titer in the infected host.
- The terms "immunogenic" protein or polypeptide as used herein also refers to an amino acid sequence which elicits an immunological response as described above. An "immunogenic" protein or polypeptide, as used herein, includes the full-length sequence of the protein, analogs thereof, or immunogenic fragments thereof. By "immunogenic fragment" is meant a fragment of a protein which includes one or more epitopes and thus elicits the immunological response described above. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N.J. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g.,
U.S. Pat. No. 4,708,871 ; Geysen et al. (1984) Proc. Natl. Acad. Sci. USA 81:3998-4002; Geysen et al. (1986) Molec. Immunol. 23:709-715. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra. - Synthetic antigens are also included within the definition, for example, polyepitopes, flanking epitopes, and other recombinant antigens. See, e.g., Bergmann et al. (1993) Eur. J. Immunol. 23:2777-2781; Bergmann et al. (1996) J. Immunol. 157:3242-3249; Suhrbier, A. (1997) Immunol. and Cell Biol. 75:402-408; Gardner et al. (1998) 12th World AIDS Conference, Geneva, Switzerland, Jun. 28-Jul. 3, 1998. Immunogenic fragments, for purposes of the present invention, will usually include at least about 3 amino acids, preferably at least about 5 amino acids, more preferably at least about 10-15 amino acids, and most preferably 25 or more amino acids, of the molecule. There is no critical upper limit to the length of the fragment, which could comprise nearly the full-length of the protein sequence, or even a fusion protein comprising at least one epitope of the protein.
- Accordingly, a minimum structure of a polynucleotide expressing an epitope is that it comprises or consists essentially of or consists of nucleotides to encode an epitope or antigenic determinant of the protein or polyprotein of interest. A polynucleotide encoding a fragment of the total protein or polyprotein, more advantageously, comprises or consists essentially of or consists of a minimum of 21 nucleotides, advantageously at least 42 nucleotides, and preferably at least 57, 87 or 150 consecutive or contiguous nucleotides of the sequence encoding the total protein or polyprotein. Epitope determination procedures, such as, generating overlapping peptide libraries (Hemmer B. et al., Immunology Today, 1998, 19 (4), 163-168), Pepscan (Geysen et al., (1984) Proc. Nat. Acad. Sci. USA, 81, 3998-4002; Geysen et al., (1985) Proc. Nat. Acad. Sci. USA, 82, 178-182; Van der Zee R. et al., (1989) Eur. J. Immunol., 19, 43-47; Geysen H.M., (1990) Southeast Asian J. Trop. Med. Public Health, 21, 523-533; Multipin.RTM. Peptide Synthesis Kits de Chiron) and algorithms (De Groot A. et al., (1999) Nature Biotechnology, 17, 533-561), and in PCT Application Serial No.
PCT/US2004/022605 (published asWO 2005007691 ), can be used in the practice of the invention, without undue experimentation. Other documents cited and incorporated herein may also be consulted for methods for determining epitopes of an immunogen or antigen and thus nucleic acid molecules that encode such epitopes. - In one embodiment, the fragments of polypeptide are selected from the sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, which are respectively encoded by the nucleotide sequences SEQ ID NOS: 31, 33, 35, 37, 39, 53, 55 and 57. The fragments of polypeptides SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58 are part of Se50, Se1459, Se595, Se528, Se358, Se1631, Se1681 and Sla, respectively.
- The polynucleotides encoding polypeptides according to the present invention, analogs thereof or fragments thereof are inserted into a vector, linked to regulatory elements such as promoter, ribosome binding region and terminator, and start codon and stop codon.
- The polypeptides, analogs thereof and fragments thereof can be produced by in vitro expression in host cells. The in vitro expression vectors are expression vectors used for the in vitro expression of proteins in an appropriate cell system. This can be produced in prokaryotic host cells, i.e. in Escherichia coli (Mahona F et al., Biochimie 1994, 46(1): 9-14; Watt M A et al., Cell Stress Chaperones 1997, 2(3): 180-90; Frey J Res. Microbiol. 1992, 143(3): 263-9) or in Lactobacillus (Seegers J F, Trends Biotechnol. 2002, 20(12): 508-515; Pouwels P H et al., Methods Enzymol. 2001, 336: 369-389), or in eukaryotic host cells, i.e. in yeast (Gemgross T U, Nat Biotechnol. 2004, 22(11): 1409-1414; Malissard M et al., Glycoconj J. 1999, 16(2): 125-139), in insect cells (Oker-Blom C et al., Brief Funct Genomic Proteomic. 2003, 2(3), 244-253), mammal cells or avian cells.
- For Escherichia coli, different strains can be used, notably BL21(DE3) strain (Novagen or Invitrogen; see Hedayati M A et al., Protein Expr Purif, 2005, 43(2): 133-139) Origami2(DE3) strain (Novagen or Invitrogen), Y1089 (Galan J E et al., Infect Immun, 1987, 55(12): 3181-3187). Vectors are advantageously plasmids, i.e. pGEX plasmids (GE Healthcare), pET plasmids (Novagen or Invitrogen) (Jiang X Y et al., J Biochem Mol Biol. 2006, 39(1): 22-25; Hedayati M A et al., Protein Expr Purif, 2005, 43(2): 133-139; Jedrzejas M J et al., Protein Expr Purif, 1998, 13(1): 83-89). Vectors can also be a virus, notably a bacteriophage, i.e. lambda-gt11 phage (Galan J E et al., Infect Immun, 1987, 55(12): 3181-3187). Another approach is to use fused genes for the production of chimeric proteins between a Streptococcus protein and a Escherichia coli protein, notably lipoprotein (Cullen P A et al., Plasmid, 2003, 49(1): 18-29), or with GST (Zhao G et al., Protein Expr Purif, 1999, 16(2): 331-339). The Streptococcal insert can be linked to promoter, i.e. bacteriophage T7 promoter (Yamamoto M et al., FEMS Microbiol Lett, 1995, 132(3): 209-213), signal peptide sequence, i.e. Borrelia burgdorferi outer surface protein A signal peptide (De B K et al., Vaccine, 2000, 18(17): 1811-1821), an Escherichia coli major outer membrane lipoprotein signal sequence (Cullen P A et al., Plasmid, 2003, 49(1): 18-29).
- For Lactobacillus, different strains can be used, notably Lactobacillus brevis, Lactobacillus plantarum, Lactobacillus casei (Seegers J F, Trends Biotechnol., 2002, 20(12): 508-515). Promoters and regulatory genes involved in production of sakacin P are suitable for establishing inducible high-level gene expression in Lactobacillus (Mathiesen G et al., Lett Appl Microbiol., 2004, 39(2): 137-143), or lactose operon promoter (Oliveira M L et al., FEMS Microbiol Lett., 2003, 227(1): 25-31). Another approach is to use fused genes for the production of chimeric proteins between a Lactobacillus protein and a Streptococcus protein (Hung J et al., FEMS Microbiol Lett., 2002, 211(1): 71-75).
- For in vitro expression in insect cells, vectors are advantageously viruses, i.e. baculoviruses (see, e.g.,
U.S. Patent No. 4,745,051 ; Vialard J. et al., J. Virol., 1990 64 (1), 37-50; Verne A., Virology, 1988, 167, 56-71; Oker-Blom C et al., Brief Funct Genomic Proteomic. 2003, 2(3), 244-253), e.g. Autographa californica Nuclear Polyhedrosis Virus AcNPV, and insect cells are Sf9 Spodoptera frugiperda cells (ATCC CRL 1711; see alsoU.S. Patents Nos. 6,228,846 ,6,103,526 ). Protein production can take place by the transfection of mammalian cells by plasmids, by replication or expression without productive replication of viral vectors on mammal cells or avian cells. Mammalian cells which can be used are advantageously hamster cells (e.g. CHO or BHK-21) or monkey cells (e.g. COS or VERO) or bovine cells (e.g. MDBK), i.e. culture of EHV-1 vectors in MDBK cells (Ibrahim el S M et al., Microbiol. Immunol., 2004, 48(11): 831-842) or in Vero cells (US-A-4,110,433 ), or culture of VEEV replicons in BHK cells (Lee J S et al., Infect. Immun., 2001, 69(9): 5709-5715). - It is understood to one of skill in the art that conditions for culturing in vitro a host cell varies according to the particular gene and that routine experimentation is necessary at times to determine the optimal conditions for culturing a protein depending on the host cell. A "host cell" denotes a prokaryotic or eukaryotic cell that has been genetically altered, or is capable of being genetically altered by administration of an exogenous polynucleotide, such as a recombinant plasmid or vector. When referring to genetically altered cells, the term refers both to the originally altered cell and to the progeny thereof.
- The in vitro expression vectors can be introduced into a suitable host cell for replication and amplification. The vectors containing the polynucleotides of interest can be introduced into the host cell by any of a number of appropriate means, including direct uptake, endocytosis, transfection, f-mating, electroporation, transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (where the vector is infectious, for instance, a retroviral vector). The choice of introducing vectors or polynucleotides will often depend on features of the host cell.
- The expressed proteins can be harvested in or from the culture supernatant after, or not after secretion (if there is no secretion a cell lysis typically occurs or is performed), optionally concentrated by concentration methods such as ultrafiltration and/or purified by purification means, such as affinity, ion exchange or gel filtration-type chromatography methods, notably by affinity chromatography, i.e. using Ni NTA Superflow (Qiagen) or Ni Sepharose fastflow (Amersham), or by gel-filtration, i.e. using Sephacryl® or Superdex® (Amersham GE Healthcare).
- The polypeptides and fragments thereof can also be obtained by extraction, notably acid extraction or mutanolysin extraction (Boschwitz J S et al., Cornell Vet., 1991, 81(1): 25-36), and purification, notably immunoprecipitation (Erickson E D et al., Can J Comp Med., 1975, 39(2): 110-115), from crude culture of streptococcal bacteria, notably of Streptococcus equi.
- The polypeptides and fragments thereof can also be synthesised chemically (Luo Y et al., Vaccine 1999, 17(7-8): 821-31).
- By "subunit vaccine composition" is meant a composition containing at least one immunogenic polypeptide or a polynucleotide able to express at least one, but not all, antigen derived from or homologous to an antigen from a pathogen of interest. Such a composition is substantially free of intact pathogen cells or particles, or the lysate of such cells or particles. Thus, a "subunit vaccine composition" is prepared from at least partially purified (preferably substantially purified) immunogenic polypeptides from the pathogen, or recombinant analogs thereof. A subunit vaccine composition can comprise the subunit antigen or antigens of interest substantially free of other antigens or polypeptides from the pathogen.
- An object of the disclosure is a subunit immunogenic composition or subunit vaccine comprising at least one polypeptide, analog thereof or fragment thereof according to the disclosure, and a pharmaceutically acceptable excipient, diluent or vehicle, and optionally an adjuvant and/or a stabilizer.
- The subunit immunogenic or vaccine composition can comprise at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof, or fragments thereof. The subunit immunogenic or vaccine composition can advantageously comprise two or three or four or five polypeptides selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof, or fragments thereof.
- The subunit immunogenic or vaccine composition can comprise at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- The subunit immunogenic or vaccine composition can advantageously comprise two or three or four or five polypeptides selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- Another object of the disclosure is a recombinant immunogenic composition or vaccine comprising at least one recombinant in vivo expression vector, and a pharmaceutically acceptable excipient, diluent or vehicle, and optionally an adjuvant and/or a stabilizer. The recombinant in vivo expression vectors are vectors comprising polynucleotides or their fragments inserted hereinto and able to express in vivo in the targeted mammal the polypeptide encoded by this polynucleotide or fragment thereof. The vectors can be a polynucleotide vectors or plasmids (
EP-A2-1001025 ; Chaudhuri P Res. Vet. Sci. 2001, 70(3), 255-6) for DNA immunogenic compositions and DNA vaccines, or can be viruses (e.g. herpesvirus such as equine herpesvirus type 1 (Trapp S et al., J. Virol. 2005, 79(9): 5445-5454),equine herpesvirus type 2,equine herpesvirus type 4; poxvirus virus such as vaccinia virus or avipox virus, like fowlpox (US-A-5,174,993 US-A-5,505,941 andUS-A-5,766,599 ) or canarypox (US-A-5,756,103 ); adenovirus such as human adenovirus (Chroboczek J et al., Virol. 1992, 186: 280-285); encephalitis virus such as venezuelean equine encephalitis virus (Pushko P et al. Virol. 1997, 239: 389-401; Davis N L et al. J. Virol. 2000, 74: 371-378)) for recombinant viral vector immunogenic compositions and recombinant viral vector vaccines. In a further embodiment, the polynucleotides or their fragments may be inserted into recombinant in vivo expression bacterial vectors, notably into Salmonella, to produce live recombinant bacterial immunogenic compositions or vaccines. - The term plasmid covers any DNA transcription unit comprising a polynucleotide according to the invention and the elements necessary for its in vivo expression in a cell or cells of the desired host or target; and, in this regard, it is noted that a supercoiled or non-supercoiled, circular plasmid, as well as a linear form, are intended to be within the scope of the invention. In a specific, non-limiting example, the pVR1020 or 1012 plasmid (VICAL Inc.; Luke C. et al., Journal of Infectious Diseases, 1997, 175, 91-97; Hartikka J. et al., Human Gene Therapy, 1996, 7, 1205-1217) can be utilized as a vector for the insertion of a polynucleotide sequence. The pVR1020 plasmid is derived from pVR1012 and contains the human tPA signal sequence. Each plasmid comprises or contains or consists essentially of, in addition to the polynucleotide or analog thereof or fragment thereof, operably linked to a promoter or under the control of a promoter or dependent upon a promoter. In general, it is advantageous to employ a strong promoter functional in eukaryotic cells. The preferred strong promoter is the immediate early cytomegalovirus promoter (CMV-IE) of human or murine origin, or optionally having another origin such as the rat or guinea pig. The CMV-IE promoter can comprise the actual promoter part, which may or may not be associated with the enhancer part. Reference can be made to
EP-A-260 148 EP-A-323 597 U.S. Patents Nos. 5,168,062 ,5,385,839 , and4,968,615 , as well as toPCT Application No WO-A-87/03905 PCT Application No. WO-A-98/00166 U.S. Patent No. 6,156,567 can be used in the practice of the invention. A promoter in the practice of the invention consequently includes derivatives and sub fragments of a full-length promoter that maintain an adequate promoting activity and hence function as a promoter, preferably promoting activity substantially similar to that of the actual or fulllength promoter from which the derivative or sub fragment is derived, e.g., akin to the activity of the truncated CMV-IE promoters ofU.S. Patent No. 6,156,567 to the activity of full-length CMV-IE promoters. Thus, a CMV-IE promoter in the practice of the invention can comprise or consist essentially of or consist of the promoter portion of the full-length promoter and/or the enhancer portion of the full-length promoter, as well as derivatives and sub fragments. Advantageously, the plasmids comprise or consist essentially of other expression control elements. It is particularly advantageous to incorporate stabilizing sequence(s), e.g., intron sequence(s), preferably the first intron of the hCMV-IE (PCT Application No. WO-A-89/01036 U.S. Patent No. 5,122,458 ), or the poly(A) signal of the rabbit β-globin gene or the poly(A) signal of the SV40 virus. - For recombinant vectors based on equine herpesvirus, in particular attenuated strains (i.e. EHV-1 KyA strains (Zhang Y et al., Virology, 2000, 268(2): 482-492)) or attenuated by mutation or deletion of genes involve in pathogenicity (Kirisawa R et al., Vet. Microbiol., 2003, 95(3): 159-174) or by serial culture passages (
US-A-4,110,433 ) can be used. For EHV-1, the insertion can be made in the intergenic region between ORF 62 and ORF 63 (Ibrahim el S M et al., Microbiol. Immunol., 2004, 48(11): 831-842; Csellner H et al., Arch. Virol., 1998, 143(11): 2215-2231), or in the genes, eventually after a partial or complete deletion of the genes, i.e. in thymidine kinase (TK) gene, ingenes 1 or 71 (Kirisawa R et al., Vet. Microbiol., 2003, 95(3): 159-174), in glycoprotein I gene and glycoprotein E gene (Matsumura T. et al., Virology, 1998, 242(1): 68-79), in IR6 protein gene (Osterrieder N et al., Virology, 1996, 217(2): 442-451), in gene 15 (EP-B1-0,668,355 ). For EHV-4, the insertion can be made in glycoprotein I gene and glycoprotein E gene (Damiani A M et al., Virus Res., 2000, 67(2): 189-202), in US2 or TK or glycoprotein E gene (US-A-5,741,696 ;US-A-5,731,188 ), eventually after a partial or complete deletion of the genes. In one embodiment the polynucleotide to be expressed is inserted under the control of a promoter functional in eukaryotic cells, advantageously a CMV-IE promoter (murine or human). A poly(A) sequence and terminator sequence can be inserted downstream the polynucleotide to be expressed, e.g. bovine growth hormone or a rabbit β-globin gene polyadenylation signal. - For recombinant vector based on poxvirus vector, a vaccinia virus or an attenuated vaccinia virus, (for instance, MVA, a modified Ankara strain obtained after more than 570 passages of the Ankara vaccine strain on chicken embryo fibroblasts; see Stickl & Hochstein-Mintzel, Munch. Med. Wschr., 1971, 113, 1149-1153; Sutter et al., Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 10847-10851; available as ATCC VR-1508; or NYVAC, see
U.S. Patent No. 5,494,807 , for instance, Examples 1 to 6 and et seq ofU.S. Patent No. 5,494,807 which discuss the construction of NYVAC, as well as variations of NYVAC with additional ORFs deleted from the Copenhagen strain vaccinia virus genome, as well as the insertion of heterologous coding nucleic acid molecules into sites of this recombinant, and also, the use of matched promoters; see alsoWO-A-96/40241 U.S. Patent No. 5,505,941 ,5,494,807 ) can be used. Attenuated canarypox viruses are described inU.S. Patent No. 5,756,103 (ALVAC) andWO-A-01/05934 U.S. Patent No. 5,766,599 which pertains to the attenuated fowlpox strain TROVAC. Reference is made to the canarypox available from the ATCC under access number VR-111. Numerous fowlpox virus vaccination strains are also available, e.g. the DIFTOSEC CT strain marketed by MERIAL and the NOBILIS VARIOLE vaccine marketed by INTERVET. For information on the method to generate recombinants thereof and how to administer recombinants thereof, the skilled artisan can refer documents cited herein and toWO-A-90/12882 U.S. Patents Nos. 4,769,330 ,4,722,848 ,4,603,112 ,5,110,587 ,5,494,807 , and5,762,938 inter alia; as to fowlpox, mention is made ofU.S. Patents Nos. 5,174,993 ,5,505,941 and5,766,599 inter alia; as to canarypox mention is made ofU.S. Patent No. 5,756,103 inter alia. When the expression vector is a vaccinia virus, insertion site or sites for the polynucleotide or polynucleotides to be expressed are advantageously at the thymidine kinase (TK) gene or insertion site, the hemagglutinin (HA) gene or insertion site, the region encoding the inclusion body of the A type (ATI); see also documents cited herein, especially those pertaining to vaccinia virus. In the case of canarypox, advantageously the insertion site or sites are ORF(s) C3, C5 and/or C6; see also documents cited herein, especially those pertaining to canarypox virus. In the case of fowlpox, advantageously the insertion site or sites are ORFs F7 and/or F8; see also documents cited herein, especially those pertaining to fowlpox virus. The insertion site or sites for MVA virus area advantageously as in various publications, including Carroll M. W. et al., Vaccine, 1997, 15 (4), 387-394; Stittelaar K. J. et al., J. Virol., 2000, 74 (9), 4236-4243; Sutter G. et al., 1994, Vaccine, 12 (11), 1032-1040; and, in this regard it is also noted that the complete MVA genome is described in Antoine G., Virology, 1998, 244, 365-396, which enables the skilled artisan to use other insertion sites or other promoters. Advantageously, the polynucleotide to be expressed is inserted under the control of a specific poxvirus promoter, e.g., the vaccinia promoter 7.5 kDa (Cochran et al., J. Virology, 1985, 54, 30-35), the vaccinia promoter I3L (Riviere et al., J. Virology, 1992, 66, 3424-3434), the vaccinia promoter HA (Shida, Virology, 1986, 150, 451-457), the cowpox promoter ATI (Funahashi et al., J. Gen. Virol., 1988, 69, 35-47), the vaccinia promoter H6 (Taylor J. et al., Vaccine, 1988, 6, 504-508; Guo P. et al. J. Virol., 1989, 63, 4189-4198; Perkus M. et al., J. Virol., 1989, 63, 3829-3836), inter alia. - For recombinant vector based on adenovirus vector, a human adenovirus (HAV), advantageously, a human adenovirus serotype 5 (Ad5) vector, an E1-deleted and/or disrupted adenovirus, an E3-deleted and/or disrupted adenovirus or an E1- and E3-deleted and/or disrupted adenovirus can be used. Optionally, E4 may be deleted and/or disrupted from any of the adenoviruses described above. For example, the human Ad5 vectors described in Yarosh et al. and Lutze-Wallace et al. can be used (see, e.g., Yarosh et al., Vaccine. 1996 Sep;14(13):1257-64 and Lutze-Wallace et al., Biologicals. 1995 Dec;23(4):271-7). In one embodiment the viral vector is a human adenovirus, in particular a
serotype 5 adenovirus, rendered incompetent for replication by a deletion in the E1 region of the viral genome. The deleted adenovirus is propagated in E1-expressing 293 cells or PER cells, in particular PER.C6 (F. Falloux et al Human Gene Therapy 1998, 9, 1909-1917). The human adenovirus can be deleted in the E3 region eventually in combination with a deletion in theE 1 region (see, e.g. J. Shriver et al. Nature, 2002, 415, 331-335, F. Graham et al Methods in Molecular Biology Vol .7: Gene Transfer and Expression Protocols Edited by E. Murray, The Human Press Inc, 1991, p 109-128; Y. Ilan et al Proc. Natl. Acad. Sci. 1997, 94, 2587-2592; S. Tripathy et al Proc. Natl. Acad. Sci. 1994, 91, 11557-11561; B. Tapnell Adv. Drug Deliv. Rev.1993, 12, 185-199;X. Danthinne et al ; K. ; K. Berkner et al Nucl. Acid Res. 1983, 11, 6003-6020; C. Chavier et al J. Virol. 1996, 70, 4805-4810). The insertion sites can be the E1 and/or E3 loci eventually after a partial or complete deletion of the E1 and/or E3 regions. Advantageously, when the expression vector is an adenovirus, the polynucleotide to be expressed is inserted under the control of a promoter functional in eukaryotic cells, such as a strong promoter, preferably a cytomegalovirus immediate-early gene promoter (CMV-IE promoter). The CMV-IE promoter is advantageously of murine or human origin. The promoter of the elongation factor 1α can also be used. A muscle specific promoter can also be used (X. Li et al Nat. Biotechnol. 1999, 17, 241-245). Strong promoters are also discussed herein in relation to plasmid vectors. A poly(A) sequence and terminator sequence can be inserted downstream of the polynucleotide to be expressed, e.g. a bovine growth hormone gene or a rabbit β-globin gene polyadenylation signal. - For recombinant vector based on Encephalitis virus, a venezuelean equine encephalitis virus (VEEV) can be used (Nelson E L et al., Breast Cancer Res. Treat., 2003, 82(3): 169-183), in particular as a replicon, that is to say as a self-replicating RNA containing all of the VEEV non-structural genes and a multiple-cloning site in place of the VEEV structural genes (Lee J S et al., Infect. Immun., 2003, 71(3): 1491-1496; Velders M P et al., Cancer Res., 2001, 61(21): 7861-7867). The polynucleotides to be expressed are inserted into this multiple-cloning site, optionally linked to the nucleotide sequence encoding a secretory sequence or a tissue plasminogen activator secretory sequence. The polynucleotides to be expressed can also be inserted downstream of the subgenomic 26S promoter in place of the viral VEEV structural genes (Lee J S et al., Infect. Immun., 2001, 69(9): 5709-5715; Pushko P et al., Vaccine, 2000, 19(1): 142-153).
- For recombinant vectors based on bacteria, Salmonella, notably Salmonella typhimurium (Yang X L et al., Biomed. Environ. Sci., 2005, 18(6): 411-418; Dunstan S J et al., FEMS Immunol. Med. Microbiol., 2003, 37(2-3): 111-119), Salmonella typhi (Santiago-Machuca A E et al., Plasmid., 2002, 47(2): 108-119) can be used. The polynucleotides to be expressed can be inserted into the flagellin gene of Salmonella (Chauhan N et al., Mol Cell Biochem., 2005, 276(1-2): 1-6), or into the aroC gene (Santiago-Machuca A E et al., Plasmid., 2002, 47(2): 108-119). The polynucleotides to be expressed can also be inserted under the control of the anaerobically inducible nirB promoter (Santiago-Machuca A E et al., Plasmid., 2002, 47(2): 108-119).
- The recombinant immunogenic or vaccine composition can contain at least one recombinant expression vector comprising at least one polynucleotide encoding a polypeptide selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof or fragments thereof. The recombinant immunogenic or vaccine composition can contain at least one recombinant expression vector comprising at least one polynucleotide encoding a polypeptide selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof. The recombinant immunogenic or vaccine composition can advantageously contain at least one recombinant expression vector comprising at least one polynucleotide encoding two or three or four or five polypeptides selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof.
- The vectors of the disclosure may further comprise at least one heterologous polynucleotide. This is useful for reproducing or replicating heterologous polynucleotides and/or for expression of heterologous polynucleotides, either in vivo or in vitro. Such vectors are also useful for preparing multivalent immunogenic or vaccine compositions, notably multivalent DNA immunogenic compositions or vaccines and multivalent recombinant viral vector immunogenic compositions or vaccines. The heterologous nucleic acid sequence advantageously codes for an immunogen, antigen or epitope from a pathogenic viral, parasitic or bacterial agent, such bacterial agent is different from the streptococcal bacteria at the origin of the polynucleotides encoding the polypeptides according to the disclosure. This heterologous sequence may encode an immunogen, antigen or epitope from western equine encephalitis virus (WEEV), eastern equine encephalitis virus (EEEV), venezuelean equine encephalitis virus (VEEV), equine influenza virus, equine herpesvirus type 1 (EHV-1), equine herpesvirus type 2 (EHV-2), equine herpesvirus type 4 (EHV-4), Equine Artheritis virus (EAV), West Nile virus (WNV), tetanus, rhodococcus. In a particular embodiment, the heterologous sequence may encode an immunogen, antigen or epitope from equine influenza virus and from EHV-1 and/or EHV-4. An immunogen or antigen is a protein or polypeptide able to induce an immune response against the pathogenic agent or a secreted antigen of the pathogenic agent, and contains one or more epitopes; an epitope is a peptide or polypeptide which is able to induce an immune response against the pathogenic agent or a secreted antigen of the pathogenic agent.
- Optionally, the subunit immunogenic composition or vaccine of the disclosure can be combined with one or more immunogens, antigens or epitopes selected from other pathogenic micro-organisms or viruses to form a multivalent subunit immunogenic composition or vaccine. For the equine, such a multivalent subunit immunogenic composition or vaccine may comprises at least one polypeptide according to the present invention and at least one immunogen, antigen or epitope from WEEV, EEEV, VEEV, equine influenza virus, EHV-1, EHV-4, EAV, WNV, tetanus, rhodococcus. In a particular embodiment, such a multivalent subunit immunogenic composition or vaccine may comprises at least one polypeptide according to the present invention and at least one immunogen, antigen or epitope from equine influenza virus and from EHV-1 and/or EHV-4.
- The pharmaceutically or veterinary acceptable excipient, diluent or vehicle may be water or saline, buffer but it may, for example, also comprise Streptococcus culture medium.
- The pharmaceutically or veterinarily acceptable carriers or vehicles or excipients are well known to the one skilled in the art. For example, a pharmaceutically or veterinarily acceptable carrier or vehicle or excipient can be a 0.9% NaCl (e.g., saline) solution or a phosphate buffer. Other pharmaceutically or veterinarily acceptable carrier or vehicle or excipients that can be used for methods of this disclosure include, but are not limited to, poly-(L-glutamate) or polyvinylpyrrolidone. The pharmaceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or combination of compounds facilitating the administration of the vector (or protein expressed from an inventive vector in vitro); advantageously, the carrier, vehicle or excipient may facilitate transfection and/or improve preservation of the vector (or protein). Doses and dose volumes are herein discussed in the general description and can also be determined by the skilled artisan from this disclosure read in conjunction with the knowledge in the art, without any undue experimentation.
- The cationic lipids containing a quaternary ammonium salt which are advantageously but not exclusively suitable for plasmids, are advantageously those having the following formula:
- Among these cationic lipids, preference is given to DMRIE (N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propane ammonium;
WO96/34109 - Advantageously, the plasmid mixture with the adjuvant is formed extemporaneously and advantageously contemporaneously with administration of the preparation or shortly before administration of the preparation; for instance, shortly before or prior to administration, the plasmid-adjuvant mixture is formed, advantageously so as to give enough time prior to administration for the mixture to form a complex, e.g. between about 10 and about 60 minutes prior to administration, such as approximately 30 minutes prior to administration.
- When DOPE is present, the DMRIE:DOPE molar ratio is advantageously about 95: about 5 to about 5:about 95, more advantageously about 1: about 1, e.g., 1:1.
- The DMRIE or DMRIE-DOPE adjuvant:plasmid weight ratio can be between about 50: about 1 and about 1: about 10, such as about 10: about 1 and about 1:about 5, and advantageously about 1: about 1 and about 1: about 2, e.g., 1:1 and 1:2.
- The immunogenic compositions and vaccines according to the invention may comprise or consist essentially of one or more adjuvants. Suitable adjuvants for use in the practice of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl derivative polymers, (2) immunostimulating sequences (ISS), such as oligodeoxyribonucleotide sequences having one ore more non-methylated CpG units (Klinman et al., Proc. Natl. Acad. Sci., USA, 1996, 93, 2879-2883;
WO98/16247 - The oil in water emulsion (3), which is especially appropriate for viral vectors, can be based on: light liquid paraffin oil (European pharmacopoeia type), isoprenoid oil such as squalane, squalene, oil resulting from the oligomerization of alkenes, e.g. isobutene or decene, esters of acids or alcohols having a straight-chain alkyl group, such as vegetable oils, ethyl oleate, propylene glycol, di(caprylate/caprate), glycerol tri(caprylate/caprate) and propylene glycol dioleate, or esters of branched, fatty alcohols or acids, especially isostearic acid esters.
- The oil is used in combination with emulsifiers to form an emulsion. The emulsifiers may be nonionic surfactants, such as: esters of on the one hand sorbitan, mannide (e.g. anhydromannitol oleate), glycerol, polyglycerol or propylene glycol and on the other hand oleic, isostearic, ricinoleic or hydroxystearic acids, said esters being optionally ethoxylated, or polyoxypropylene-polyoxyethylene copolymer blocks, such as Pluronic, e.g., L121. Among the type (1) adjuvant polymers, preference is given to polymers of crosslinked acrylic or methacrylic acid, especially crosslinked by polyalkenyl ethers of sugars or polyalcohols. These compounds are known under the name carbomer (Pharmeuropa, vol. 8, no. 2, June 1996). One skilled in the art can also refer to
U.S. Patent No. 2,909,462 , which provides such acrylic polymers crosslinked by a polyhydroxyl compound having at least three hydroxyl groups, preferably no more than eight such groups, the hydrogen atoms of at least three hydroxyl groups being replaced by unsaturated, aliphatic radicals having at least two carbon atoms. The preferred radicals are those containing 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals can also contain other substituents, such as methyl. Products sold under the name Carbopol (BF Goodrich, Ohio, USA) are especially suitable. They are crosslinked by allyl saccharose or by allyl pentaerythritol. Among them, reference is made to Carbopol 974P, 934P and 971P. As to the maleic anhydride alkenyl derivative copolymers, preference is given to EMA (Monsanto), which are straight-chain or crosslinked ethylene-maleic anhydride copolymers and they are, for example, crosslinked by divinyl ether. Reference is also made to J. Fields et al., Nature 186: 778-780, June 4, 1960. -
- R1 and R2, which can be the same or different, represent H or CH3
- x = 0 or 1, preferably x = 1
- y=1 or 2, with x + y = 2.
- For EMA, x = 0 and y = 2 and for carbomers x = y = 1.
These polymers are soluble in water or physiological salt solution (20 g/l NaCl) and the pH can be adjusted to 7.3 to 7.4, e.g., by soda (NaOH), to provide the adjuvant solution in which the expression vector(s) can be incorporated. The polymer concentration in the final vaccine composition can range between 0.01 and 1.5% w/v, advantageously 0.05 to 1% w/v and preferably 0.1 to 0.4% w/v. - The cytokine or cytokines (5) can be in protein form in the immunogenic or vaccine composition, or can be co-expressed in the host with the immunogen or immunogens or epitope(s) thereof. Preference is given to the co-expression of the cytokine or cytokines, either by the same vector as that expressing the immunogen or immunogens or epitope(s) thereof, or by a separate vector therefor.
- The disclosure comprehends preparing such combination compositions; for instance by admixing the active components, advantageously together and with an adjuvant, carrier, cytokine, and/or diluent.
- Cytokines that may be used in the present disclosure include, but are not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), interferon α (IFN α), interferon β (IFN β), interferon γ, (IFN γ), interleukin-1α (IL-1α), interleukin-1 β (IL-1 β), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12 (IL-12), tumor necrosis factor α (TNF α), tumor necrosis factor β (TNF β), and transforming growth factor β (TGF β). It is understood that cytokines can be co-administered and/or sequentially administered with the immunogenic or vaccine composition of the present invention. Thus, for instance, the vaccine of the instant invention can also contain an exogenous nucleic acid molecule that expresses in vivo a suitable cytokine, e.g., a cytokine matched to this host to be vaccinated or in which an immunclogical response is to be elicited (for instance, a canine cytokine for preparations to be administered to dogs).
- Advantageously, the pharmaceutical and/or therapeutic compositions and/or formulations according to the invention comprise or consist essentially of or consist of an effective quantity to elicit a therapeutic response of one or more expression vectors and/or polypeptides as discussed herein; and, an effective quantity can be determined from this disclosure, including the documents incorporated herein, and the knowledge in the art, without undue experimentation.
- The recombinant viral vector immunogenic compositions and the recombinant viral vector vaccines according to the invention may be freeze-dried advantageously with a stabiliser. Freeze-drying can be done according to well-known standard freeze-drying procedures. The pharmaceutically or veterinary acceptable stabilisers may be carbohydrates (e.g. sorbitol, mannitol, lactose, sucrose, glucose, dextran, trehalose), sodium glutamate (Tsvetkov T et al., Cryobiology 1983, 20(3): 318-23; Israeli E et al., Cryobiology 1993, 30(5): 519-23), proteins such as peptone, albumin, lactalbumin or casein, protein containing agents such as skimmed milk (Mills C K et al., Cryobiology 1988, 25(2): 148-52; Wolff E et al., Cryobiology 1990, 27(5): 569-75), and buffers (e.g. phosphate buffer, alkaline metal phosphate buffer). An adjuvant may be used to make soluble the freeze-dried preparations.
- Further the present disclosure concerns the use of at least one polypeptide having an amino acid sequence as shown in SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof or fragments thereof, for the treatment and/or vaccination of mammals against streptococcal infection, notably of equine, canine and human species. In one embodiment, these fragments are selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof. A particular embodiment concerns the use of at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 18, 20, 22, 24, 26, 32, 34, 36, 38, 40, 48, 50, 52, 54, 56 and 58, or analogs thereof, for the treatment and/or vaccination of equines against strangles disease. A preferred embodiment concerns the use of at least one polypeptide selected from the group consisting of sequences SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof, for the treatment and/or vaccination of equines against strangles disease. In the invention the fragments are SEQ ID NOS 31 or 32.
- A further embodiment concerns the use of at least one polypeptide having an amino acid sequence as shown in SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or analogs thereof or fragments thereof, for the preparation of a subunit vaccine protecting equine against Strepcoccus equi infection. This further embodiment concerns preferrably the use of at least one polypeptide having an amino acid sequence as shown in SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof, for the preparation of a subunit vaccine protecting equine against Strepcoccus equi infection.
- Another further embodiment concerns the use of at least one recombinant vector and of at least one polynucleotide inserted therein coding for a polypeptide having an amino acid sequence as shown in SEQ ID NOS: 18, 20, 22, 24, 26, 48, 50 and 52, or an analog thereof or a fragment thereof, and said vector is able to express in vivo this polypeptide in a mammal susceptible to streptococcal infection, for the preparation of a recombinant vaccine protecting equine against Strepcoccus equi infection. This further embodiment concerns preferrably the use of at least one recombinant vector and of at least one polynucleotide inserted therein coding for a polypeptide having an amino acid sequence as shown in SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or an analog thereof, and said vector is able to express in vivo this polypeptide in a mammal susceptible to streptococcal infection, for the preparation of a recombinant vaccine protecting equine against Strepcoccus equi infection.
- An additional embodiment concerns the use of at least one recombinant vector and at least one polynucleotide inserted therein, wherein said polynucleotide has a nucleotide sequence as shown in SEQ ID NOS: 17, 19, 21, 23, 25, 31, 33, 35, 37, 39, 47, 49, 51, 53, 55 and 57, or an analog thereof, and said vector is able to express in vivo the polypeptide encoded by said polynucleotide in a mammal susceptible to streptococcal infection, for the preparation of a recombinant vaccine protecting equine against Strepcoccus equi infection.
- In particular, combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of at least one polypeptide selected from a first group of polypeptides consisting of SEQ ID NOS: 18, 20, 22, 24, 26, 32, 34, 36, 38, 40, 48, 50, 52, 54, 56 and 58, or analogs thereof or combinations thereof, and at least one another Streptococcus equi immunogen, which is not present in this first group, notably at least one immunogen selected from a second group of polypeptides consisting of FNZ protein, EAG protein, SFS protein, SEC protein, SFSC1 fragment, FNZN fragment, SEC2.16 fragment, SEC1.18 fragment, SclC1 fragment (
WO-A-2004/032957 ) and SEQ ID NOS: 28, 30 or analogs thereof or fragments thereof, or combinations thereof. In preferred combinations of polypeptides, this first group consists of SEQ ID NOS: 32, 34, 36, 38, 40, 54,56 and 58, or analogs thereof or combinations thereof. Further the present disclosure also concerns the use of these combinations of peptides for the preparation of subunit vaccines protecting equines against Streptococcus equi infection. In these embodiments, the use of polypeptides may be replaced by the use of recombinant expression vectors according to the present invention comprising at least one polynucleotide encoding said polypeptides. In particular, at least one recombinant expression vector comprising at least one polynucleotide encoding at least one polypeptide selected from a first group of polypeptides consisting of SEQ ID NOS: 18, 20, 22, 24, 26, 32, 34, 36, 38, 40, 48, 50, 52, 54, 56 and 58, or analogs thereof, and at least one polynucleotide encoding at least one another Streptococcus equi immunogen, which is not present in this first group, notably at least one immunogen selected from a second group of polypeptides consisting of FNZ protein, EAG protein, SFS protein, SEC protein, SFSC1 fragment, FNZN fragment, SEC2.16 fragment, SEC1.18 fragment, SclC1 fragment (WO-A-2004/032957 ) and SEQ ID NOS: 28, 30 or analogs thereof or fragments thereof, or combinations thereof, are used for the treatment and/or vaccination of equines against strangles disease. In a preferred embodiment, this first group consists of SEQ ID NOS: 32, 34, 36, 38, 40, 54, 56 and 58, or analogs thereof or combinations thereof. Further the present invention also concerns the use of these recombinant expression vectors for the preparation of recombinant vaccines protecting equines against Streptococcus equi infection. - In a particular embodiment, the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22 and 26, or analogs thereof, or fragments thereof. In a more preferred embodiment, the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36 and 40, or analogs thereof.
- In a particular embodiment, the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22, 26 and 50, or analogs thereof, or fragments thereof. In a more preferred embodiment, the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36, 40 and 56, or analogs thereof.
- In a particular embodiment, the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22, 26 and 20, or analogs thereof, or fragments thereof. In a more preferred embodiment, the combinations cf polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36, 40 and 34, or analogs thereof.
- In a particular embodiment, the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 52, 48, 22, 26 and 18, or analogs thereof, or fragments thereof. In a more preferred embodiment, the combinations of polypeptides to be used for the treatment and/or vaccination of equine against strangles disease are combination of polypeptides SEQ ID NOS: 58, 54, 36, 40 and 32, or analogs thereof.
- Further the present disclosure relates to methods to immunise against or to prevent streptococcal infection in mammals, preferably in equine, canine and in human species. According to these methods, (1) a subunit immunogenic composition or vaccine of the present invention, or (2) a recombinant immunogenic composition or vaccine of the present disclosure, or their combinations, are administered. Of course, embodiments of the disclosure may be employed with other vaccines or immunogenic compositions that are not of the invention, e.g., in prime-boost processes, such as where a vaccine or immunogenic composition of the disclosure is administered first and a different vaccine or immunogenic composition is administered thereafter, or vice versa. Particular prime-boost processes may be that a subunit vaccine or immunogenic composition of the disclosure is administered first and a recombinant vaccine or immunogenic composition of the invention is administered thereafter, or vice versa.
- The administration may be notably made by intramuscular (IM), intradermal (ID), subcutaneous (SC) or transdermal injection or via intranasal, intratracheal, oral administration, or through the ears or the lip. The immunogenic composition or the vaccine according to the disclosure is administered by syringe, a syringe with a microneedle (i.e. BD™ Intradermal Delivery System of Becton, Dickinson and Company, Franklin Lakes, NJ, USA), needleless apparatus (like for example Pigjet, Avijet, Dermojet or Biojector (Bioject, Oregon, USA), see
US-A-2006/0034867 ) or a spray. The administration is preferrably made by IM injection with a syringe, or by transdermal injection with a needleless apparatus or with a syringe with a microneedle (i.e. BD™ Intradermal Delivery System), or by intranasal or oral administration with a spray, i.e. a liquid nebulisation of a vaccine of the invention, or by oral or nasal administration of a micronized powder of a freeze-dried vaccine according to the invention. - The quantity of immunogenic compositions or vaccines can be determined and optimised by the skilled person, without undue experimentation from this disclosure and the knowledge in the art. Generally an animal (including a human) may be administered approximately 104-109 CFUs, advantageously approximately 105-108 CFUs and more advantageously approximately 106-108 CFUs in a single dosage unit of recombinant viral immunogenic compositions or vaccines of the present invention; approximately 10ng-1mg, advantageously approximately 100ng-500µg and more advantageously approximately 1µg-250µg per plasmid type in a single dosage unit of recombinant DNA immunogenic compositions or vaccines of the present invention; approximately 5µg-1mg, advantageously approximately 50µg-500µg and more advantageously approximately 100µg-200µg in a single dosage unit of subunit immunogenic compositions or vaccines of the present invention.
- In the case of therapeutic and/or pharmaceutical compositions based on a plasmid vector, a dose can comprise, consist essentially of or consist of, in general terms, about in 1 µg to about 2000 µg, advantageously about 50 µg to about 1000 µg and more advantageously from about 100 µg to about 800 µg of plasmid expressing the antigen, epitope, immunogen, peptide or polypeptide of interest. When the therapeutic and/or pharmaceutical compositions based on a plasmid vector is administered with electroporation the dose of plasmid is generally between about 0.1 µg and 1mg, advantageously between about 1 µg and 100 µg, advantageously between about 2 µg and 50 µg. The dose volumes can be between about 0.1 and about 2 ml, advantageously between about 0.2 and about 1 ml. These doses and dose volumes are suitable for the treatment mammalian target species.
- The volume of one single dosage unit by syringe can be between about 0.2 ml and about 5.0 ml and advantageously between about 0.5 ml and about 2.0 ml and more advantageously about 1.0 ml. The volume of one single dosage unit by needleless apparatus can be between about 0.1 ml and about 1.0 ml and advantageously between about 0.2 ml and about 0.5 ml. The volume of one single dosage unit by liquid spray can be between about 2.0 ml and about 10.0 ml and and advantageously about 5.0 ml (for powder spray, the quantities administered are corresponding to the equivalent volumes).
- In a particular method, foals, that is to say horses of 2 to 6 months old and preferably 3 to 4 months old, are vaccinated with subunit vaccines of the present invention, adjuvanted with CTB and/or CTA and/or Carbopol®, via the intranasal or oral route.
- In another particular method, foals are vaccinated with recombinant viral vaccines of the present invention, adjuvanted or not with Carbopol®, via the oral route with a spray and liquid nebulisation. Preferrably, the viral vectors of these recombinant viral vaccines are EHV-4 or EHV-2, or EHV-1.
- In another particular method, foals are vaccinated with recombinant viral vaccines of the present invention, via the lips with a syringe. Preferrably, the viral vectors of these recombinant viral vaccines are EHV-4 or EHV-2 or EHV-1.
- Preferably for the vaccination of horses and mares, two administrations of subunit vaccines of the present invention, adjuvanted with Carbopol® and/or CpG, and or emulsion are made by IM injection with a syringe. Boost administrations may be injected every 6 months or annually. For pregnant mares, a boost administration may be injected 2 to 4 weeks before the expected foaling date.
- Polypeptides of the disclosure and fragments thereof may also be used in therapy.
- The polypeptides and fragments may also be used as reagents in antibody-antigen reactions. Accordingly, another aspect of the disclosure is thus a diagnostic method and/or kit for detecting infection by the streptococcal bacterium. Kits, e.g. ELISA, can include at least one polypeptide or fragment according to the disclosure (e.g., at least one polypeptide identified by sequence herein or a fragment thereof as herein discussed).
- Antibodies against the herein polypeptides or fragments (e.g., polypeptides identified by sequence herein or fragments thereof as herein discussed) can be used as a diagnostic reagent or in passive immunization or vaccination or in therapy. The amounts of antibody administered in passive immunization can be the same as or analogous to amounts used in the art, such that from the knowledge in the art, the skilled artisan can practice passive immunization without undue experimentation.
- Proteins encoded by the novel viruses of the present disclosure, or their fragments, can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with an antigen of the present disclosure, or its fragment, or a mutated antigen. Serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al. (1985) J. Chrom. 348:363-370. If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known procedures.
- Another aspect of the disclosure is an antibody preparation comprising an antibody specific to a polypeptide or a fragment according to the disclosure and methods of diagnosis using the same. With respect to an antibody specific to a polypeptide, it is meant that the antibody binds preferentially to the polypeptide, e.g., the antibody binds to the polypeptide and not to other polypeptides or has a specificity to the polypeptide that is acceptably particular to the polypeptide such that the antibody can be used to isolate the polypeptide from a sample or detect its presence in a sample with no more than 5% false positives, using techniques known in the art or discussed in documents cited herein, including Sambrook, infra.
- Antibodies can be polyclonal or monoclonal.
- If polyclonal antibodies are desired, a selected animal (e.g. mouse, rabbit, goat, horse, etc.) is immunized with a polypeptide or a fragment. Serum from the immunized animal is collected and treated according to known procedures and possibly purified. See, e.g. Jurgens et al. J. Chrom., 1985, 348: 363-370.
- Monoclonal antibodies to the proteins and to the fragments thereof, can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by using hybridoma technology is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., Hybridoma Techniques (1980); Hammerling et al., Monoclonal Antibodies and T-cell Hybridomas (1981); Kennett et al., Alonoclonal Antibodies (1980); see also
U.S. Pat. Nos. 4,341,761 ;4,399,121 ;4,427,783 ;4,444,887 ;4,452,570 ;4,466,917 ;4,472,500 ,4,491,632 ; and4,493,890 . Panels of monoclonal antibodies produced against the desired protein, or fragment thereof, can be screened for various properties; i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are useful in purification, using immunoaffinity techniques, of the individual antigens which they are directed against. Both polyclonal and monoclonal antibodies can also be used for passive immunization or can be combined with subunit vaccine preparations to enhance the immune response. Polyclonal and monoclonal antibodies are also useful for diagnostic purposes. - One embodiment of the disclosure is a method of eliciting an immune response against the antigen, epitope, immunogen, peptide or polypeptide of interest in an animal, comprising administering a formulation for delivery and expression of a recombinant vaccine in an effective amount for eliciting an immune response. Still another embodiment of the disclosure is a method of inducing an immunological or protective response in an animal, comprising administering to the animal an effective amount of a formulation for delivery and expression of an antigen, epitope, immunogen, peptide or polypeptide of interest wherein the formulation comprises a recombinant vaccine and a pharmaceutically or veterinarily acceptable carrier, vehicle or excipient.
- The disclosure relates to a method to elicit, induce or stimulate the immune response of an animal, advantageously a mammal or a vertebrate.
- Another embodiment of the disclosure is a kit for performing a method of inducing an immunological or protective response against an antigen, epitope, immunogen, peptide or polypeptide of interest in an animal comprising a recombinant vaccine and instructions for performing the method of delivery in an effective amount for eliciting an immune response in the animal.
- The invention will now be further described by way of the following non-limiting examples.
- The IgG antibody responses directed towards Streptococcus equi cell surface proteins in sera taken from ponies intranasally challenged with 4 doses of Streptococcus equi strain 4047 were determined by ELISA. These Streptococcus equi proteins were obtened by in vitro expression in Escherichia coli. The antibody responses in sera from the six ponies receiving the higher doses of 3x107 and 3x105 cfu were averaged and compared to those from ponies challenged with 3000 and 30 cfu of Streptococccus equi 4047. Ponies receiving the higher doses developed strangles. Those receiving the low doses remained healthy throughout the study. On the basis of the results of this study, polypeptides of Streptococcus equi were selected for expression in Escherichia coli and for test of efficacy in mice and in ponies.
- Polynucleotides encoding fragments of Se50, Se1459 and Se358 were produced using Vent DNA polymerase (New England Biolabs® Inc.) as per the manufacturers recommended conditions with a 5 minute denaturation step followed by 35 cycles using 30 seconds annealing at 50-55°C, 1 minute extension at 72°C, and 30 second denaturing at 95°C. Products were finished off with a 4-minute 72°C extension. The template in each case was Streptococcus equi strain 4047 chromosomal DNA. The fragments of Se50, Se1459 and Se358 are those designated as SEQ ID NOS: 32, 34 and 40, respectively.
- Polynucleotides encoding fragments of Se528 and Se595 were produced using the pfu polymerase with same conditions as above apart from the extension time extended to two minutes at 72°C. The fragments of Se528 and Se595 are those designated as SEQ ID NOS: 38 and 36, respectively.
Table 1: Primers used to clone and sequence recombinant subunits. Primer name Sequence Function SEQ ID NO: 5'50GST AAAGGATCCTACAGCCAGCAGCACTAAAA Se50 cloning 1 3'50GST AAAGAATTCTTGGGCAGCTTCTTCTA Se50 cloning 2 5'1459GST TTTGGATCCTATCGGAACCCAATCCATAT Se1459 cloning 3 3'1459GST AAAGAATTCATTTTTAAGTTCAAACTC Se1459 cloning 4 5'595GST AAAGGATCCTAGCTACCCTCATCACAGGA Se595 cloning 5 3'595GST TTTGAATTCTTGTTTTTTAGGTGTTGC Se595 cloning 6 5'528 LONG TTTGGATCCTAGAGGTAGTTGAAGTTTGGCCTAATGGG Se528 cloning 7 3'528 LONG AAAGAATTCTTTTTCTGTCTTGTTGAAGTAATCTGCCC Se528 cloning 8 ASW49 GACGGATCCCCTCTAATGGTGGAAACAAAGGAAGC Se358 cloning 9 ASW50* GACTGAATTCAAACAAAGCACAACACCAG Se358 cloning 10 5'pGEX GGGCTGCAAGCCACGTTTGGTG Sequencing 11 3'pGEX CCGGGAGCTGCATGTGTCAGAGG Sequencing 12 595 seq1 AAAGAGCTAATCTGGCAG Sequencing Se595 13 595 seq2 CTCAATTGGAGGCTACAG Sequencing Se595 14 595 seq3 TGACGCTTCCAAAGCAAG Sequencing Se595 15 595 seq4 CTCCGGAAACACCAAAGG Sequencing Se595 16 * The recombinant Se358 ends at the actual stop codon for Se358 as the ASW50 primer site is located down stream from the gene. - All PCR products were purified using the Qiaquick PCR purification kit (Qiagen) with a 32µl elution volume, then digested with the addition of EcoRI buffer (3.5µl) (New England Biolabs® Inc.), BamHI (0.75µl) and EcoRI (0.75µl) for 2 hours at 37°C. 1 µg of pGEX-3X plasmid (GE Healthcare) was also digested with EcoRI and BamHI as described above. The pGEX-3X plasmids have a multiple cloning site, a tac promoter, glutathione S-transferase gene (GST) and stop codons in all three frames, for the production of GST fusion proteins and their isolation and purification.
- All digestion products were run on 0.7% TAE agarose gels, the desired restriction product excised and purified using the Qiaquick gel extraction kit (Qiagen) with a 35µl final elution.
- Ligation reactions were set up using 16.5µl of purified digested PCR product and 1µl of pGEX-3X plasmid with 2µl of ligase buffer and 0.5µl of ligase, and incubated overnight at room temperature (rtp).
- The ligation reactions were transformed into E.coli DH10B strain and plated onto L-agar plates supplemented with 50µg/ml ampicillin and incubated overnight at 37°C. Transformants were tested for the presence of insert by colony PCR. A single colony was resuspended in 4µl of water and 2µl of this was added to a Taq DNA polymerase PCR reaction containing the appropriate cloning primers for the polynucleotide of interest and a 35 cycle extension was performed as described above (1 minute for Se50, Se1459 and Se358 and 2 minutes for Se595 and Se528). The presence of the desired insert was confirmed by running the PCR reaction on 0.7% TAE agarose gels.
- Plasmids of each of the clones were prepared and sequenced using the 5' and 3' pGEX-3X PCR primers for all of the clones (Table 1). Due to its size, Se595 was also sequenced using the additional primers listed above (Table 1). All of the cloned polynucleotides were confirmed to have the same sequence as the assembled Streptococcus equi strain 4047 genome sequence (http://www.sanger.ac.uk/Projects/S_equi/).
- Clones of Se1459, Se595, Se528, Se50 and Se358 were induced for expression using the following protocol. A single colony was inoculated into 50ml 2 x YT culture medium containing 50µg/ml ampicillin and was grown overnight with shaking at 220 rpm at 37°C. This culture was then added to 500ml of pre-warmed (37°C) and pre-gassed 2 x YT and incubated for 1 hour at 37°C.
- For all cultures, after 1 hour, 200µl was removed and the cells were collected for analysis (this being the pre-induction sample), IPTG (isopropyl-beta-D-thiogalactopyranoside) was added to a final concentration of 0.1mM, and the temperature was lowered to 28°C. The culture was induced for a further four hours and a 100µl sample was removed for analysis, after which the cells were harvested by centrifugation and stored at-70°C.
- All samples were analysed using 10% SDS-PAGE.
- For Se1459, Se595, Se528, Se50 and Se358, the pellets were resuspended in 20ml of ice cold PBS (Oxoid Limited, catalog # BR0014G), PMSF (Phenylmethyl sulphonyl fluoride) was added to a final concentration of 0.1mM and the cells were lysed by sonication on ice with 6x10 second pulses with a 10 second rest between each pulse. Triton X-100 was added to 0.1% (v/v) and the insoluble and intact cells were removed by centrifugation (11,000g, 5
min 4°C). Samples of the soluble bacterial lysate and insoluble material were analysed by SDS-PAGE. DTT (dithiothreitol; Cleland's reagent) (5mM) was added and 1.3ml of glutathione sepharose 4B was added (equates to 1ml of beads, these were pre-washed three times with 20 ml PBS). The mixture was incubated at room temperature for 1 hour and then the beads were collected by centrifugation (800g, 2 min, rtp) and washed three times with 50 ml of ice cold PBST (PBS with 0.1% v/v Triton X-100). Samples of each wash (washes 1-3) were taken for analysis by SDS-PAGE as was a sample of the fusion protein attached to the beads. All samples were analysed using 10% SDS-PAGE. - Removal of the GST carrier was done for all fusion proteins by protease cleavage.
- For Se1459, Se595, Se528, Se50 and Se358, cleavage reactions were performed with the fusion protein attached to the glutathione sepharose beads. The beads were first equilibriated once with 20ml of wash buffer (Tris-HCL, 50 mM, pH 7.5, NaCl, 150 mM) and then twice with 20ml cleavage buffer (wash buffer with CaCl2, 1.0mM) and finally resuspended in 1ml of cleavage buffer. Factor Xa (New England Biolabs® Inc.) (50 units) was added and incubated on a rotary mixer for 16 hours at room temperature. The released protein was recovered by pelleting the glutathione beads (800g, 2 min, rtp) and retaining the supernatant. The beads were washed twice with 1ml of wash buffer and the supernatant was retained each time. Aliquots of each supernatant and the remaining glutathione beads were analysed by SDS-PAGE.The beads were washed three times with wash buffer 2 (Tris-HCL, 50 mM, pH8.0) and eluted with 3ml of
wash buffer 2 containing 5.0mM reduced glutathione for 2 min at room temperature followed by pelleting the beads (800g, 2 min, rtp) and retaining the supernatant. This elution was repeated twice and the purity of each fraction was analysed by SDS-PAGE. - All the proteins were dialysed twice in 5 litres of 20mM sodium phosphate buffer pH7.4 at 4°C overnight.
- After dialysis, any insoluble material was removed by centrifugation (10000g, 2 min, 4°C), and then it was stored at -70°C.
- The objective of this study was to determine if vaccination with Streptococcus equi subunit vaccine protected mice from subsequent intranasal Streptococcus equi challenge.
- Five Streptococcus equi subunit vaccines were used, Se595, Se358, Se1459, Se50 and Se528. All these vaccines used the Streptococcus equi proteins obtained in Example 2. The Se595, Se358, Se1459, Se50 and Se528 recombinant Streptococcus equi proteins were purified by buffer exchanged into 20mM Sodium Phosphate pH7.4 and concentrated to give a concentration equivalent to the molar concentration of Se358 at 10µg/ml where possible. Proteins, Se595 and Se528 were insoluble at the desired concentration. The actual protein concentrations used are shown in Table 2.
Table 2: Actual doses of recombinant subunits administered Protein Dose administered Dose equivalent to Se358 Se595 11.2µg 5.3µg Se358 10µg 10µg Se1459 1.7µg 10µg Se50 1.9µg 9.6µg Se528 4.2µg 3.4µg - Purified proteins in 20mM Sodium Phosphate pH 7.4, were diluted 1:3 in TS6 adjuvant (example 1 of US-A-2005/0079185) prior to administration.
- Groups of 20 3-4 week old female BalbC mice were vaccinated on day 0 (D0) with each of five Streptococcus equi subunit vaccines. Vaccinations were given by intramuscular injection in the thigh and intranasally. These mice were given a booster vaccination after 4 weeks (D28) and challenged with Streptococcus equi after a further 2 weeks (D42). An additional control group receiving no vaccination was also included, and was challenged on D42. A group of 5 control mice was not vaccinated or challenged with Streptococcus equi (see Table 3).
- The group size is sufficient to detect 50% protection of vaccinated mice with 80% infection of controls. Blood was taken before vaccination, before boost, before challenge and on euthanasia to determine the level of antibody response to vaccination and challenge.
- Streptococcus equi strain 4047 was grown for challenge in Todd Hewitt broth (THB) supplemented with 10% foetal calf serum (FCS). An overnight culture was diluted 1:20 to inoculate fresh pre-warmed and gassed THB+10% FCS and the culture grown until an OD600nm of 0.3 was reached. At this point, dilutions of the culture were made. Following preparation of the required dose of Streptococcus equi strain 4047, mice were sedated with 100mg/kg of Ketaset by intramuscular injection and challenged by intranasal administration of 10µl of challenge inocula containing approximately 1x104 cfu S. equi.
- Immediately after challenge, the dose administered was quantified by back titration and was found to contain 0.9x104 cfu.
- All the mice were carefully monitored to ensure complete recovery from sedation and checked regularly for the onset of clinical signs of disease. These included malaise, shivering or staring coat and were taken as a sign of moderate effect with the onset of more severe effects possible. Mice were finally euthanased.
- Clinical observations were recorded daily throughout the study and mice were weighed pre vaccination, pre boost, pre challenge and then daily post challenge. Nasal dabs were taken from mice post challenge to quantify the level of Streptococcus equi shedding. A post mortem examination was carried out on all mice.
Table 3: Summary of study protocol # of mice Age of mice Vaccine Subunit Dose Booster Challenge dose (cfu) Route 20 3-4 weeks Se595 + adjuvant 20µl IN + IM Yes 1x104 10µl IN 20 3-4 weeks Se358 + adjuvant 20µl IN + IM Yes 1x104 10µl IN 20 3-4 weeks Se1459 + Adjuvant 20µl IN + IM Yes 1x104 10µl IN 20 3-4 weeks Se50 + adjuvant 20µl IN + IM Yes 1x104 10µl IN 20 3-4 weeks Se528 + adjuvant 20µl IN + IM Yes 1x104 10µl IN 60 3-4 weeks No vaccine No vaccine No 1x104 10µl IN 5 3-4 weeks None None No none 10µl IN - The vaccination phase proceeded without incident, all groups gained weight in line with controls. No adverse injection site reactions were identified. All mice seroconverted with respect to the vaccination administered.
- Following challenge, Groups vaccinated with Se595, Se358, Se1459, Se528 and Se50 generally had reduced clinical signs of disease, reduced weight loss, more weight gain, reduced nasal colonisation and improved survival when compared with controls. Each mouse was examined on the day of challenge and on each of the following 7 days for the occurrence of symptoms associated with Streptococcus equi (lethargy, weight loss, sneezing, piloerection, hunched up, inner ear imbalance). Mice were examined at least 4 times a day. The following recording and scoring method was applied (Table 4)
Table 4: Strangles scoring method Observation Score Normal 0 Slight piloerection 1 Piloerection 3 Quiet 3 Marked sneezing 3 Hunched 5 Rapid breathing 5 Ear imbalance 5 Immobile 10 - For example: A mouse with piloerection that is quiet, hunched and immobile would score 3 + 3 + 5 + 10 = 21.
- Weights of mice were analysed on a spreadsheet each day to determine %weight loss relative to the day of challenge.
- Following challenge, the nose of each mouse was touched onto a clearly labelled Streptococcal selective agar plate each day (bioMerieux). Plates were streaked to determine if viable S. equi bacteria were present. The level of S. equi shedding was graded according to the following 4 point scoring system; 0 = no growth, 1 = 1-10 colonies present, 2 = 11-100 colonies present, 3 = greater than 100 colonies and 4 = confluent growth.
- Blood samples were taken from the thigh vein. Serum was prepared and stored frozen at -20°C or below until use.
- Clinical signs of disease were observed from D44, 2 days post challenge. The vaccinated groups generally had lower clinical signs than the control groups. Mice vaccinated with Se50 and Se358 had the lowest level of clinical signs of disease. Those vaccinated with Se595 had clinical signs of disease for a reduced period compared with controls (
FIG. 1 ). On examining the mean percentage change in mass following challenge, relative to the day of challenge (D42), it was apparent that Groups vaccinated with Se528, Se1459 and Se50 had a slightly reduced weight loss. However, Se358 and Se595 vaccinated mice appeared best protected (FIG. 2 ). - As expected, the mean number of β-haemolytic bacteria isolated from nasal dabs increased following challenge, peaking at D45 (3 days post challenge). On D45, the lowest nasal dabs scores were seen in groups vaccinated with Se358, Se595, Se50 and Se1459. The vaccinated groups generally had lower scores than the control groups. The exception being Se358 vaccinated mice, which peaked on D46 (
FIG. 3 ).Table 5: IgG Serological responses Sera dilution in ELISA Seroconversion Se595 1:80000* All mice seroconverted Se358 1:160000* All mice seroconverted Se1459 1:100* All mice seroconverted Se50 1:160000* All mice seroconverted Se528 1:3000* All mice seroconverted *Sera dilution to achieve an ELISA reading of around 1.5 in preliminary studies.
**Sera dilution to achieve an ELISA reading of around 0.3 in preliminary studies. - Polynucleotides encoding fragments of Se1631, Se1681 and Sla were produced using Vent DNA polymerase (New England Biolabs® Inc.) as per the manufacturers recommended conditions with a 5 minute denaturation step followed by 35 cycles using 30 seconds annealing at 50-55°C, 1 minute extension at 72°C, and 30 second denaturing at 95°C. Products were finished off with a 4-minute 72°C extension. The template in each case was Streptococcus equi strain 4047 chromosomal DNA.
- The fragments of Se1631, Se1681 and Sla are those designated as SEQ ID NOS: 53, 55 and 57, respectively.
Table 6: Primers used to clone and sequence recombinant subunits. Primer name Sequence Function SEQ ID NO: 5'1631GST AAAGGATCCTGCAGTCTACAAATGACAATAC Se1631 cloning 41 3'1631GST AAAGAATTCTTATTTTTCTGACTTAGATTTAGAAG Se1631 cloning 42 5'1681GST AAAGGATCCTGGCGACTACCCTAGCAGGACAAAC Se1681 cloning 43 3'1681GST AAAGAATTCTTATGTATCTTGACAGTGCTTAAG Se1681 cloning 44 5'SLAGST CCCGGATCCTAGAAGGGATAAATGATAAAATAG Sla cloning 45 3'SLAGST TTTGAATTCTTACAAAACATCTACTACTGGCAAC Sla clowning 46 - All PCR products were purified using the Qiaquick PCR purification kit (Qiagen) with a 32µl elution volume, then digested with the addition of EcoRI buffer (3.5µl) (New England Biolabs® Inc.), BamHI (0.75µl) and EcoRI (0.75µl) for 2 hours at 37°C. 1 µg of pGEX-3X plasmid (GE Healthcare) was also digested with EcoRI and BamHI as described above. The pGEX-3X plasmids have a multiple cloning site, a tac promoter, glutathione S-transferase gene (GST) and stop codons in all three frames, for the production of GST fusion proteins and their isolation and purification.
- All digestion products were run on 0.7% TAE agarose gels, the desired restriction product excised and purified using the Qiaquick gel extraction kit (Qiagen) with a 35 µl final elution.
- Ligation reactions were set up using 1 6.5µl of purified digested PCR product and 1µl of pGEX-3X plasmid with 2µl of ligase buffer and 0.5µl of ligase, and incubated overnight at room temperature (rtp).
- The ligation reactions were transformed into E.coli DH10B strain and plated onto L-agar plates supplemented with 50µg/ml ampicillin and incubated overnight at 37°C. Transformants were tested for the presence of insert by colony PCR. A single colony was resuspended in 4µl of water and 2µl of this was added to a Taq DNA polymerase PCR reaction containing the appropriate cloning primers for the polynucleotide of interest and a 35 cycle extension was performed as described above. The presence of the desired insert was confirmed by running the PCR reaction on 0.7% TAE agarose gels.
- Plasmids of each of the clones were prepared and sequenced using the 5' and 3' pGEX-3X PCR primers for all of the clones (Table 6). All of the cloned polynucleotides were confirmed to have the same sequence as the assembled Streptococcus equi strain 4047 genome sequence (http://www.sanger.ac.uk/Projects/S_equi/).
- All clones were induced for expression using the following protocol. A single colony was inoculated into 50ml 2 x YT culture medium containing 50µg/ml ampicillin and was grown overnight with shaking at 220 rpm at 37°C. This culture was then added to 500ml of pre-warmed (37°C) and pre-gassed 2 x YT and incubated for 1 hour at 37°C. After 1 hour, 200µl was removed and the cells were collected for analysis (this being the pre-induction sample), IPTG (isopropyl-beta-D-thiogalactopyranoside) was added to a final concentration of 0.1mM, and the temperature was lowered to 28°C. The culture was induced for a further four hours and a 100µl sample was removed for analysis, after which the cells were harvested by centrifugation and stored at -70°C.
- All samples were analysed using 10% SDS-PAGE.
- The pellets were resuspended in 20ml of ice cold PBS (Oxoid Limited, catalog # BR0014G), PMSF (Phenylmethyl sulphonyl fluoride) was added to a final concentration of 0.1mM and the cells were lysed by sonication on ice with 6x10 second pulses with a 10 second rest between each pulse. Triton X-100 was added to 0.1 % (v/v) and the insoluble and intact cells were removed by centrifugation (11,000g, 5
min 4°C). Samples of the soluble bacterial lysate and insoluble material were analysed by SDS-PAGE. DTT (dithiothreitol; Cleland's reagent) (5mM) was added and 1.3ml of glutathione sepharose 4B was added (equates to 1ml of beads, these were pre-washed three times with 20 ml PBS). The mixture was incubated at room temperature for 1 hour and then the beads were collected by centrifugation (800g, 2 min, rtp) and washed three times with 50 ml of ice cold PBST (PBS with 0.1% v/v Triton X-100). Samples of each wash (washes 1-3) were taken for analysis by SDS-PAGE as was a sample of the fusion protein attached to the beads. All samples were analysed using 10% SDS-PAGE. - Removal of the GST carrier was done for all fusion proteins by protease cleavage.
- Cleavage reactions were performed with the fusion protein attached to the glutathione sepharose beads. The beads were first equilibriated once with 20ml of wash buffer (Tris-HCL, 50 mM, pH 7.5, NaCl, 150 mM) and then twice with 20ml cleavage buffer (wash buffer with CaCl2, 1.0mM) and finally resuspended in 1ml of cleavage buffer. Factor Xa (New England Biolabs® Inc.) (50 units) was added and incubated on a rotary mixer for 16 hours at room temperature. The released protein was recovered by pelleting the glutathione beads (800g, 2 min, rtp) and retaining the supernatant. The beads were washed twice with 1ml of wash buffer and the supernatant was retained each time. Aliquots of each supernatant and the remaining glutathione beads were analysed by SDS-PAGE.The beads were washed three times with wash buffer 2 (Tris-HCL, 50 mM, pH8.0) and eluted with 3ml of
wash buffer 2 containing 5.0mM reduced glutathione for 2 min at room temperature followed by pelleting the beads (800g, 2 min, rtp) and retaining the supernatant. This elution was repeated twice and the purity of each fraction was analysed by SDS-PAGE. - The beads were washed three times with wash buffer 2 (Tris-HCL, 50 mM, pH8.0) and eluted with 3ml of
wash buffer 2 containing 5.0 mM reduced glutathione for 2 min at room temperature followed by pelleting the beads (800g, 2 min, rtp) and retaining the supernatant. This elution was repeated twice and the purity of each fraction was analysed by SDS-PAGE. - All the proteins were dialysed twice in 5 litres of 20mM sodium phosphate buffer pH7.4 at 4°C overnight.
- After dialysis, any insoluble material was removed by centrifugation (10000g, 2 min, 4°C), and then it was stored at -70°C.
- Groups of 20 3/4 week old female BalbC mice were vaccinated with each of Se1631, Se 1681 and Sla S. equi peptides, and a GST + adjuvant control group. This group size is sufficient to detect 50% protection of mice with 80% infection of controls. An additional control group of 5 mice receiving no vaccination or challenge was included (see Table 7).
- Three Streptococcus equi subunit vaccines were used, Se1631, Se1681358 and Sla. All these vaccines used the Streptococcus equi proteins obtained in Example 4.
- Recombinant proteins were prepared for vaccination by centricon concentration in 0.02M phosphate buffer pH 7.4 to 1.5 mg/ml and adding 2 parts of TS6 adjuvant (example 1 of US-A-2005/0079185).
- Mice were vaccinated on
Day 0 and boosted on Day 28. IM vaccinations were administered into the left hind leg onDay 0 and the right hind leg on Day 28 according to the following table. IN vaccinations will be administered via a pipette onto the nares of mice. - Blood was taken before vaccination, before boost and before challenge to determine the level of antibody response to vaccination.
- Mice were challenged with S. equi after a further 2 weeks. S. equi strain 4047 were prepared as described in example 3. Following dilution to the required dose, 10µl were administered to sedated mice by the intranasal route in a contained environment. Mice were carefully monitored to ensure complete recovery from sedation and checked regularly for the onset of clinical signs of disease. These include malaise, shivering or staring coat and were taken as a sign of moderate effect with the onset of more severe effects possible.
Table 7: Summary of study protocol # of mice Age of mice Vaccine Subunit Dose Booster Challenge dose (cfu) Route 20 3-4 weeks Se1631 + adjuvant 20µl IN + IM Yes 1x104 10µl IN 20 3-4 weeks Se1681 + adjuvant 20µl IN + IM Yes 1x104 10µl IN 20 3-4 weeks Sla + adjuvant 20µl IN + IM Yes 1x104 10µl IN 20 3-4 weeks GST + adjuvant 20µl IN + IM Yes 1x104 10µl IN 5 3-4 weeks None None No none 10µl IN - Clinical observations were recorded daily throughout the study (for the scoring method see Table 4) and mice were weighed pre vaccination, pre boost, pre challenge and then daily post challenge. Nasal dabs were taken from mice post challenge to quantify the level of S. equi shedding.
- Clinical signs of disease were observed from D44, 2 days post challenge. The vaccinated groups generally had lower clinical signs than the control groups. Mice vaccinated with Se1631 had the lowest level of clinical signs of disease. Those vaccinated with Se1681 and Sla had clinical signs of disease for a reduced period compared with controls (
FIG. 4 ). - On examining the mean percentage change in mass following challenge, relative to the day of challenge (D42), it was apparent that Groups vaccinated with Se1681, Se1631 and Sla had a slightly reduced weight loss. On day D49, Sla vaccinated mice appeared less protected (
FIG. 5 ). - As expected, the mean number of β-haemolytic bacteria isolated from nasal dabs increased following challenge, peaking for the control group at D49 (7 days post challenge). On D49, the lowest nasal dabs scores were seen in groups vaccinated with Se1631 and Se1681. The vaccinated groups generally had lower scores than the control groups. The exception being Sla vaccinated mice, which peaked on D48 (
FIG. 6 ). On examining percentage of mice surviving and not losing more than 7% weight (FIG. 7 ), it was apparent that Groups vaccinated with Se1631, Se1681 and Sla had a reduced weight loss and a better surviving rate than the control groups. -
- <110> ANIMAL HEALTH TRUST MERIAL
- <120> Vaccine against Streptococci
- <130>
SE 5 - <160> 58
- <170> PatentIn version 3.2
- <210> 1
<211> 29
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 1
aaaggatcct acagccagca gcactaaaa 29 - <210> 2
<211> 26
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 2
aaagaattct tgggcagctt cttcta 26 - <210> 3
<211> 29
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 3
tttggatcct atcggaaccc aatccatat 29 - <210> 4
<211> 27
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 4
aaagaattca tttttaagtt caaactc 27 - <210> 5
<211> 29
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 5
aaaggatcct agctaccctc atcacagga 29 - <210> 6
<211> 27
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 6
tttgaattct tgttttttag gtgttgc 27 - <210> 7
<211> 38
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 7
tttggatcct agaggtagtt gaagtttggc ctaatggg 38 - <210> 8
<211> 38
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 8
aaagaattct ttttctgtct tgttgaagta atctgccc 38 - <210> 9
<211> 35
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 9
gacggatccc ctctaatggt ggaaacaaag gaagc 35 - <210> 10
<211> 29
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 10
gactgaattc aaacaaagca caacaccag 29 - <210> 11
<211> 22
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 11
gggctgcaag ccacgtttgg tg 22 - <210> 12
<211> 23
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 12
ccgggagctg catgtgtcag agg 23 - <210> 13
<211> 18
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 13
aaagagctaa tctggcag 18 - <210> 14
<211> 18
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 14
ctcaattgga ggctacag 18 - <210> 15
<211> 18
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 15
tgacgcttcc aaagcaag 18 - <210> 16
<211> 18
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 16
ctccggaaac accaaagg 18 - <210> 17
<211> 906
<212> DNA
<213> Streptococcus equi - <400> 17
- <210> 18
<211> 302
<212> PRT
<213> Streptococcus equi - <400> 18
- <210> 19
<211> 1092
<212> DNA
<213> Streptococcus equi - <400> 19
- <210> 20
<211> 364
<212> PRT
<213> Streptococcus equi - <400> 20
- <210> 21
<211> 2019
<212> DNA
<213> Streptococcus equi - <400> 21
- <210> 22
<211> 673
<212> PRT
<213> Streptococcus equi - <400> 22
- <210> 23
<211> 1155
<212> DNA
<213> Streptococcus equi - <400> 23
- <210> 24
<211> 385
<212> PRT
<213> Streptococcus equi - <400> 24
- <210> 25
<211> 930
<212> DNA
<213> Streptococcus equi - <400> 25
- <210> 26
<211> 310
<212> PRT
<213> Streptococcus equi - <400> 26
- <210> 27
<211> 1287
<212> DNA
<213> Streptococcus equi - <400> 27
- <210> 28
<211> 429
<212> PRT
<213> Streptococcus equi - <400> 28
- <210> 29
<211> 2004
<212> DNA
<213> Streptococcus equi - <400> 29
- <210> 30
<211> 668
<212> PRT
<213> Streptococcus equi - <400> 30
- <210> 31
<211> 165
<212> DNA
<213> Streptococcus equi - <400> 31
- <210> 32
<211> 55
<212> PRT
<213> Streptococcus equi - <400> 32
- <210> 33
<211> 135
<212> DNA
<213> Streptococcus equi - <400> 33
- <210> 34
<211> 45
<212> PRT
<213> Streptococcus equi - <400> 34
- <210> 35
<211> 1827
<212> DNA
<213> Streptococcus equi - <400> 35
- <210> 36
<211> 609
<212> PRT
<213> Streptococcus equi - <400> 36
- <210> 37
<211> 1032
<212> DNA
<213> Streptococcus equi - <400> 37
- <210> 38
<211> 344
<212> PRT
<215> Streptococcus equi - <400> 38
- <210> 39
<211> 867
<212> DNA
<213> Streptococcus equi - <400> 39
- <210> 40
<211> 289
<212> PRT
<213> Streptococcus equi - <400> 40
- <210> 41
<211> 31
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 41
aaaggatcct gcagtctaca aatgacaata c 31 - <210> 42
<211> 35
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 42
aaagaattct tatttttctg acttagattt agaag 35 - <210> 43
<211> 34
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 43
aaaggatcct ggcgactacc ctagcaggac aaac 34 - <210> 44
<211> 33
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 44
aaagaattct tatgtatctt gacagtgctt aag 33 - <210> 45
<211> 33
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 45
cccggatcct agaagggata aatgataaaa tag 33 - <210> 46
<211> 34
<212> DNA
<213> Artificial - <220>
<223> Oligonucleotides as PCR primer - <400> 46
tttgaattct tacaaaacat ctactactgg caac 34 - <210> 47
<211> 1002
<212> DNA
<213> Streptococcus equi - <400> 47
- <210> 48
<211> 333
<212> PRT
<213> Streptococcus equi - <400> 48
- <210> 49
<211> 1179
<212> DNA
<213> Streptococcus equi - <400> 49
- <210> 50
<211> 393
<212> PRT
<213> Streptococcus equi - <400> 50
- <210> 51
<211> 573
<212> DNA
<213> Streptococcus equi - <400> 51
- <210> 52
<211> 191
<212> PRT
<213> Streptococcus equi - <400> 52
- <210> 53
<211> 930
<212> DNA
<213> Streptococcus equi - <400> 53
- <210> 54
<211> 310
<212> PRT
<213> Streptococcus equi - <400> 54
- <210> 55
<211> 600
<212> DNA
<213> Streptococcus equi - <400> 55
- <210> 56
<211> 200
<212> PRT
<213> Streptococcus equi - <400> 56
- <210> 57
<211> 309
<212> DNA
<213> Streptococcus equi - <400> 57
- <210> 58
<211> 103
<212> PRT
<213> Streptococcus equi - <400> 58
Claims (15)
- An immunizing composition comprising at least one polypeptide consisting of an amino acid sequence as shown in SEQ ID NO: 32.
- An immunizing composition comprising at least one recombinant vector and at least one polynucleotide inserted therein coding for a polypeptide consisting of an amino acid sequence as shown in SEQ ID NO: 32 and said vector is able to express in vivo this polypeptide in a mammal susceptible to streptococcal infection caused by Streptococcus equi.
- An immunizing composition comprising at least one recombinant vector and at least one polynucleotide inserted therein, wherein said polynucleotide consists of a nucleotide sequence as shown in SEQ ID NO 31, and said vector is able to express in vivo the polypeptide encoded by said polynucleotide in a mammal susceptible to streptococcal infection caused by Streptococcus equi.
- The immunizing composition of claim 3, wherein the vector is an expression vector.
- The immunizing composition of claim 4, wherein the vector is a plasmid, or a virus.
- The immunizing composition of claim 5, wherein the vector is a virus selected from the group consisting of a poxvirus, an equine herpesvirus (EHV), a human adenovirus, and an equine encephalitis virus.
- Use of at least one polypeptide consisting of an amino acid sequence as shown in SEQ ID NO: 32 for the preparation of a medicament for eliciting an immunogenic response in equine against Streptococcus equi infection.
- Use of at least one recombinant vector as defined in one of the claims 2 to 6 in the preparation of a medicament for eliciting an immunogenic response in equine against Streptococcus equi infection.
- An antibody preparation comprising at least one antibody specific for a polypeptide as defined in the claim 1 or 2, which antibody is polyclonal or monoclonal, or a fragment of said antibody.
- A diagnostic kit for detecting infection by a streptococcal bacterium comprising at least one polypeptide as defined in the claim 1 or 2, or an antibody preparation of the claim 9.
- A diagnostic method for detecting infection by a streptococcal bacterium, comprising using a diagnostic kit of claim 10 and detecting in a sample the polypeptide or an antibody specific to that polypeptide.
- Use of the antibody preparation of claim 9 in the preparation of a medicament for passive immunization wherein said antibody preparation is formulated for administration to an equine susceptible to infection by Streptococcus equi or infected by Streptococcus equi.
- The antibody preparation of claim 10 for use in passive immunization wherein said antibody preparation is formulated for administration to an equine susceptible to infection by Streptococcus equi or infected by Streptococcus equi.
- A polypeptide consisting of an amino acid sequence as shown in SEQ ID NO: 32 for use in eliciting an immunogenic response in equine against Streptococcus equi infection.
- A recombinant vector as defined in one of the claims 2 to 6 for use in eliciting an immunogenic response in equine against Streptococcus equi infection.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16184627.4A EP3167900B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against streptococci |
EP14157011.9A EP2759307B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against Streptococci |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78693606P | 2006-03-29 | 2006-03-29 | |
PCT/US2007/065427 WO2007115059A2 (en) | 2006-03-29 | 2007-03-29 | Vaccine against streptococci |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16184627.4A Division EP3167900B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against streptococci |
EP14157011.9A Division EP2759307B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against Streptococci |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2019687A2 EP2019687A2 (en) | 2009-02-04 |
EP2019687A4 EP2019687A4 (en) | 2012-02-15 |
EP2019687B1 true EP2019687B1 (en) | 2014-03-19 |
Family
ID=38564199
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07759635.1A Active EP2019687B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against streptococci |
EP16184627.4A Revoked EP3167900B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against streptococci |
EP14157011.9A Active EP2759307B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against Streptococci |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16184627.4A Revoked EP3167900B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against streptococci |
EP14157011.9A Active EP2759307B1 (en) | 2006-03-29 | 2007-03-29 | Vaccine against Streptococci |
Country Status (8)
Country | Link |
---|---|
US (1) | US7455844B2 (en) |
EP (3) | EP2019687B1 (en) |
JP (2) | JP2009531464A (en) |
AU (1) | AU2007233252C1 (en) |
BR (1) | BRPI0709282B8 (en) |
CA (1) | CA2647566C (en) |
NZ (1) | NZ571459A (en) |
WO (1) | WO2007115059A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7455844B2 (en) | 2006-03-29 | 2008-11-25 | Merial Limited | Vaccine against streptococci |
WO2009075646A1 (en) | 2007-12-13 | 2009-06-18 | Bengt Guss | Improved immunizing composition |
ES2887335T3 (en) * | 2010-03-17 | 2021-12-22 | Univ Cornell | Vaccine against drugs of abuse based on altered adenovirus |
US20110229516A1 (en) * | 2010-03-18 | 2011-09-22 | The Clorox Company | Adjuvant phase inversion concentrated nanoemulsion compositions |
EP3135684B1 (en) | 2010-05-26 | 2023-06-28 | Intervacc AB | Vaccine against streptococcal infections based on recombinant fusion proteins |
GB201122121D0 (en) | 2011-12-22 | 2012-02-01 | Animal Health Trust | Diagnostic test for bacterial pathogens |
US10004811B2 (en) | 2012-04-13 | 2018-06-26 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
KR101694676B1 (en) * | 2015-12-10 | 2017-01-10 | 우진 비앤지 주식회사 | Streptococcus equi strain and the vaccine composition comprising the same |
JP6951429B2 (en) * | 2016-09-20 | 2021-10-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH | New swine flu vaccine |
CN109790550B (en) | 2016-09-20 | 2024-02-09 | 勃林格殷格翰动物保健有限公司 | Novel promoters |
CN109715219B (en) | 2016-09-20 | 2024-03-01 | 勃林格殷格翰动物保健有限公司 | Canine adenovirus vector |
EP3515481A1 (en) * | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New ehv insertion site orf70 |
WO2023203238A1 (en) | 2022-04-22 | 2023-10-26 | Intervacc Ab | Streptococcus suis vaccine composition comprising immunogenic fusion polypeptides |
Family Cites Families (283)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4110433A (en) | 1976-04-23 | 1978-08-29 | Philips Roxane, Inc. | Equine rhinopneumonitis virus |
US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
EP0043718B1 (en) | 1980-07-07 | 1984-11-28 | National Research Development Corporation | Improvements in or relating to cell lines |
US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
JPS5873993U (en) | 1981-11-12 | 1983-05-19 | 三菱電機株式会社 | 2 cylinder rotary compressor |
US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5008182A (en) | 1986-01-10 | 1991-04-16 | Cetus Corporation | Detection of AIDS associated virus by polymerase chain reaction |
US5656493A (en) | 1985-03-28 | 1997-08-12 | The Perkin-Elmer Corporation | System for automated performance of the polymerase chain reaction |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
NZ221790A (en) | 1986-09-12 | 1990-07-26 | Genentech Inc | Method for the continuous production of a heterologous protein in a eukaryotic host cell |
US5731188A (en) | 1986-11-20 | 1998-03-24 | Syntro Corporation | Recombinant equine herpesviruses |
US5618702A (en) | 1988-08-19 | 1997-04-08 | City Of Hope | PCR amplification of mRNA |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
DE3743138A1 (en) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | SLIP RINGLESS, ELECTROMAGNETIC OVERLOAD CLUTCH |
US5817797A (en) | 1988-06-01 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Sequencing DNA; a modification of the polymerase chain reaction |
US5447839A (en) | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
US5639871A (en) | 1988-09-09 | 1997-06-17 | Roche Molecular Systems, Inc. | Detection of human papillomavirus by the polymerase chain reaction |
US5182377A (en) | 1988-09-09 | 1993-01-26 | Hoffmann-La Roche Inc. | Probes for detection of human papillomavirus |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5389512A (en) | 1988-10-07 | 1995-02-14 | Hoffman-La Roche Inc. | Method for determining the relative amount of a viral nucleic acid segment in a sample by the polymerase chain reaction |
US5639611A (en) | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
US5229297A (en) | 1989-02-03 | 1993-07-20 | Eastman Kodak Company | Containment cuvette for PCR and method of use |
US6645758B1 (en) | 1989-02-03 | 2003-11-11 | Johnson & Johnson Clinical Diagnostics, Inc. | Containment cuvette for PCR and method of use |
US5241363A (en) | 1989-07-10 | 1993-08-31 | General Atomics | Micropipette adaptor with temperature control for PCR amplification |
US5023171A (en) | 1989-08-10 | 1991-06-11 | Mayo Foundation For Medical Education And Research | Method for gene splicing by overlap extension using the polymerase chain reaction |
US5219727A (en) | 1989-08-21 | 1993-06-15 | Hoffmann-Laroche Inc. | Quantitation of nucleic acids using the polymerase chain reaction |
US5213961A (en) | 1989-08-31 | 1993-05-25 | Brigham And Women's Hospital | Accurate quantitation of RNA and DNA by competetitive polymerase chain reaction |
DE3929144A1 (en) | 1989-09-02 | 1991-03-07 | Behringwerke Ag | DETECTION OF INFLUENZA-A VIRUS BY POLYMERASE CHAIN REACTION (PCR) AFTER REVERSE TRANSCRIPTION OF A AREA OF THE VIRAL HAEMAGGLUTININ GENE |
US5082780A (en) | 1989-09-12 | 1992-01-21 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5232829A (en) | 1989-09-29 | 1993-08-03 | Hoffmann-La Roche Inc. | Detection of chlamydia trachomatis by polymerase chain reaction using biotin labelled lina primers and capture probes |
US5231015A (en) | 1989-10-18 | 1993-07-27 | Eastman Kodak Company | Methods of extracting nucleic acids and pcr amplification without using a proteolytic enzyme |
NL9000134A (en) | 1990-01-19 | 1991-08-16 | Stichting Res Fonds Pathologie | PRIMERS AND METHOD FOR DETECTING HUMAN PAPILLOMA VIRUS GENOTYPS BY M.B.V. PCR. |
DK0515506T3 (en) | 1990-02-16 | 2000-05-08 | Hoffmann La Roche | Method for detecting carcinogenic human papillomaviruses |
US5198337A (en) | 1990-04-13 | 1993-03-30 | State Of Oregon | Assay for gene deletion of GST-1 in human samples based on the polymerase chain reaction |
GB9015845D0 (en) | 1990-07-19 | 1990-09-05 | Emery Vincent C | Diagnostic method |
US5712125A (en) | 1990-07-24 | 1998-01-27 | Cemv Bioteknik Ab | Competitive PCR for quantitation of DNA |
EP1790723A3 (en) | 1990-09-27 | 2008-10-22 | Invitrogen Corporation | Direct cloning of PCR amplified nucleic acids |
US5484699A (en) | 1990-09-28 | 1996-01-16 | Abbott Laboratories | Nucleotide sequences useful as type specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods |
US5858725A (en) | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
WO1992007095A1 (en) | 1990-10-15 | 1992-04-30 | Stratagene | Arbitrarily primed polymerase chain reaction method for fingerprinting genomes |
US6703236B2 (en) | 1990-11-29 | 2004-03-09 | Applera Corporation | Thermal cycler for automatic performance of the polymerase chain reaction with close temperature control |
KR100236506B1 (en) | 1990-11-29 | 2000-01-15 | 퍼킨-엘머시터스인스트루먼츠 | Apparatus for polymerase chain reaction |
US5491225A (en) | 1991-12-19 | 1996-02-13 | Hoffmann-La Roche Inc. | PCR primers for detection of legionella species and methods for controlling visual intensity in hybridization assays |
US5437975A (en) | 1991-02-25 | 1995-08-01 | California Institute Of Biological Research | Consensus sequence primed polymerase chain reaction method for fingerprinting genomes |
JP3602530B2 (en) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | Genetically engineered vaccine strain |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US5436144A (en) | 1991-04-08 | 1995-07-25 | Health Research, Inc. | Process for performing PCR in mammalian cells |
US5514568A (en) | 1991-04-26 | 1996-05-07 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction |
US5512463A (en) | 1991-04-26 | 1996-04-30 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction library mutagenesis |
CA2065719A1 (en) | 1991-04-30 | 1992-10-31 | John B. Findlay | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle |
US5665539A (en) | 1991-07-12 | 1997-09-09 | The Regents Of The University Of California | Immuno-polymerase chain reaction system for antigen detection |
AU645915B2 (en) | 1991-07-23 | 1994-01-27 | F. Hoffmann-La Roche Ag | Improvements in the in situ PCR |
US5279952A (en) | 1991-08-09 | 1994-01-18 | Board Of Regents, The University Of Texas System | PCR-based strategy of constructing chimeric DNA molecules |
CA2114950A1 (en) | 1991-08-10 | 1993-02-11 | Michael J. Embleton | Treatment of cell populations |
CA2077135A1 (en) | 1991-08-30 | 1993-03-01 | Joh-E Ikeda | A method of dna amplification |
US5224778A (en) | 1991-11-12 | 1993-07-06 | The Perkin Elmer Corporation | Temperature verification for polymerase chain reaction systems |
ZA929351B (en) | 1991-12-11 | 1993-06-04 | Igen Inc | Electrochemiluminescent label for DNA assays. |
US6033854A (en) | 1991-12-16 | 2000-03-07 | Biotronics Corporation | Quantitative PCR using blocking oligonucleotides |
US5589333A (en) | 1992-02-03 | 1996-12-31 | Thomas Jefferson University | In situ polymerase chain reaction |
US5420009A (en) | 1992-03-23 | 1995-05-30 | The United States Of America As Represented By The Secretary Of Agriculture | Detection of Xanthomonas campestris pv. citri by hybridization and polymerase chain reaction assays |
AU4248593A (en) | 1992-05-14 | 1993-12-13 | Mark Holodniy | Polymerase chain reaction assays for monitoring antiviral therapy |
US5741696A (en) | 1992-08-07 | 1998-04-21 | Syntro Corporation | Recombinant equine herpesviruses |
US5804383A (en) | 1992-08-21 | 1998-09-08 | The Regents Of The University Of California | Method and assay for detection of the expression of allele-specific mutations by allele-specific in situ reverse transcriptase polymerase chain reaction |
US5565339A (en) | 1992-10-08 | 1996-10-15 | Hoffmann-La Roche Inc. | Compositions and methods for inhibiting dimerization of primers during storage of polymerase chain reaction reagents |
AU5298393A (en) | 1992-10-08 | 1994-05-09 | Regents Of The University Of California, The | Pcr assays to determine the presence and concentration of a target |
US5393657A (en) | 1992-11-30 | 1995-02-28 | Genetics Institute, Inc. | Detection of residual host cell DNA by PCR |
US5340728A (en) | 1992-12-09 | 1994-08-23 | E. I. Du Pont De Nemours And Company | Method for amplification of targeted segments of nucleic acid using nested polymerase chain reaction |
US5364790A (en) | 1993-02-16 | 1994-11-15 | The Perkin-Elmer Corporation | In situ PCR amplification system |
US5639606A (en) | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
US5876978A (en) | 1993-04-06 | 1999-03-02 | Medical College Of Ohio | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
US5643765A (en) | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
US5494795A (en) | 1993-05-05 | 1996-02-27 | The United States Of America As Represented By The Secretary Of The Navy | Specific oligonucleotide primers for detection of pathogenic campylobacter bacteria by polymerase chain reaction |
US5712090A (en) | 1993-05-18 | 1998-01-27 | Iowa State University Research Foundation, Inc. | PCR-based assay for Mycoplasma hyopneumoniae |
GB9312508D0 (en) | 1993-06-17 | 1993-08-04 | Bioteknologisk Inst | Compounds |
EP0648845B1 (en) | 1993-07-08 | 2002-10-09 | Johnson & Johnson Clinical Diagnostics, Inc. | Method for coamplification of two different nucleic acid sequences using polymerase chain reaction |
EP0726315B1 (en) | 1993-07-23 | 2001-10-17 | Hans Prof. Dr. Wolf | Epstein-Barr virus DNA sequences encoding a diagnostically relevant virus capsid antigen, expression clones derived through polymerase chain reaction and the use of this recombinant antigen in diagnostic tests |
WO1995004161A1 (en) | 1993-07-29 | 1995-02-09 | Sergio Danilo Junho Pena | Method for recognition of the nucleotide sequence of a purified dna segment |
US5556773A (en) | 1993-08-06 | 1996-09-17 | Yourno; Joseph | Method and apparatus for nested polymerase chain reaction (PCR) with single closed reaction tubes |
WO1995006137A1 (en) | 1993-08-27 | 1995-03-02 | Australian Red Cross Society | Detection of genes |
US6017699A (en) | 1993-09-15 | 2000-01-25 | The University Of Pittsburgh | PCR identification and quantification of important Candida species |
US5426026A (en) | 1993-09-15 | 1995-06-20 | University Of Pittsburgh | PCR identification of four medically important candida species using one primer pair and four species-specific probes |
EP0668355B1 (en) | 1993-12-20 | 1999-04-07 | Akzo Nobel N.V. | Vaccine for the protection of horses against equine herpesvirus infection |
US5512462A (en) | 1994-02-25 | 1996-04-30 | Hoffmann-La Roche Inc. | Methods and reagents for the polymerase chain reaction amplification of long DNA sequences |
DE4408700C1 (en) | 1994-03-15 | 1995-04-13 | Albrecht Dr Med Wiedenmann | Selective detection of live, infectious cryptosporidia oocysts by means of the polymerase chain reaction (PCR) |
US5585238A (en) | 1994-04-25 | 1996-12-17 | Ciba-Geigy Corporation | Detection of fungal pathogens using the polymerase chain reaction |
US6087097A (en) | 1994-05-12 | 2000-07-11 | Mayo Foundation For Medical Education And Research | PCR detection of Borrelia burgdorferi |
US5766889A (en) | 1994-06-08 | 1998-06-16 | The Perkin-Elmer Corporation | Method for determining the characteristics of the concentration growth of target nucleic acid molecules in polymerase chain reaction sample |
US6613560B1 (en) | 1994-10-19 | 2003-09-02 | Agilent Technologies, Inc. | PCR microreactor for amplifying DNA using microquantities of sample fluid |
GB2294322A (en) | 1994-10-21 | 1996-04-24 | Zeneca Ltd | Telomere variant repeat mapping |
US5629178A (en) | 1994-10-28 | 1997-05-13 | Genetics & Ivf Institute | Method for enhancing amplification in the polymerase chain reaction employing peptide nucleic acid (PNA) |
US6410223B1 (en) | 1994-11-04 | 2002-06-25 | The United States Of America As Represented By The Secretary Of Agriculture | Direct polymerase chain reaction assay, or bio-PCR |
US6258529B1 (en) | 1994-12-01 | 2001-07-10 | Oravax, Inc. | PCR amplification of rearranged genomic variable regions of immunoglobulin genes |
US5652102A (en) | 1994-12-05 | 1997-07-29 | The United States Of America As Represented By The Secretary Of Agriculture | Assay for enterohemorrhagic Escherichia coli 0157:H7 by the polymerase chain reaction |
CA2139070C (en) | 1994-12-23 | 2010-03-30 | Burton W. Blais | Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction |
US5565340A (en) | 1995-01-27 | 1996-10-15 | Clontech Laboratories, Inc. | Method for suppressing DNA fragment amplification during PCR |
CA2168712A1 (en) | 1995-02-07 | 1996-08-08 | John William Henderson Sutherland | Use of exonuclease and/or glycosylase as supplements to anti-polymerase antibody to increase specificity in polymerase chain reaction |
US5576197A (en) | 1995-04-07 | 1996-11-19 | Molecular Bio-Products | Polymerase chain reaction container and methods of using the same |
US5780222A (en) | 1995-04-10 | 1998-07-14 | Alpha Therapeutic Corporation | Method of PCR testing of pooled blood samples |
US5654144A (en) | 1995-04-24 | 1997-08-05 | The United States Of America As Represented By The Secretary Of The Army | Detection of Yersinia using the polymerase chain reaction |
EP0826063A1 (en) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
DE69610304T2 (en) | 1995-05-05 | 2001-04-05 | Perkin Elmer Corp | METHODS AND REAGENTS FOR COMBINING A PCR AMPLIFICATION WITH A HYBRIDIZATION ASSAY |
JP3579497B2 (en) | 1995-05-12 | 2004-10-20 | 株式会社飼料作物改良増殖技術研究所 | Individual identification method by PCR reaction using MI primer |
US6586250B1 (en) | 1995-05-16 | 2003-07-01 | Washington University | Method of PCR-based gene targeting |
US5693467A (en) | 1995-05-19 | 1997-12-02 | The American Type Culture Collection | Mycoplasma polymerase chain reaction testing system using a set of mixed and single sequence primers |
DE19518769C2 (en) | 1995-05-22 | 1997-04-17 | Gsf Forschungszentrum Umwelt | Inter-LINE-PCR |
ES2154506B1 (en) | 1995-06-07 | 2001-11-16 | Estivill Palleja Xavier | CHARACTERIZATION PROCEDURE FOR A NEW MOLECULAL CLONING TECHNIQUE (PCR ALU-SPLICE) OF A GENETIC SEQUENCE OF THE HUMAN CHROMOSOME 21 AND NEW DSCRI GENETIC SEQUENCE OF THE CRITICAL SYNDROME DEDOWN OF SUCH CHROMOSOMA, CHARACTERIZED ACCORDING TO THE MACHINE. |
US5793927A (en) | 1995-06-07 | 1998-08-11 | Hitachi America, Ltd. | Methods for monitoring and modifying a trick play data stream to insure MPEG compliance |
CA2223104A1 (en) | 1995-06-07 | 1996-12-19 | Jonathan P. Duvick | Pcr-based cdna subtractive cloning method |
CA2188713A1 (en) | 1995-10-27 | 1997-04-28 | Robert Collu | Internal standards for quantitative competitive pcr |
US6015664A (en) | 1995-11-03 | 2000-01-18 | Mcw Research Foundation | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
US6048688A (en) | 1996-11-12 | 2000-04-11 | Kimberly-Clark Corporation | Method for detection of Pseudomonas aeruginosa using polymerase chain reaction |
US5776686A (en) | 1995-12-29 | 1998-07-07 | The United States Of America As Represented By The Secretary Of Agriculture | Development of a PCR-based method for identification of Tilletia indica, causal agent of Karnal bunt of wheat |
US5716784A (en) | 1996-02-05 | 1998-02-10 | The Perkin-Elmer Corporation | Fluorescence detection assay for homogeneous PCR hybridization systems |
AU2264197A (en) | 1996-02-09 | 1997-08-28 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Restriction display (rd-pcr) of differentially expressed mrnas |
US5702884A (en) | 1996-03-12 | 1997-12-30 | Johnson & Johnson Clinical Diagnostics, Inc. | Whole blood sample preparation for polymerase chain reaction using ammonium chloride and a carboxylic acid or metal carboxylate for selective red blood cell lysis |
US5627054A (en) | 1996-04-05 | 1997-05-06 | The United States Of America As Represented By The Secretary Of The Army | Competitor primer asymmetric polymerase chain reaction |
US5774497A (en) | 1996-04-12 | 1998-06-30 | Hewlett-Packard Co | Method and apparatus for PCR jitter measurement in an MPEG-2 transport stream |
US5883924A (en) | 1996-04-12 | 1999-03-16 | Hewlett Packard Company | Method and apparatus for PCR jitter measurement in an MPEG-2 transport stream using sliding window |
EP0912766B2 (en) | 1996-06-04 | 2011-12-14 | University of Utah Research Foundation | Monitoring hybridization during pcr |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
DE69740033D1 (en) | 1996-07-03 | 2010-12-09 | Merial Inc | RECOMBINANT DOG ADENOVIRUS 2 (CAV2), WHICH CONTAINS EXOGENOUS DNA |
FR2751227B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA AGAINST CANINE CONDITIONS, ESPECIALLY RESPIRATORY AND DIGESTIVE CONDITIONS |
US6001572A (en) | 1996-07-26 | 1999-12-14 | Univera Pharmaceuticals, Inc. | Method of identifying Aloe using PCR |
US5858718A (en) | 1997-07-08 | 1999-01-12 | Smithkline Beecham Corporation | Pcr a |
US5905732A (en) | 1996-08-27 | 1999-05-18 | Zenith Electronics Corporation | PCR restamper |
US5874221A (en) | 1996-08-28 | 1999-02-23 | The United States Of America As Represented By The Secretary Of Agriculture | Species specific method for the PCR detection of phythophthora |
US6312930B1 (en) | 1996-09-16 | 2001-11-06 | E. I. Du Pont De Nemours And Company | Method for detecting bacteria using PCR |
JP4111403B2 (en) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Immunostimulatory polynucleotide / immunomodulatory molecule complex |
US5861251A (en) | 1996-10-15 | 1999-01-19 | Bioneer Corporation | Lyophilized reagent for polymerase chain reaction |
US5814453A (en) | 1996-10-15 | 1998-09-29 | Novartis Finance Corporation | Detection of fungal pathogens using the polymerase chain reaction |
JPH10117765A (en) | 1996-10-18 | 1998-05-12 | Ngk Insulators Ltd | Specimen holder and its production |
US5958686A (en) | 1996-10-28 | 1999-09-28 | The United States Of America As Represented By The Secretary Of The Army | Simple PCR technique for detecting and differentiating bacterial pathogens |
US5863731A (en) | 1996-11-01 | 1999-01-26 | The Penn State Research Foundation | Polymerase chain reaction-based diagnostic test for the detection of Xanthomonas campestris pathovar pelargonii |
US5800997A (en) | 1996-11-01 | 1998-09-01 | Novartis Finance Corporation | Detection of maize fungal pathogens using the polymerase chain reaction |
US5780271A (en) | 1996-11-13 | 1998-07-14 | North Carolina State University | PCR assays for phytophthora species |
US5811296A (en) | 1996-12-20 | 1998-09-22 | Johnson & Johnson Clinical Diagnostics, Inc. | Blocked compartments in a PCR reaction vessel |
US6309840B1 (en) | 1997-01-03 | 2001-10-30 | The Chinese Univerisity Of Hong Kong | Polymerase chain reaction-restriction fragment length polymorphism test for the authentication of herbal Chinese medicines |
US5876977A (en) | 1997-01-03 | 1999-03-02 | The Chinese University Of Hong Kong | Polymerase chain reaction-restriction fragment length polymorphism test for the authentication of traditional chinese medicines |
US5952200A (en) | 1997-02-06 | 1999-09-14 | University Of South Carolina | Method of diagnosing cancer in human cells using a reverse transcriptase-polymerase chain reaction for identifying the presence of stromelysin-3 |
US5909468A (en) | 1997-03-28 | 1999-06-01 | Scientific-Atlanta, Inc. | Method and apparatus for encoding PCR data on a frequency reference carrier |
ATE486961T1 (en) | 1997-04-03 | 2010-11-15 | Life Technologies Corp | METHODS AND PRODUCTS FOR REVERSE TRANSCRIPTION COUPLED WITH POLYMERASE CHAIN REACTION (RT-PCR) |
US5849497A (en) | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
EP0917590A1 (en) | 1997-04-04 | 1999-05-26 | Innogenetics N.V. | Isothermal polymerase chain reaction by cycling the concentration of divalent metal ions |
US6143496A (en) | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
WO1998048046A2 (en) | 1997-04-22 | 1998-10-29 | Bavarian Nordic Research Institute A/S | Taqmantm-pcr for the detection of pathogenic e. coli strains |
DE19717085C2 (en) | 1997-04-23 | 1999-06-17 | Bruker Daltonik Gmbh | Processes and devices for extremely fast DNA multiplication using polymerase chain reactions (PCR) |
US5936968A (en) | 1997-05-28 | 1999-08-10 | Sarnoff Corporation | Method and apparatus for multiplexing complete MPEG transport streams from multiple sources using a PLL coupled to both the PCR and the transport encoder clock |
JP3120453B2 (en) | 1997-06-19 | 2000-12-25 | トヨタ自動車株式会社 | Method for holding and reacting microdroplets |
US6465638B2 (en) | 1997-06-25 | 2002-10-15 | Ortho-Clinical Diagnostics, Inc. | Multiplexed PCR assay for detecting disseminated Mycobacterium avium complex infection |
US6348336B1 (en) | 1997-07-01 | 2002-02-19 | Alpha Therapeutic Corporation | Process for purification of PCR test samples |
CA2243730C (en) * | 1997-07-29 | 2009-12-22 | Akzo Nobel N.V. | Streptococcus equi vaccine |
US5827695A (en) | 1997-08-04 | 1998-10-27 | Novartis Finance Corporation | Detection of wheat fungal pathogens using the polymerase chain reaction |
US6207425B1 (en) | 1997-09-11 | 2001-03-27 | City Of Hope | Bidirectional PCR amplification of specific alleles |
AU9743398A (en) | 1997-09-16 | 1999-04-05 | Delfts Diagnostic Laboratory B.V. | Detection and identification of human papillomavirus by pcr and type-specific r everse hybridization |
US5888740A (en) | 1997-09-19 | 1999-03-30 | Genaco Biomedical Products, Inc. | Detection of aneuploidy and gene deletion by PCR-based gene- dose co-amplification of chromosome specific sequences with synthetic sequences with synthetic internal controls |
GB9720926D0 (en) | 1997-10-03 | 1997-12-03 | Molecular Sensors Ltd | Intelligent control of nucleic amplification procedures including the polymerase chain reaction |
US6103468A (en) | 1997-10-07 | 2000-08-15 | Labatt Brewing Company Limited | Rapid two-stage polymerase chain reaction method for detection of lactic acid bacteria in beer |
JP2001520054A (en) | 1997-10-23 | 2001-10-30 | エグザクト サイエンシーズ コーポレイション | Method for detecting contamination in molecular diagnostics using PCR |
US5976842A (en) | 1997-10-30 | 1999-11-02 | Clontech Laboratories, Inc. | Methods and compositions for use in high fidelity polymerase chain reaction |
US6218153B1 (en) | 1997-10-31 | 2001-04-17 | Transgenomic, Inc. | Target DNA amplification by MIPC and PCR |
DE19752898A1 (en) | 1997-11-28 | 1999-08-05 | Centeon Pharma Gmbh | Method for the detection of high concentrations of four in blood plasma and / or blood serum by means of the polymerase chain reaction |
EP0921196A1 (en) | 1997-12-02 | 1999-06-09 | Roche Diagnostics GmbH | Modified DNA-polymerase from carboxydothermus hydrogenoformans and its use for coupled reverse transcription and polymerase chain reaction |
US6632653B1 (en) | 1997-12-08 | 2003-10-14 | Thomas W. Astle | Continuous polymerase chain reaction apparatus with multiple temperature stations |
US6537752B1 (en) | 1997-12-08 | 2003-03-25 | Thomas W. Astle | Temperature control system for polymerase chain reaction |
US6794133B1 (en) | 1997-12-11 | 2004-09-21 | The General Hospital Corporation | Broad range PCR amplification techniques |
US6268153B1 (en) | 1997-12-19 | 2001-07-31 | Michelle Lizotte-Waniewski | Polymerase chain reaction diagnostic assays for the detection of dirofilaria immitis in blood and mosquitoes |
US6844158B1 (en) | 1997-12-22 | 2005-01-18 | Hitachi Chemical Co., Ltd. | Direct RT-PCR on oligonucleotide-immobilized PCR microplates |
KR100271236B1 (en) | 1998-02-02 | 2000-11-01 | 김춘호 | Dpll for pcr clock recovery using a normalizing mathod |
EP1058688A4 (en) | 1998-02-03 | 2004-10-06 | Xy Inc | Specific oligonucleotide primers for detection of bovine male chromosome presence by polymerase chain reaction and method |
GB9803382D0 (en) | 1998-02-19 | 1998-04-15 | Secr Defence | Detection system |
US6358680B1 (en) | 1998-02-20 | 2002-03-19 | Syngenta Participations Ag | Detection of wheat and barley fungal pathogens using the polymerase chain reaction |
US5912129A (en) | 1998-03-05 | 1999-06-15 | Vinayagamoorthy; Thuraiayah | Multi-zone polymerase/ligase chain reaction |
US6258537B1 (en) | 1998-03-16 | 2001-07-10 | Clemson University | Method of diagnosing gummy stem blight in plants using a polymerase chain reaction assay |
DE19813317A1 (en) | 1998-03-26 | 1999-09-30 | Roche Diagnostics Gmbh | Nucleic acid amplification involving primer extension preamplification, especially for whole genome amplification |
US6258570B1 (en) | 1998-04-17 | 2001-07-10 | University Of Pittsburgh | PCR assay for bacterial and viral meningitis |
US6068974A (en) | 1998-04-29 | 2000-05-30 | Klann; Richard Chris | Specific, highly sensitive, nested PCR detection scheme for the pseudorabies virus |
US6818437B1 (en) | 1998-05-16 | 2004-11-16 | Applera Corporation | Instrument for monitoring polymerase chain reaction of DNA |
US6468743B1 (en) | 1998-05-18 | 2002-10-22 | Conagra Grocery Products Company | PCR techniques for detecting microbial contaminants in foodstuffs |
US6037129A (en) | 1998-05-28 | 2000-03-14 | Medical University Of South Carolina | Multi-marker RT-PCR panel for detecting metastatic breast cancer |
US6355422B1 (en) | 1998-06-24 | 2002-03-12 | City Of Hope | Single tube PCR assay for detection of chromosomal mutations: application to the inversion hotspot in the factor VIII gene including optional use of subcycling PCR |
GB9815799D0 (en) | 1998-07-21 | 1998-09-16 | Pharmagene Lab Limited | Quantitative analysis of gene expression |
US6268143B1 (en) | 1998-08-05 | 2001-07-31 | Kansas State University Research Foundation | Automated high throughput E. coli o157:H7 PCR detection system and uses thereof |
US6046039A (en) | 1998-08-19 | 2000-04-04 | Battelle Memorial Institute | Methods for producing partially digested restriction DNA fragments and for producing a partially modified PCR product |
US6638716B2 (en) | 1998-08-24 | 2003-10-28 | Therasense, Inc. | Rapid amperometric verification of PCR amplification of DNA |
US6518020B1 (en) | 1998-09-18 | 2003-02-11 | Heska Corporation | Haemobartonella PCR methods and materials |
US6300072B1 (en) | 1998-09-18 | 2001-10-09 | Heska Corporation | PCR methods and materials for detecting bartonella species |
USD445907S1 (en) | 1998-09-19 | 2001-07-31 | Advanced Biotechnologies, Limited | PCR multiwell strip |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
US6183963B1 (en) | 1998-10-23 | 2001-02-06 | Signalgene | Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay |
DE19849348A1 (en) | 1998-10-26 | 2000-04-27 | Univ Ludwigs Albert | Identification and/or sequencing of an unknown DNA or RNA sequence adjacent to a known DNA or RNA region comprises linker-mediated PCR following amplification by linear PCR |
US6001612A (en) | 1998-11-06 | 1999-12-14 | Yang; Robert Che-An | Heteroduplex PCR cloning |
US6503750B1 (en) | 1998-11-25 | 2003-01-07 | The Regents Of The University Of California | PCR thermocycler |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
US6153412A (en) | 1998-12-07 | 2000-11-28 | Bioneer Corporation | Lyophilized reagent for polymerase chain reaction |
US6261431B1 (en) | 1998-12-28 | 2001-07-17 | Affymetrix, Inc. | Process for microfabrication of an integrated PCR-CE device and products produced by the same |
US6372484B1 (en) | 1999-01-25 | 2002-04-16 | E.I. Dupont De Nemours And Company | Apparatus for integrated polymerase chain reaction and capillary electrophoresis |
US6221595B1 (en) | 1999-03-01 | 2001-04-24 | Syngenta Participations Ag | Detection of Monilinia spp. using the polymerase chain reaction |
US6316192B1 (en) | 1999-03-11 | 2001-11-13 | Jianhua Luo | Method for enrichment of unique DNA fragments through cyclical removal of PCR adapter attached to DNA fragments whose sequences are shared between two DNA pools |
US6368834B1 (en) | 1999-04-06 | 2002-04-09 | Genome Technologies, Llc | PCR genome walking with synthetic primer |
US6303343B1 (en) | 1999-04-06 | 2001-10-16 | Caliper Technologies Corp. | Inefficient fast PCR |
USD441091S1 (en) | 1999-04-24 | 2001-04-24 | Advanced Biotechnologies Limited | PCR plate |
US6180349B1 (en) | 1999-05-18 | 2001-01-30 | The Regents Of The University Of California | Quantitative PCR method to enumerate DNA copy number |
US6258567B1 (en) | 1999-05-29 | 2001-07-10 | The Regents Of The University Of California | Preparation of 13C/15N-labeled oligomers using the polymerase chain reaction |
AU785093B2 (en) | 1999-06-14 | 2006-09-14 | Sanofi Pasteur, Inc. | CoRT-PCR assay for the discrimination of endogenous reverse transcriptase activity in eukaryotic cell lines from infectious retrovirus contamination |
US6284455B1 (en) | 1999-07-13 | 2001-09-04 | Academia Sinica | Diagnosis of penaeus monodon-type baculovirus by PCR |
FR2796397B1 (en) | 1999-07-16 | 2006-09-01 | Merial Sas | FELIN CALICIVIRUS GENES AND VACCINES, INCLUDING RECOMBINANT VACCINES |
US6319673B1 (en) | 1999-08-10 | 2001-11-20 | Syngenta Participations Ag | PCR-based detection and quantification of Tapesia yallundae and Tapesia acuformis |
US6225093B1 (en) | 1999-09-07 | 2001-05-01 | Decode Genetics Ehf. | Detection of C4A deletion by long range PCR |
US6383755B1 (en) | 1999-09-08 | 2002-05-07 | Clontech Laboratories, Inc. | Methods and kits for determining the fidelity of polymerase chain reaction conditions |
US6146834A (en) | 1999-09-10 | 2000-11-14 | The United States Of America As Represented By The Secretary Of Agriculture | PCR primers for detection of plant pathogenic species and subspecies of acidovorax |
US6423499B1 (en) | 1999-09-10 | 2002-07-23 | The United States Of America, As Represented By The Secretary Of Agriculture | PCR primers for detection and identification of plant pathogenic species, subspecies, and strains of acidovorax |
US6300073B1 (en) | 1999-10-01 | 2001-10-09 | Clontech Laboratories, Inc. | One step RT-PCR methods, enzyme mixes and kits for use in practicing the same |
US6309837B1 (en) | 1999-10-13 | 2001-10-30 | Clemson University | PCR-based method for identifying a fusarium wilt-resistant genotype in plants |
US6642000B1 (en) | 1999-11-12 | 2003-11-04 | University Of Chicago | PCR amplification on microarrays of gel immobilized oligonucleotides |
JP3131633B1 (en) | 1999-11-26 | 2001-02-05 | 農林水産省食品総合研究所長 | Method for detecting plant genes by PCR |
US6855521B2 (en) | 1999-12-01 | 2005-02-15 | The United States Of America As Represented By The Secretary Of The Navy | Serotype and dengue group specific flurogenic probe based PCR (TaqMan) assays against the respective C and NS5 genomic and 3′ non-coding regions of dengue virus |
US6251607B1 (en) | 1999-12-09 | 2001-06-26 | National Science Council Of Republic Of China | PCR primers for the rapid and specific detection of Salmonella typhimurium |
US6316195B1 (en) | 1999-12-23 | 2001-11-13 | The United States Of America As Represented By The Secretary Of Agriculture | Method for differentiating between the casual agents of karnal bunt wheat fungus and ryegrass smut using PCR |
US6699713B2 (en) | 2000-01-04 | 2004-03-02 | The Regents Of The University Of California | Polymerase chain reaction system |
US6485907B1 (en) | 2000-01-11 | 2002-11-26 | Syngenta Participations Ag | PCR-based detection of Rhizoctonia cerealis |
JP2001269188A (en) | 2000-03-11 | 2001-10-02 | Roche Diagnostics Gmbh | Dna polymerase b variant exhibiting enhanced performance in pcr |
US6432646B1 (en) | 2000-03-16 | 2002-08-13 | The University Of Melbourne | PCR-based identification of Eimeria species and strains |
US6346384B1 (en) | 2000-03-27 | 2002-02-12 | Dade Behring Inc. | Real-time monitoring of PCR using LOCI |
BRPI0001536B1 (en) | 2000-04-04 | 2015-09-29 | Fundacao Oswaldo Cruz | method for diagnosing infection by genus schistosoma parasites and kit for use in diagnosing schistosoma sp infection |
US6448014B2 (en) | 2000-04-19 | 2002-09-10 | Research Development Foundation | PCR-hybridization assays specific for integrated retroviruses |
US6248567B1 (en) | 2000-04-24 | 2001-06-19 | Wisconsin Alumni Research Foundation | Template-specific termination in a polymerase chain reaction |
US6887664B2 (en) | 2000-06-06 | 2005-05-03 | Applera Corporation | Asynchronous primed PCR |
WO2001096600A2 (en) | 2000-06-16 | 2001-12-20 | Syngenta Participations Ag | Detection of mycosphaerella using the polymerase chain reaction |
US6596492B2 (en) | 2000-07-11 | 2003-07-22 | Colorado State University Research Foundation | PCR materials and methods useful to detect canine and feline lymphoid malignancies |
US6379932B1 (en) | 2000-07-17 | 2002-04-30 | Incyte Genomics, Inc. | Single primer PCR amplification of RNA |
US6650719B1 (en) | 2000-07-19 | 2003-11-18 | Tektronix, Inc. | MPEG PCR jitter, frequency offset and drift rate measurements |
US6558929B2 (en) | 2000-09-15 | 2003-05-06 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forshung E.V. | PCR reaction mixture for fluorescence-based gene expression and gene mutation analyses |
US6744789B1 (en) | 2000-09-26 | 2004-06-01 | The Directv Group, Inc. | System and method for translating MPEG packets which include PCR data into DIRECTV packets which include RTS data |
US6465637B1 (en) | 2000-10-30 | 2002-10-15 | Council Of Scientific & Industrial Research | Species specific DNA sequences and their utilization in identification of viola species and authentication of “banafsha” by polymerase chain reaction |
US6544782B1 (en) | 2000-11-13 | 2003-04-08 | Synthegen Systems | pREM: a positive selection vector system for direct PCR cloning |
JP3844996B2 (en) | 2000-11-15 | 2006-11-15 | エフ.ホフマン−ラ ロシュ アーゲー | Melting curve analysis method for repetitive PCR products |
US6569678B1 (en) | 2000-11-27 | 2003-05-27 | Synthegen Systems, Inc. | pRGR: a positive selection vector system for direct cloning of PCR amplified DNA fragments |
DE60210413T2 (en) * | 2001-01-03 | 2006-09-07 | Epitopix Llc, Willmar | COMPOSITIONS FOR IMMUNIZING AND USE THEREOF |
CA2438130A1 (en) | 2001-02-13 | 2002-08-22 | Children's Hospital Research Foundation | Quantitative epstein barr virus pcr rapid assay |
US6566067B2 (en) | 2001-02-14 | 2003-05-20 | Synthegen Systems, Inc. | High fidelity PCR cloning |
US6645720B2 (en) | 2001-03-09 | 2003-11-11 | Syngenta Participations Ag | Detection of fungal pathogens using the polymerase chain reaction |
US6586233B2 (en) | 2001-03-09 | 2003-07-01 | The Regents Of The University Of California | Convectively driven PCR thermal-cycling |
US6733999B2 (en) | 2001-03-29 | 2004-05-11 | University Of Nevada | Method for detection of Stachybotrys chartarum in pure culture and field samples using quantitative polymerase chain reaction |
US6426215B1 (en) | 2001-04-06 | 2002-07-30 | Pe Corporation (Ny) | PCR plate cover and maintaining device |
EP1414750A4 (en) | 2001-04-23 | 2005-01-19 | Monsanto Technology Llc | Pcr-based monitoring in wastewater biotreatment systems |
CA2344599C (en) | 2001-05-07 | 2011-07-12 | Bioneer Corporation | Selective polymerase chain reaction of dna of which base sequence is completely unknown |
US6770440B1 (en) | 2001-05-31 | 2004-08-03 | The United States Of America As Represented By The Secretary Of Agriculture | Polymerase chain reaction assay for the detection of Toxoplasma gondii |
US6514750B2 (en) | 2001-07-03 | 2003-02-04 | Pe Corporation (Ny) | PCR sample handling device |
US6403341B1 (en) | 2001-08-02 | 2002-06-11 | Wayne M. Barnes | Magnesium precipitate hot start method for PCR |
US6846631B2 (en) | 2001-09-24 | 2005-01-25 | Syngenta Participations Ag | Detection of Fusarium species infecting corn using the polymerase chain reaction |
US6783940B2 (en) | 2001-10-31 | 2004-08-31 | Applera Corporation | Method of reducing non-specific amplification in PCR |
JP3779600B2 (en) | 2001-11-27 | 2006-05-31 | 株式会社日立製作所 | PCR primer and method for determining the base sequence of PCR primer |
DE60219132T2 (en) | 2002-02-01 | 2007-12-13 | Bruker Daltonik Gmbh | Mutation analysis by PCR and mass spectrometry |
US6855522B2 (en) | 2002-02-27 | 2005-02-15 | Indian Council Of Medical Research | Species-specific PCR assay for detection of Leishmania donovani in clinical samples of kala-azar and post kala-azar dermal leishmaniasis |
US6951726B2 (en) | 2002-09-24 | 2005-10-04 | Mississippi State University | Real-time PCR assay of the bacterium Edwardsiella ictaluri in channel catfish |
US8404245B2 (en) * | 2002-10-11 | 2013-03-26 | Intervacc Ab | Immunization of non-human mammals against Streptococcus equi |
JP2006528647A (en) | 2003-07-24 | 2006-12-21 | メリアル リミテッド | New vaccine formulation |
DK1765387T3 (en) | 2004-06-04 | 2013-03-04 | Merial Ltd | NEEDLE-FREE ADMINISTRATION OF FELV VACCINES |
US7455844B2 (en) | 2006-03-29 | 2008-11-25 | Merial Limited | Vaccine against streptococci |
-
2007
- 2007-03-29 US US11/692,968 patent/US7455844B2/en active Active
- 2007-03-29 NZ NZ571459A patent/NZ571459A/en unknown
- 2007-03-29 EP EP07759635.1A patent/EP2019687B1/en active Active
- 2007-03-29 JP JP2009503260A patent/JP2009531464A/en active Pending
- 2007-03-29 CA CA2647566A patent/CA2647566C/en active Active
- 2007-03-29 EP EP16184627.4A patent/EP3167900B1/en not_active Revoked
- 2007-03-29 WO PCT/US2007/065427 patent/WO2007115059A2/en active Application Filing
- 2007-03-29 EP EP14157011.9A patent/EP2759307B1/en active Active
- 2007-03-29 AU AU2007233252A patent/AU2007233252C1/en active Active
- 2007-03-29 BR BRPI0709282A patent/BRPI0709282B8/en active IP Right Grant
-
2012
- 2012-08-03 JP JP2012173146A patent/JP2013010764A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2007233252C1 (en) | 2013-05-23 |
AU2007233252B9 (en) | 2012-07-26 |
CA2647566C (en) | 2017-01-03 |
NZ571459A (en) | 2011-09-30 |
JP2009531464A (en) | 2009-09-03 |
AU2007233252A1 (en) | 2007-10-11 |
EP2759307A2 (en) | 2014-07-30 |
BRPI0709282A2 (en) | 2011-07-05 |
EP2019687A4 (en) | 2012-02-15 |
EP2759307A3 (en) | 2014-12-10 |
US7455844B2 (en) | 2008-11-25 |
BRPI0709282B1 (en) | 2018-11-21 |
CA2647566A1 (en) | 2007-10-11 |
US20070243195A1 (en) | 2007-10-18 |
AU2007233252B2 (en) | 2012-01-12 |
EP3167900B1 (en) | 2018-11-21 |
EP2759307B1 (en) | 2016-11-09 |
EP2019687A2 (en) | 2009-02-04 |
JP2013010764A (en) | 2013-01-17 |
EP3167900A1 (en) | 2017-05-17 |
WO2007115059A2 (en) | 2007-10-11 |
WO2007115059A3 (en) | 2008-10-16 |
BRPI0709282B8 (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2019687B1 (en) | Vaccine against streptococci | |
Zheng et al. | The virulence-related rhoptry protein 5 (ROP5) of Toxoplasma gondii is a novel vaccine candidate against toxoplasmosis in mice | |
KR102136437B1 (en) | Reassortant btv and ahsv vaccines | |
KR101840360B1 (en) | Vaccine composition for preventing or treating brucellosis comprising LPS O-antigen deleted Salmonella mutant expressing pan-Brucella immunogen | |
Rafiqi et al. | Immune response and protective efficacy of Eimeria tenella recombinant refractile body protein, EtSO7, in chickens | |
Wang et al. | Construction of glutathione peroxidase (GPx) DNA vaccine and its protective efficiency on the orange-spotted grouper (Epinephelus coioides) challenged with Vibrio harveyi | |
KR101846478B1 (en) | Vaccine composition comprising recombinant protein for preventing swine mycoplasma infection | |
Fu et al. | Glyceraldehyde-3-phosphate dehydrogenase, an immunogenic Streptococcus equi ssp. zooepidemicus adhesion protein and protective antigen | |
JP2011506433A (en) | Modified immune composition | |
Du et al. | A novel lumazine synthase molecule from Brucella significantly promotes the immune-stimulation effects of antigenic protein | |
US8008268B2 (en) | Vaccines against vesicular stomatitis | |
Phonvisay et al. | Evaluation of long-term antibody response and cross-serotype reaction in ducks immunised with recombinant outer membrane protein A and CpG ODN | |
US10881722B2 (en) | Epizootic hemorrhagic disease vaccine | |
Chessa et al. | Genetic immunization with the immunodominant antigen P48 of Mycoplasma agalactiae stimulates a mixed adaptive immune response in BALBc mice | |
EP1539810B1 (en) | Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses thereof | |
EP4061413A1 (en) | A novel vaccine against heamophilus parasuis | |
JP2023503057A (en) | A novel vaccine against Haemophilus parasuis | |
CA2719553A1 (en) | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof | |
CA2716973A1 (en) | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof | |
US9695221B2 (en) | Recombinant outer membrane proteins from Brachyspira hyodysenteriae and uses thereof | |
Beutinger Marchioro | Immune responses following vaccination of pigs and mice against Mycoplasma hyopneumoniae | |
Bzdawka | Spreading of Actinobacillus pleuropneumoniae in the pig farm. A field case |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081021 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MINKE, JULES, MAARTEN Inventor name: AUDONNET, JEAN-CHRISTOPHE, FRANCIS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120118 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/315 20060101ALI20120112BHEP Ipc: A61K 39/295 20060101AFI20120112BHEP Ipc: A61P 31/04 20060101ALI20120112BHEP Ipc: G01N 33/569 20060101ALI20120112BHEP Ipc: A61K 39/09 20060101ALI20120112BHEP |
|
17Q | First examination report despatched |
Effective date: 20120828 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20131011 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 657215 Country of ref document: AT Kind code of ref document: T Effective date: 20140415 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007035667 Country of ref document: DE Effective date: 20140430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 657215 Country of ref document: AT Kind code of ref document: T Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140719 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140619 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007035667 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140721 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
26N | No opposition filed |
Effective date: 20141222 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007035667 Country of ref document: DE Effective date: 20141222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070329 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140329 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602007035667 Country of ref document: DE Representative=s name: D YOUNG & CO LLP, DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230323 Year of fee payment: 17 Ref country code: FR Payment date: 20230322 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230321 Year of fee payment: 17 Ref country code: DE Payment date: 20220620 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240321 Year of fee payment: 18 |